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Abstract 
As a result of our ageing population, the demand for novel approaches to the repair of bone 
defects caused by trauma, infection and surgical intervention is ever increasing.  This increase 
in clinical demand has highlighted the deficiencies of autogenous grafts, such as poor 
availability and donor site morbidity and consequently there has been a drive to develop new 
synthetic bone replacement materials. Since the 1980‟s calcium phosphate cements (CPC‟s) 
have attracted a great deal of interest due to their chemical similarities to natural bone; 
chemical, physical and mechanical characteristics have been investigated and manipulated to 
maximise osteoconductivity and osteointegration.  Despite these advanatageous properties, 
the CPC has not surplanted the autogenous tissue graft as the gold-standard bone replacement 
material owing to perceived difficulties in clinical application and long-term stability 
following implantation. 
 
In this thesis, a range of approaches to address issues that have prevented the widespread 
clinical uptake of CPC‟s by: (1) limiting water availability during the setting reaction of a 
brushite cement to produce monetite (the anhdydrous form of brushite) based cement, which 
is known to be extensively resorbed during implantation, but previously could not be formed 
by a cementing reaction; (2) encapsulating the aqueous component of the cement to produce a 
material that can be supplied in a „ready-mixed‟ form and will set following a change in 
temperature from 4 °C to 37 °C; (3) incorporating therapeutic molecules as a prophylactic 
measure to prevent implant-associated infections; and (4) Manipulating the degradation 
properties of the material by incorporating porosity with a non-toxic pore former.  
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Figure 2.1: The processes of bone remodelling (Russell T.Turner & Jean 
D.Sibonga 2009).  (A) Quiescent phase is when bone surface is inactive.  Neither 
bone resorption nor bone formation is occurring on this region of bone surface; (B) 
Resorption phase where osteoclasts remove a discrete packet of bone, creating a 
cavity, a temporary weak spot or link; (C) Formation phase when osteoblasts form a 
bone matrix, which fills in the cavity (the cement line defines the boundary between 
the newly formed bone and the surface excavated by osteoclasts at the end of the 
resorption phase (B)); (D) Quiescent phase again the inactive bone surface, this 
time after a completed remodelling cycle (the new surface may be under filled (1), 
exactly filled (2), or overfilled (3), reflecting a local decrease, no change, or 
increase in bone mass, respectively).   
 
Figure 2.2: The hierarchical structure of bone (M.A.K.Liebschner & 
M.A.Wettergreen 2003). 
 
 
Figure 5.1: Image of spheres of the cement paste during immersion in PBS; (A) 
MCPM control cements (β-TCP + MCPM + water) and (B) MCPM cement paste 
(β-TCP + MCPM + glycerol).  Images demonstrate the washout resistance of the 
paste formulations compared to the control samples; no visible degradation of the 
cement was evident. 
 
Figure 5.2: Scanning electron micrographs of cement fracture surfaces without 
(A) and with (B) the addition of sodium alginate and glycerol.  The addition of 
the sodium alginate and glycerol resulted in a marked change in the morphology 
of the crystals within the cement matrix from predominantly blade-like to 
irregularly shape.  
 
Figure 5.3: Effect of storage, of the paste formulation (at 4 ºC) prior to setting, on 
the compressive strengths exhibited by the hardened material. 
 
Figure 5.4: SEM micrographs show microstructure of the fractured surface of the 
aged cement samples.  Samples were aged for 90 days in total; here we can see the 
minimal effect on the microstructure of the monetite cements over the period of 
time.  Sample A illustrates the sample at day 0; sample B at day 3; sample C at day 
7; sample D at day 14; sample E at day 28 and sample F at day 90. 
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Figure 5.5:  A schematic diagram illustrating the sections of cement dissected from 
the hardened cement cylinder (A) following immersion in PBS for a period of 20 h 
and the crystalline phase composition of each corresponding layer (B).  
 
Figure 5.6: There was an upper limit on the distance that the methylene blue 
solution could perfuse the hardening cement paste, with samples of 10 and 15 mm 
in length being the only samples completely perfused (A), the rate of perfusion 
reduced significantly with time, showing that the cement hardening reaction 
provided a barrier to perfusion.  B) Shows cement paste cylinders of 10, 20 and 30 
mm of length following 9 days immersion in methylene blue solution. 
 
Figure 5.7: XRD results of the different layers of the cement paste sample.  Layer 
1 = outer most layer and layer 5 = inner most layer.  The graph proves that the 
water-glycerol exchange is more efficient near the surface compared to the inner 
layer.  The various peaks are indicative of the composition of the samples; ■ 
Monetite; ○ Brushite; ● β-tri-calcium phosphate (β-TCP); □ Monocalcium 
phosphate monohydrate (MCPM). 
 
Figure 5.8: Compares the diffraction patterns of the MCPM control cement (β-TCP 
+ MCPM + water) (bottom) with the paste formulation before (middle) and after 
(top) the cement paste has hardened.  The various peaks are indicative of the 
composition of the samples; ■ Monetite; ○ Brushite; ● β-tri-calcium phosphate (β-
TCP); □ Monocalcium phosphate monohydrate (MCPM). 
 
Figure 5.9: Compares the diffraction patterns of the MCPM paste formulation 
(made using glycerol and alginate) with varying amounts of alginate.  The various 
peaks are indicative of the composition of the samples; ■ Monetite; ○ Brushite; ● 
β-tri-calcium phosphate (β-TCP); □ Monocalcium phosphate monohydrate 
(MCPM). 
 
Figure 5.10: Effect of the variation in gelling agent of the paste formulation on the 
compressive strengths exhibited by the hardened material; all samples were 
prepared in the same manner. 
 
Figure 5.11: Compares the diffraction patterns of the MCPM control cement (β-
TCP + MCPM + water) (bottom) with the paste formulation after the cement paste 
has hardened, using various different gelling agents.  The various peaks are 
indicative of the composition of the samples; ■ Monetite; ○ Brushite; ● β-tri-
calcium phosphate (β-TCP); □ Monocalcium phosphate monohydrate (MCPM). 
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Figure 5.12: SEM micrographs show microstructure of the fractured surface of the 
different cement samples; each sample is composed using different gelling agent.  
Sample A illustrates the gelling agent Alginate; sample B uses Agarose; sample C 
uses Carrageenan; sample D uses Chitosan; sample E uses Gellan gum and sample 
F uses Gelatine.  Here we can see the minimal effect on the microstructure of the 
monetite cements with varying the gelling agent.   
 
 
Figure 6.1: Typical forms of spherical microcapsules, which are made by various 
different methods, depending on the application.  Matrix and single-wall are 
typically relatively easy to manufacture, compared to multi-wall and multi-core, 
which require more complex processing methods.  
 
Figure 6.2: The chemical structures of Eudragit RS 100 (A) and Eudragit S100 (B) 
(Reproduced from (Rohm Pharma 2003)). 
 
Figure 6.3: Illustration of the production of Microspheres by the solvent 
evaporation method using acetone/liquid paraffin system (Azarmi et al. 2002;Oth & 
Mos 1989).   
 
Figure 6.4: The graph illustrates the cumulative release, in percentage, of OA 
released against time in hours, over an 8 h period at the different temperatures; at 
37 ºC the thermo-sensitive polymer releases the encapsulated content; at 4 ºC the 
content should remain encapsulated.  The graph illustrates the mean values of the 
data points from all the batches produced (error bars are also indicated). 
  
Figure 6.5: SEM micrographs of Eudragit S100 microspheres at 200 x 
magnifications (A) and (B).  The morphology illustrated in the SEM micrographs 
clearly shows all of spheres to be broken. At 5,000 x magnifications (C) it can be 
seen that the microspheres do produce a hollow sphere, with a relatively smooth 
surface.  Cracks or wrinkled-like surface of the microspheres may be attributed to 
the heat created by the high voltage of the electron beam. 
 
Figure 6.6: The graph illustrates the cumulative release, in percentage, of OA 
released against time in hours, over an 8 hour period at the different pH; at pH7.4 
the pH-sensitive polymer released the encapsulated content; at pH 4 the content 
should remain encapsulated.  The graph illustrates the mean values of the data 
points from all the batches produced (error bars are also indicated). 
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Figure 6.7: Eudragit S100 prepared by solvent evaporation method using 
acetone/liquid paraffin system (Figure 6.3).  The micrograph shows the fragments 
of the microspheres, the fluffy flake-like structure created by this method does not 
allow the encapsulation of OA (A) and PPA (B).   
 
Figure 6.8: The graph illustrates the cumulative release in percentage of OA (A) 
and PPA (B) released against time in hours, at the different pHs;  pH7 the pH-
sensitive polymer releases the encapsulated content; at pH 4 the content should 
remain encapsulated, however results show total release of microsphere content.  
The graph illustrates the mean values of the data points from all the batches 
produced (error bars are also indicated).  Eudragit S100 prepared by solvent 
evaporation method using acetone/liquid paraffin system (Figure 6.3). 
 
Figure 6.9: (A) Eudragit
®
 RL microspheres without any encapsulated acids.  
Microspheres were prepared by solvent evaporation method using acetone/liquid 
paraffin system (Figure 6.3).  (B) and (C) Higher magnification of the 
microspheres to emphasize the binding of the microspheres.   
 
Figure 6.10: Eudragit
®
 RL microspheres with OA (A and B) and PPA (C and D) 
encapsulated.  Microspheres were prepared by solvent evaporation method (Figure 
6.3).  Micrographs show the difference in morphology of the two microspheres; 
with OA encapsulated the surface is smooth, with a porous interior structure; with 
the PPA the microspheres exhibited a porous surface, on closer inspection the 
interior was hollow (similar to the non encapsulated microspheres produced) or 
porous within the same batch. 
 
Figure 6.11: The graph illustrates the particle size distribution of the two 
microspheres produced; Eudragit S100 (A) and Eudragit RL (B), using the two 
different methods. 
 
Figure 6.12: Illustrates the cumulative release (%) of OA and PPA over, (A) 24 h 
period at 37 ºC; (B) OA and (C) PPA release over an 8 h period at the different 
temperatures; 37 ºC the thermo-sensitive polymer releases the encapsulated content; 
at 4 ºC the content remain encapsulated.  Illustrating the mean values of the data 
points from all the batches produced (error bars are also indicated). 
 
Figure 6.13: Compares the diffraction patterns of the control cement (β-TCP + 
OA+ water) with the varying concentrations of OA paste formulations using 
microspheres staggered on top.  The various peaks are indicative of the composition 
of the samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP). 
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Figure 6.14: Compares the diffraction patterns of the control cement (β-TCP + OA 
(A) or PPA (B) + water) with the paste formulations using Eudragit RL 
microspheres with the encapsulated OA (A) or PPA (B).  The various peaks are 
indicative of the composition of the samples; ○ Brushite; ● β-tri-calcium phosphate 
(β-TCP). 
 
Figure 6.15: (A) SEM micrographs of the fracture surface of the set cement 
produced using Eudragit RL microspheres to encapsulate the OA component (500 
X magnified); (B) A higher magnification (1,000 X) of the cements needle-like 
microstructure; and (C) the surface of the cement at 1,500 X magnifications that 
shows both brushite crystals and Eudragit RL microspheres.  Eudragit
®
 RL 
microspheres were prepared by solvent evaporation method using acetone/liquid 
paraffin system (Figure 6.3).   
 
Figure 6.16: (A) SEM micrographs of the fracture surface of the set cement 
produced using Eudragit RL microspheres to encapsulate the PPA component (500 
X magnified); (B) A higher magnification (1,000 X) of the cements needle-like 
microstructure; and (C) the surface of the cement at 1,500 X magnifications that 
shows both brushite crystals and Eudragit RL microspheres fused together; small 
amounts of degraded polymer is visible, which appears to be fusing the brushite 
crystal together in some areas.  Eudragit
®
 RL microspheres were prepared by 
solvent evaporation method using acetone/liquid paraffin system (Figure 6.3).   
 
Figures 6.17: The images show the effect of storage at 4 ºC with the use of 
microspheres S100 (A) and RL100 (B). 
 
Figures 6.18: Illustrates that similarity in the composition of the control 
pyrophosphate modified brushite cement (bottom) and the Eudragit encapsulated 
PPA cement after being in storage at 4 ºC for 90 days then; heated to 37 ºC to allow 
hardening (middle) and without being exposed to a change in the environment to 
allow hardening (top).  The various peaks are indicative of the composition of the 
samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP). 
 
Figure 6.19: Shows the particle size distribution of the microspheres produced 
using PCL; the speed at which there were produced had a large effect on the PSD: 
6,000 rpm (A); 3,000 rpm (B); 1,500 rpm (C); and 750 rpm (D). 
 
Figure 6.20: Shows the ESEM micrographs of the microspheres produced using 
PCL; (A) shows spectrum 1 – outer layer of the microsphere, (B) shows spectrum 2 
– the inside of the microsphere, both relate to the EDS analysis in Table 6.2. 
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Figure 6.21: The graph illustrates the cumulative release, in percentage, of PPA 
released against time in hours, for a total of 2 h at room temperature of 22 ºC the 
content should remain encapsulated, however, here the contrary is demonstrated.  
The graph illustrates the mean values of the data points from all the batches 
produced (error bars are also indicated). 
 
Figure 6.22: The graph illustrates the compressive strengths (A) of the cements 
compared to the relative porosities (B) at each homogeniser speed (750, 1500, 
3000, 6000 rpm). 
 
 
Figure 7.1: The concentration of the drug in the eluent per day, of VH from the 
three cement matrices; two brushite based cements are compared to the traditional 
HA cement, with the MIC line. 
 
Figure 7.2: Illustration of the inhibition zone around the cements in both loaded 
and unloaded cement matrices (A); the digital images of the inhibition zones (B). 
 
Figure 7.3: SEM images of the microstructure of (A) typical brushite structure, 
illustrates needle-like thin ling crystals and (B) HA cement, characterised by flat 
densely packed crystals. 
 
Figure 7.4: Compares the diffraction patterns of the samples as shown in the SEM 
micrographs of the various cement formulations.  The various peaks are indicative 
of the composition of the samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP); 
* Tetracalcium phosphate (TTCP), which remained in small amount in the HA 
cement (at 28˚ and 29˚ 2θ). 
 
Figure 7.5: FTIR spectra of the apatite cement and brushite cements (both OA 
and PPA brushite cements).  The spectra of all CaP based materials indicated the 
presence of phosphate groups at the range of 1070-1140 cm 
-1
.  In addition, the 
peak at 872 cm 
-1
 of the brushite cements was indicative of the presence of HPO4
2-
 
groups.    
 
Figure 7.6: Illustrates the concentration of the antibiotic – gentamicin sulphate  and 
vancomycin hydrochloride released from the β-TCP + OA cement, stored in PBS 
with at an agitation of 100 spm at 37 °C over a period of 24 days. 
 
Figure 7.7: Illustrates the concentration of the antibiotic – gentamicin sulphate 
and vancomycin hydrochloride released from the β-TCP + PPA cement, stored in 
PBS with at an agitation of 100 spm at 37 °C over a period of 24 days. 
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Figure 7.8: SEM images of the control OA cement sample; (A) illustrates small 
short brushite-like structure before and (B) demonstrates fused needle-like 
structures to create irregular globular structures, after being immersed in PBS for 
24 days. 
 
Figure 7.9: SEM images of the control PPA cement sample; (A) exhibits obvious 
needle-like structures indicating presence of brushite, before and (B) illustrates 
irregular globular structures, after being immersed in PBS for 24 h. 
 
Figure 7.10: SEM images of the GS loaded OA cement sample; (A) before and (B) 
after being immersed in PBS for 24 days.  Sharp defined fine need-like structures, 
3–5 μm in length indicative of presence of brushite; no change in morphology 
indicated here. 
 
Figure 7.11: SEM images of the GS loaded PPA cement sample; (A) illustrates 
some brushite-like structure before and (B) demonstrates fused needle-like 
structures to create flat planes (10 μm in length), after being immersed in PBS for 
24 days. 
 
Figure 7.12: SEM images of the VH loaded OA cement sample, (A) before and (B) 
after being immersed in PBS for 24 days.  Smooth flat plates over 10 μm in length; 
slightly needle-like indicating presence of brushite with larger crystals; no change 
in morphology indicated. 
 
Figure 7.13: SEM images of the VH loaded PPA cement sample; (A) before and 
(B) after being immersed in PBS for 24 days.  Sharp defined need-like structures, 
3–7 μm in length indicative of presence of brushite; no change in morphology 
indicated here. 
 
Figure 7.14: Average inhibition zones produced by OA cements grown on; S. 
aureus samples, after 48 h at 37 °C (A) and S. epidermidis samples, after 48 h at 37 
°C (B).  The control cement illustrates some low antimicrobial activity. 
 
Figure 7.15: Average inhibition zones produced by PPA cements grown on; S. 
aureus samples, after 48 h at 37 °C (A), and (B) average inhibition zones of S. 
epidermidis samples, after 48 h at 37 °C.  The control cement illustrates some low 
antimicrobial activity. 
 
Figure 7.16: Images of the Inhibition Zones exhibited by GS (A) and VH (B) 
loaded OA cements compared with the inhibition zone produced by control OA 
cement (C), which indicates that the control cement illustrates some low 
antimicrobial activity. 
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Figure 7.17: Images of the Inhibition Zones exhibited by GS (A) and VH (B) 
loaded PPA cements compared with the inhibition zone produced by control PPA 
cement (C), which indicates that the control cement illustrates some low 
antimicrobial activity. 
 
Figure 7.18: Inhibition Zones exhibited by the cements compared to the mass of 
cement samples placed in the centre of the lawn of culture; OA cement (A) and 
PPA cement (B). 
 
 
Figure 8.1:  Illustrates the set-up of the set up of the calcium alginate bead 
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Figure 8.9: Graphs illustrate the degradation of the non porous orthophosphate 
brushite cements over a period of 730 days (2 years).  The graph is plotted using 
common logs to allow a clear view of the compressive strengths over this long 
period of time (n = 6).  No results were recorded for day 545 and 730, as the 
samples had degraded too far to be measured using the same conditions; most 
samples beyond days 365 remained in particulate form. 
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Chapter One 
Introduction 
Tissue engineering may be defined as the application of biological, chemical, and engineering 
principles toward the repair, restoration, or regeneration of living tissue by using biomaterials, 
cells, and growth factors alone or in combination.  Today's world of orthopaedic biomaterials 
is expanding rapidly driven by ageing demographics, product advances, an increasing number 
of sport injuries and changing patient care strategies.  Strategies to replace damaged bone 
have employed, such as stem cells, bone growth factors, gene therapy, synthetic bone fillers, 
implant coatings and various resorbable implantable materials. 
 
At present, the autograft is the gold standard in bone grafting, as it provides an appropriate 
three-dimensional structure, physiology, associated biological components and an 80–90% 
success rate (Cook et al. 1994).  Autografts, however, are not always an option as they are 
limited by the supply of available donor tissue and the threat of donor-site morbidity 
(Giannoudis et al. 2005).  Allografts and synthetic bone graft substitutes are alternative bone 
grafting methods that are also currently employed (Amendola & Stolley 2009).  While a 
certain amount of success has been achieved using these procedures, both are associated with 
drawbacks (Arrington et al. 1996).  The threat of disease transmission and the difficulty of 
preserving graft bioactivity limit the success of allograft procedures (Friedlaender et al. 
1999).  Furthermore, neither synthetic bone graft substitutes nor allografts incorporate every 
aspect of natural tissue, such as osteoblastic precursor cells and growth factors, and are 
therefore unable to match the autograft.     
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Ceramic materials that are specially developed for use as medical and dental implants are 
termed bioceramics.  They include alumina and zirconia, bioactive glasses, glass-ceramics, 
coatings and composites, hydroxyapatite and resorbable calcium phosphates, and radiotherapy 
glasses (Hench 1991).  Bioceramics can have structural functions as joint or tissue 
replacements, can be used as coatings to improve the integration of metal implants, and can 
function as resorbable lattices which provide temporary structures and a framework that can 
be replaced by the body‟s natural healing processes.   
 
The perfect material for medical applications would not only be compatible within the 
implanted site, but also have physical properties similar to those of the tissue being replaced 
or repaired. Although ceramics exhibit appropriate chemical and corrosion-resistant 
properties, they are notoriously brittle.  Researchers therefore have required ways of 
combining desirable ceramics with other materials to tailor properties such as strength and 
elasticity to meet system requirements (Williams 1979).  Composites, functionally gradient 
materials, and coatings have been studied to optimise material choices to produce solutions 
for the rapidly growing requirements in clinical applications including orthopaedics, 
otolaryngology, maxilla-facial and plastic surgery, oral surgery, periodontology, and tumour 
therapy.  Since ceramic materials exhibit such brittle properties and are difficult to fabricate 
complex shapes, a subdivision of ceramics, cements are explored to be developed and used in 
place of traditional bioceramics materials.  
 
Since one of the earliest reports of a calcium phosphate cement (CPC) formulation by Brown 
and Bhow (Brown & Chow 1985) there has been much progress in the development of CPCs. 
Hydroxyapatite (HA) cements have been used to facilitate adhesion of metal implants (Prado 
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Da Silva et al. 2001) and have also been used as bone graft replacements themselves (Barralet 
et al. 2002c;Charriere et al. 2003;Chung & Park 2007).  HA has been the core focus in the 
development of CPCs over the past decade with ceramic materials for bone and dental 
replacements.  However, in recent years other forms of CPC such as the brushite cement has 
been widely developed to meet the reported issues associated with HA cements.  Brushite 
based cements have an important advantage over HA based cements in that they are sparingly 
soluble in physiological conditions and hence can be more extensively resorbed following 
implantation.  Although work on brushite based cements means that the material can now be 
applied either as a putty or through a hypodermic needles, sets in an appropriate timeframe 
and can be inherently antibacterial, there are still several important drawbacks that mean that 
the material has not been widely taken up in the clinic.  These include: 
1. The metastability of brushite, which means that hydrolysis, may occur, resulting in 
long-term implant stability, as brushite is converted to HA. 
2. The need for precise mixing in the operating theatre.  Since material mixing and 
handling are critical to mechanical performance, deviations in the operating theatre 
may lead to an increased risk of implant failure. 
3. An unpredictable degradation rate, meaning that it is difficult to ensure appropriate 
degradation in all patients. 
4. A long-term risk of infection following implantation of the cement. 
 
This thesis presents a collection of studies that aimed to address these shortcomings by 
modifying cement chemistry (Chapter 5), separating the reactive components of the cement 
mix using microencapsulation (Chapter 6), loading antibiotics into the cement matrices 
(Chapter 7), and by incorporating macroporosity using alginate beads (Chapter 8). 
4 
 
Chapter Two 
Bone 
Bone is a specialised type of connective tissue, characterised by the presence of cells in a hard 
and dense matrix.  The matrix contains collagen, ground substance, and bone mineral.  The 
bone mineral consists of complexes of calcium phosphates in amorphous and crystalline 
fractions (Horner 2004).  The mineral components are approximately 30% amorphous 
calcium phosphate [Ca3(PO4)2] and a little less than 70% nanocrystalline hydroxyapatite 
[Ca10(PO4)6(OH)2] (McTighe et al. 1995), which strengthens the whole structure.  This 
chapter presents a concise review of the main functions of the bone, giving details of the 
structure and types of bone and their mechanical properties.  Additionally, a summary of the 
existing synthetic grafts and the current clinical needs are also outlined. 
 
2.1 Bone cells 
The bone cells primarily responsible for the bone deposition and resorption are osteoblasts 
(bone forming) and osteoclasts (bone resorbing) (Katagiri & Takahashi 2002).  Osteoclasts 
are multinucleated, giant cells derived by differentiation and fusion of haematopoietic cells of 
the monocyte macrophage lineage.  Their bone degradation function depends on the 
organization of the actin cytoskeleton forming a cavity where protons and proteases degrade 
mineral and organic matrix, respectively.  The relative activity of osteoclasts and osteoblasts 
determines how bone is remodelled (Kobayashi 2003), the biological process for the renewal 
of the bone tissue and maintenance of mechanical integrity, metabolic function and calcium 
homeostasis in healthy adults.   
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2.1.1 Osteoprogenitor 
Osteoprogenitor cells are mesenchymal stem cells that differentiate into osteoblasts and 
osteocytes (Liu et al. 2003).  They are immature progenitor cells, located in the periosteum 
and the bone marrow.  Osteoprogenitors differentiate under the influence of growth factors; in 
particular the bone morphogenetic proteins (BMPs), which stimulate the division of 
osteoprogenitors and potentially increase osteogenesis, to form osteoblasts.  
 
2.1.2 Osteoblast 
Osteoblasts are responsible for bone matrix synthesis.  They secrete a collagen rich substance 
essential for later mineralization of hydroxyapatite.  The collagen fibres are organised to form 
osteoid; spiral fibres of bone matrix.  Osteoblasts cause calcium salts to precipitate from the 
body fluids and bond with the newly formed osteoid to mineralize the bone tissue.  Alkaline 
phosphatase (ALP) is present in high concentrations in osteoblasts and is secreted during 
osteoblastic activity.  Osteoblasts have oestrogen receptors, which can promote the number of 
osteoblasts, therefore increasing collagen production (Sommerfeldt et al. 2001). 
 
2.1.3 Osteocytes 
About 90% of all cells of the human skeleton are osteocytes, which are the key in controlling 
the extracellular concentration of calcium and phosphate, and are directly stimulated by 
calcitonin and inhibited by the Parathyroid hormone (Vaananen 1996).  Osteocytes are 
derived from osteoblasts and are basically osteoblasts surrounded by the products they 
secreted.  Cytoplasmic processes of the osteocyte extend away from the cell toward other 
osteocytes in small channels called canaliculi; these enable exchange of nutrients and waste 
products to maintain the viability of the osteocyte. 
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2.1.4 Osteoclast 
Osteoclasts are formed by the fusion of cells of the monocyte-macrophage cell line.  The main 
feature of osteoclasts is their ability to resorb fully mineralized bone.  The osteoclasts secrete 
growth factors, such as RANK ligand and M-CSF (Macrophage colony-stimulating factor), 
that stimulate osteoclast differentiation from mononuclear cells.  The differentiation, 
recruitment and inhibition of osteoclasts are controlled by numerous hormonal and growth 
factors (Vaananen et al. 2000).  Osteoclasts also express acid phosphatise, carbonic 
anhydrases, and secrete protons (H+), to degrade bone minerals and extracellular matrix. 
 
Bone Remodelling 
In bone remodelling , osteoclastic resorption occurs simultaneous with osteoblastic bone 
formation (Sommerfeldt et al. 2001).  Active osteoclasts often have a fine brush-like border 
where they are in contact with the bone.  In the process of bone resorption, the ground 
substance of bone appears to become modified prior to resorption by osteoclasts.  During 
osteoclastic resorption, the bone marrow cavity is enlarged which leads to an overall 
reduction in bone tissue.  Osteoclasts attach to the tissue surface and proliferate (Vaananen 
1996).  The renewal of bone is responsible for bone strength throughout our life (Figure 2.1).  
During childhood and the beginning of adulthood, bone becomes larger, heavier and denser; 
bone formation is favoured over bone resorption.  There are several factors that can 
compromise balanced bone remodelling, such as disease, aging and injuries (O'Flaherty & 
Ellen 2000).  
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Figure 2.1: The processes of bone remodelling (Russell T.Turner & Jean D.Sibonga 2009).  
(A) Quiescent phase is when bone surface is inactive.  Neither bone resorption nor bone 
formation is occurring on this region of bone surface; (B) Resorption phase where osteoclasts 
remove a discrete packet of bone, creating a cavity, a temporary weak spot or link; (C) 
Formation phase when osteoblasts form a bone matrix, which fills in the cavity (the cement 
line defines the boundary between the newly formed bone and the surface excavated by 
osteoclasts at the end of the resorption phase (B)); (D) Quiescent phase again the inactive 
bone surface, this time after a completed remodelling cycle (the new surface may be under 
filled (1), exactly filled (2), or overfilled (3), reflecting a local decrease, no change, or 
increase in bone mass, respectively).   
 
2.2 Structure 
Bone is a composite material that exists on at least 5 hierarchical levels (Figure 2.2): whole 
bone, architecture, tissue, lamellar, and ultrastructure (Liebschner & Wettergreen 2003).  The 
macrostructure is the overall shape of the bone, i.e. the Femur; the macrostructure level can 
dimensionally measure approximately 3–750 mm and is composed of the architectural level, 
which contains the microstructure that defines the spatial distribution of the bone.  The 
8 
 
architectural level can measure from 75–200 µm in cancellous bone and 100–300 µm in 
cortical bone.  Beneath the architectural level is the tissue level, which is inherent to the actual 
material properties of bone; this level can, in the case of cancellous and cortical bone measure 
from 20–75 µm and 20–100 µm, respectively.  The lamellar level is below the tissue level and 
is composed of the sheets of collagen and minerals deposited by osteoblasts (Majeska 2001).  
At the lamellar level for both cancellous and cortical bone the typical measurements of the 
structure are between 1–20 µm.  The final level is the ultrastructural level which incorporates 
chemical and quantum interactions (van der Linden et al. 2001), which can be measure 0.06–
0.4 µm for cancellous bone and 0.06–0.6 µm for cortical bone. 
 
 
Figure 2.2: The hierarchical structure of bone (Liebschner & Wettergreen 2003). 
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2.2.1 Types of bone 
Bone is categorized into 2 types: cortical (compact) bone and cancellous (trabecular) bone.  
Although both bone types are composed of the same materials, each one contains different 
proportions of the organic and inorganic materials, degree of porosity and organization.  
Furthermore, the combination of cortical and cancellous bone varies according to the location 
in the body, which is dependent on the applied mechanical loading.  Various bone tissue types 
have different mechanical characteristics that regulate calcium phosphate levels to bear 
various combinations of the loading modes: tensile, compressive, bending and torsion (Ho 
2005).  Both cortical and cancellous bones display time dependent mechanical behaviour, as 
well as damage susceptibility during cyclic loading (Rho et al. 1998). 
 
The architecture of bone can be described in two ways: woven and lamellar.  Woven bone 
structure exists in newborns, callus, and metaphyseal regions.  It is characterised by a fast 
growth rate, is very coarse tissue with no uniform collagen orientation and may slowly grow 
into a lamellar structure.  Lamellar bone is slowly formed and highly oriented tissue.  Each 
layer of lamellar bone is embedded with differently oriented collagen.  Close to 100% of 
normal adult bone is lamellar bone (Sikavitsas et al. 2001). 
 
2.2.2 Cortical bone 
The main structures in cortical bone are the osteon, Haversian canal and interstitial lamella.  
The Haversian canal contains nerves and blood vessels that transport blood and nutrients to 
cells, and is surrounded by the cancellous bone.  Each osteon is about 20 μm in diameter and 
located less than 100 μm away from the central blood supply.  Therefore, osteons always lie 
along the Haversian canal; they may branch out and interlock with each other.  The interstitial 
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lamella consists of collagen fibres surrounded by a mineralised matrix.  The lamella is 
continuous with the osteons but is not adjacent to any haversian canal (Mohsin et al. 2006).  
Cortical bone is a dense structure with a porosity ranging between 5–10%.  It is primarily 
found in the shaft of long bones and forms the outer shell around trabecular bone at the end of 
joints and the vertebrae.  Cortical bone is roughly four times the mass of trabecular bone 
(Augat & Schorlemmer 2006) and contributes significantly to the mechanical strength of bone 
(Wachter et al. 2002).  Typically, exhibiting compressive strength of up to 200 MPa and a 
tensile strength of approximately 130 MPa (Patka et al. 1995), when tested longitudinally to 
the osteons; these values are reduced by approximately half when tested transversely to the 
long axis of the osteons (Natali & Meroi 1989). 
 
2.2.3 Cancellous bone 
Cancellous bone has a spongy or porous nature, found at the ends of all long bones and found 
within flat and irregular bones, such as the sternum, pelvis, and spine (Keaveny et al. 2001).  
Mainly composed of the interstitial lamellae with small cavities of bone cells called lacunae at 
the boundaries, and is always surrounded by cortical bone.  The microstructural trabeculae 
that make up the cancellous bone are composed of trabecular tissue material, which is a three 
dimensional interconnected open porous space, resulting in a cellular solid type of material.  
The microstructure is typically oriented so that there is a “grain” direction along which 
mechanical stiffness and strength are greatest.  This microstructural directionality gives 
cancellous bone anisotropy of mechanical properties (Choi & Goldstein 1992).  The porosity 
of cancellous bone ranges from 30–90% with pores containing bone marrow.  Cancellous 
bone is rather weaker then cortical bone, with compressive strength of approximately 1.5–50 
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MPa and tensile strength of approximately 3–20 MPa; cancellous bone has a high specific 
impact resistance and due to a higher porosity is considerably lighter (Carter & Hayes 1977).   
 
2.2.4 Comparison of cortical and cancellous bone 
The mechanical properties of human cortical bone from the tibia, femur, and humerus have 
been found to vary between individuals, although the density may remain the same (Augat & 
Schorlemmer 2006).  The cortical bone has less regional heterogeneity compared to the 
cancellous bone, therefore, the bulk mechanical properties of cortical bones are quite reliable 
even when comparing various regions of the body (van Eijden 2000).  Comparatively, the 
bulk mechanical properties of cancellous bone have a rather broad range and have shown to 
vary by a factor of 2–5 MPa from bone to bone (Rho et al. 1998).  Since the proportion of 
cortical and cancellous tissue of each bone varies with their shape and mechanical function, 
the properties of bone in each region cannot be adequately expressed in single values 
(Goldstein 1987).  The elastic moduli in the longitudinal direction were not very different 
between the various types of cortical bone (Choi et al. 1990).  The elastic moduli in the radial 
direction tend to be much lower than the longitudinal direction.  In human cancellous bone, 
mechanical properties vary significantly around the periphery and along the length (Rho et al. 
1995).  However, there is no difference in the mechanical properties of the humerus, the 
proximal tibia, and the lumbar vertebrae (van Eijden 2000). 
 
2.3 Function 
Bone is an incredibly specialised tissue, having several specialised functions.  Many of the 
key functions are discussed in detail in this section.  The function of the bone is to provide a 
framework for the body.  Apart from the primary function of providing mechanical support 
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for movement, the bone also has the marrow where the blood cells are synthesized.  Another 
key function is maintaining calcium homeostasis in the body and also enabling storage of 
minerals like calcium, phosphorus, and many more.  Additionally, bone remodelling is an 
essential function, this renews and maintains bone health and is involved in growth and 
development.   
 
2.3.1 Support and Protection  
The skeleton acts as a framework for the body; this scaffold-like structure allows the muscles 
to attach to them for support.  This frame defines the basic shape of the body.  The human 
body has many vital organs, which require a certain level of protection from damage by daily 
trauma.  Bone provides protection; the skull protects the brain; the ribs shield the heart and 
lungs; the vertebrae protect the spinal cord and the pelvis provides protection to portions of 
the digestive tract (Martini 2001). 
 
2.3.2 Mineral storage 
Bone serves as a vast reservoir of calcium; this aids in the homeostasis of bodily fluids.  
Stimulating net resorption of bone mineral releases calcium and phosphate into blood and 
suppressing this effect allows calcium to be deposited in bone.  Calcitonin is a hormone that 
functions to reduce blood calcium levels (Talmage et al. 1980).  It is secreted in response to 
hypercalcaemia and effects include; (1) suppressed renal tubular and re-absorption of calcium, 
which increases excretion of calcium into urine; and (2) inhibits osteoclastic activity (bone 
resorption), which would minimise fluxes of calcium from bone into blood.  To counteract 
this effect when the calcium concentration of bodily fluid is reduced, the release of 
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parathyroid hormone (PTH) causes an increase in osteoclastic activity resulting in bone 
resorption and an increase in the calcium levels in bodily fluids (Kurbel et al. 2003). 
 
2.3.3 Production of blood cells 
Bone marrow is the flexible tissue found in the hollow interior of bones; there are two types 
of bone marrow.  Red marrow consists of connective tissue (stroma) in which exist 
haemopoetic stem cells and produces the components of blood such as, red blood cells, 
platelets and most white blood cells (Moghimi 1995).  This type of marrow is found mainly in 
the flat bones, such as the hip bone, sturnum, skull, ribs, vertebrae and shoulder blades, and in 
the cancellous material at the epiphyseal ends of the long bones such as the femur and 
humerus.  At birth, all bone marrow is red, with age it isconverted to yellow marrow, yet half 
of adult bone marrow remains as red marrow (Gurevitch et al. 2007).  Yellow marrow 
consists of connective tissue containing fat cells and is used as an energy store, which is 
found in the hollow interior of the middle portion of long bones (Petrakis 1966). 
 
2.3.4 Movement 
Bones are connected by joints, attached to muscles via tendons which allow complex 
movements.  As the muscles contract and relax, the complex movements are developed and 
the body is able to control each movement precisely. 
 
2.4 Factors influencing the mechanical properties of bone 
Bone‟s mechanical properties depend on the structure and microstructure of the bone.  Bone 
has a variety of features that contribute to its resistance to fracture, such as the structural 
properties of bone which include; thickness and cross-sectional area, but microstructural 
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properties such as porosity, crystallinity or microcracks also contribute to bone‟s mechanical 
integrity (Augat & Schorlemmer 2006).  Bone is a damageable, viscoelastic composite and 
most of all a living material capable of self-repair and therefore exhibits a complex range of 
mechanical properties.  Variables such as race, age, gender, location of the bone and the level 
of activity of the patient, all lead to a variation in the mechanical properties of bone (Strube et 
al. 2008).   
 
2.4.1 Age 
Mineralisation of bone also has a marked effect on the mechanical properties of bone with 
age.  In young bone the hydroxyapatite to collagen ratio of the bone increases so 
strengthening the bone; the hydroxyapatite to collagen ratio continues increasing until bone is 
hypermineralised (Zioupos et al. 2000).  However, once hypermineralisation is reached the 
bone weakens due to increase in mature crystals which are more brittle.  The bone turnover 
rate is significantly affected with ageing which is about 5% per decade for individuals 30 
years of age and is about 25% per decade for individuals 60 years of age (O'Flaherty & Ellen 
2000).  A high bone turnover rate can lead to a reduction of bone strength and increased 
fracture risk. 
 
2.4.2 Gender 
In post-menopausal women, as their age increases their bone density decreases at a faster rate 
than other individuals, resulting in osteoporosis and an increase of fracture risk.  A study was 
carried out on cortical thickness which demonstrated that thickness is similar in males and 
females because endocortical apposition in females contributes to final cortical thickness, 
even though earlier completion of longitudinal growth and earlier inhibition of periosteal 
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apposition produces a smaller bone in females (Seeman 2008).  A study on children and 
adolescents showed that in individuals younger than 17 years, the rate of bone mineral density 
accumulation in the post anterior spine is more rapid in females than in males, whereas in 
individuals older than 19 years, the reverse was found.  Additionally, in children younger than 
14 years, bone mineral density measurements taken from the lateral spine, the neck of the 
femur, and the total hip, correlated with age similarly in both genders (Wu et al. 2005). 
 
2.4.3 Diet 
The food we consume has a great affect on the bone density and therefore the strength of the 
bones.  The lack of calcium and vitamins (particularly D3) result in a low bone mineral 
density due to the inability of the osteoblast to cause mineralisation.  This leads to the 
reduction in the hydroxyapatite to collagen ratio, consequently reducing the strength of bone. 
 
2.4.4 Loading 
Loading is required for bone integrity; the absence of continual loading results in resorption 
by cortical thinning.  Hypertrophy is a result of overloading, resulting in a deposition of the 
mineral phase on the periosteal surface.  Several authors conducted animal studies to 
demonstrate the effect of loading (Kodama et al. 1999;Yingling et al. 2001); generally 
concluding that cyclic loading has a significant effect on the bone mineral density.  Another 
study on the effects of loading demonstrated that the cross sectional area of professional 
tennis players arms had increased by over 39% when comparing the playing arm with the 
non-playing arm (Jones et al. 1977).  A more recent animal study demonstrated exercised 
sheep with elevated estradiol levels (hormone derived from cholesterol; represents oestrogen 
in humans).  The in vivo variation in
 
estradiol level alters osteoblast sensitivity to exercise 
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induced
 
sheep, affecting cortical bone responses to mechanical loading (Devlin & Lieberman 
2007).  Exercised sheep exhibited higher level of estradiol (levels increased by; 27% in femur, 
6% in tibia and 14% in metatarsal). 
 
2.5 The need for bone replacement  
An imbalance in formation and resorption of bone may be involved in bone rescue after injury 
or disease.  However, bone has a limited capacity to recover and the missing bone must often 
be supplied as a biomaterial (Beaman et al. 2006).  Interactions between the bone replacement 
material and bone cells determines the success or failure of the repair process (Logeart-
Avramoglou et al. 2005).   
 
2.5.1 Diseases and Infections  
Many diseases can occur leading to the removal or replacement of the natural bone; this 
section will outline some of these common diseases, infections and congenital disorders.   
 
Osteoporosis 
Osteoporosis is a common skeletal disease that may cause severe bone loss and may result in 
fractures of the vertebra, hip and mandible; most common among the elderly.  In osteoporosis 
the bone mineral density is reduced, bone microarchitecture is disrupted, and the amount and 
variety of non-collagenous proteins in bone is altered (Rico 1997).  The underlying 
mechanism in all cases of osteoporosis is an imbalance between bone resorption and 
formation.  The three main mechanisms by which osteoporosis develop are; an inadequate 
peak bone mass (the skeleton develops insufficient mass and strength during growth), 
excessive bone resorption and inadequate formation of new bone during remodelling (Raisz 
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2005).  The consequence of these three mechanisms underlies the development of fragile bone 
tissue.  Hormonal factors strongly determine the rate of bone resorption; lack of oestrogen 
increases bone resorption as well as decreasing the deposition of new bone that normally 
takes place in load-bearing bones (Lee et al. 2003).  In addition to oestrogen, calcium 
metabolism plays a significant role in bone turnover, and deficiency of calcium and vitamin D 
leads to impaired bone deposition.  In addition, the parathyroid glands react to low calcium 
levels by secreting Parathyroid Hormone, which increases bone resorption to ensure sufficient 
calcium in the blood (Raisz 2005;Kurbel et al. 2003).  Osteoporosis is most common in 
women after menopause (Riggs et al. 1982;Raisz 2005), but may also develop in men, and in 
anyone with particular hormonal disorders and other chronic diseases or as a result of 
medications.  Osteoporosis occurs in 20% of people over the age of 70 years and in 16% of 
postmenopausal women (Dickenson et al. 1981).  
 
Osteomyelitis 
Osteomyelitis is a bacterial infection of bone and bone marrow in which the resulting 
inflammation can lead to a reduction of blood supply to the bone.  The infection may be 
localized or it may spread through the periosteum, cortex, marrow, and cancellous tissue and 
tends to occur near the joints of the limbs (Lew & Waldvogel 2004b).  The cause of infection 
may be due to an open injury to the bone, e.g. open fracture with bone ends piercing the skin.  
A minor trauma can lead to a blood clot around the bone, cutting off the blood supply to that 
area. Infection, such as urinary tract infections may lead to bacteria in the bloodstream, which 
can be deposited in a localized area causing bacterial site growth due to the destruction of 
bone.  The infection can be acute, sudden, and rapidly worsening; or can be chronic, over a 
long period of time, and not easily resolved (Ratner 1996).  Bacteria or fungus is often 
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responsible for Osteomyelitis causing pus to be produced within the infected bone, which may 
result in an abscess, depriving the bone of its blood supply (Ellis & O'Brien 1974).  The 
organisms involved are dependent on how the infection was caused, for example, with 
haematogenous osteomyelitis the infectious agents include; S. aureus, Enterobacteriacae 
organisms, group A and B Streptococcus species, and H. influenza (Lew & Waldvogel 
2004b).  In chronic infections, the site of infection may be surgically treated by the removal of 
dead bone tissue.  Spaces left by the removed bone tissue are filled with bone graft or by 
packing material to promote the growth of new bone tissue. 
 
2.5.2 Congenital disorders 
Cleft lip (cheiloschisis) and cleft palate (palatoschisis) are the two main types of clefting 
congenital deformity caused by abnormal facial development during gestation.  A cleft is a 
split or opening in the uvula; it is the failure of fusion of the body's natural structures that 
form before birth.  A cleft lip or palate can be successfully treated with surgery soon after 
birth.  The hole in the roof of the mouth caused by a cleft connects the mouth directly to the 
nasal cavity.  Cleft lips or palates occur in somewhere between 1 in 600–800 births worldwide 
(Yavuzer & Jackson 2001).  Possible treatment options include speech therapy, prosthetics, 
augmentation of the posterior pharyngeal wall, lengthening of the palate, and surgical 
procedures (Sloan 2000). 
 
2.5.3 Trauma 
Traumas are severe injuries which cause excessive damage to bodily tissues.  In the case of 
severe trauma bone grafts are used to prevent deformity and restore function, as bone can be 
broken or damaged which often needs repairing or removal.  Motor accidents are the single 
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most common source of bone trauma, small numbers of falls and personal accidents also 
account for bone trauma; however these are more common in older or osteoporotic patients.  
Orthopaedic trauma surgery requires the regular use of bone grafts to help promote 
appropriate healing of musculoskeletal injuries (De Long et al. 2007).   
 
2.6 Bone grafting 
Bone is the second most common replaced tissue in the body, after blood.  On average 
annually, there are over 2.2 million bone graft procedures worldwide (Lewandrowski et al. 
2000).  Bone grafts are used to provide structural stability and to stimulate osteogenesis and 
bone healing in fractures (ADA Division of Science 2002).  Bone grafting materials are 
osteoconductive or osteoinductive (Giannoudis et al. 2005).  In osteoconduction, the graft acts 
as a scaffold for the deposition of new bone, facilitating the formation of blood vessels and 
Haversian systems into the bone scaffold.  In osteoinduction, the graft actively stimulates the 
stem cells from the surrounding tissues to differentiate into osteoblasts to form new bone 
(Rose & Rosenberg 2001).  Osteointegration is also another essential element of bone 
regeneration; this is the extent to which the host bone bonds to the grafting material. 
 
There are a large number of commercially available bone graft alternatives for orthopaedic 
applications.  These vary in composition, mechanism of action and characteristics.  Table 2.1 
demonstrates some of the types of grafts currently in use.  However, only 10% of the 
procedures use synthetic materials because the approved synthetic grafts are considered to be 
inferior to the use of autograft or allograft (Lewandrowski et al. 2000).  Conversely, as more 
research seeks for grafting materials that can provide better osteogenesis, osteoinduction and 
osteoconduction characteristics, combined with the shortage in biological grafts synthetic 
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materials for bone replacements expand in all fields of orthopaedics, neurosurgery and 
dentistry (Cook et al. 1995).  
 
Table 2.1: Summary of the currently available osteoconductive scaffolds (Giannoudis et al. 
2005). 
 
 
 
2.6.1 Biological materials 
Natural bone tissue may be crushed into powder and placed around a fracture or a fusion site.  
One of the advantages of using natural materials is that they do not present the problem of 
toxicity and may carry specific protein binding sites to assist bone healing and integration.  
An ideal bone graft material should possess four elements: (1) osteogenic cells that allow the 
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growth of the various stages of bone regeneration, (2) an osteoconductive matrix that provides 
a scaffold for bone ingrowth, (3) osteoinductive factors that can stimulate osteoprogenitor 
cells to differentiate into osteoblasts, and (4) structural integrity that can sustain the 
mechanical loading in situ.  There are three commonly used biological bone graft materials: 
autograft, allograft and xenograft (Beaman et al. 2006). 
 
Autograft 
The use of autologous bone is the “gold standard” for augmentation of bone healing and 
repair.  It is the process of taking bone from the patients‟s own body; it can be classified as 
either vascularised or nonvascularised (Schimandle & Boden 1997a).  Currently autografts are 
the most successful graft material available; advantages include the capability of immediate 
bone formation, ease of incorporation and lack of risk of disease transmission.  One of the 
greatest advantages with these grafts means that the vascularised grafts retain their existing 
network of nutrient blood vessels which allow immediate adaptation of the bone graft with the 
implant by providing an instant and intact blood supply.  However, autograft harvesting is 
associated with a complication rate of 8.5–20% including haematoma formation, blood loss, 
nerve injury, hernia formation, infection, arterial injury, urethral injury, fracture, pelvic 
instability, cosmetic defects, tumour transplantation, and sometimes chronic pain at the donor 
site (Giannoudis et al. 2005).  Autografts are not viable for patients with severe bone damage 
that require a large amount of bone graft material.    Another major drawback to this form of 
transplant is that the surgical harvesting of vascularised autograft is very time consuming, 
extremely invasive and can create significant morbidity at the donor site (Vail & Urbaniak 
1996). 
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Allograft 
Allograft bone is transplanted from one person to another and is most commonly used as an 
alternative for autograft bone in spinal fusion surgery (Schimandle & Boden 1997a).  The use 
of allograft bone has been expanding in the last decade as a result of improved methods, 
preparation and storage, technical advances in surgical methods, and the need to avoid donor 
site complications associated with using autograft (Giannoudis et al. 2005).  While allografts 
are versatile and widely used, especially in spinal surgeries, concerns exist regarding their 
ability to consistently achieve a successful fusion and the possibility of infectious disease 
transmission, for example, HIV, Hep B and Hep C (Arrington et al. 1996).  Allograft has a 
high infection rate up to 10–12% and more than 80% of infected allografts are associated with 
clinical failure (Vaccaro et al. 2005).  Allograft is prepared in fresh, frozen or freeze-dried 
forms, cortical or cancellous.  Fresh allografts are not often used as they might create an 
immune response or transmit diseases (Friedlaender et al. 1999).  On the other hand frozen 
and freeze-dried allograft are more osteoconductive but are considered to have weak 
osteoinductive capabilities compared with fresh allograft. 
 
Comparison of autografts and allografts 
There are several advantages and disadvantages of both autografts and allografts; Table 2.2 
illustrates these.  Although 90% of all graft materials used for the replacement of bone tissue 
is autografts or allografts, these replacement materials posses many disadvantages.  This is 
one of the many stimuli for the research in the development of synthetic bone replacement 
materials to address and overcome the downfalls of auto/allograft bone exhibit.  
 
 
23 
 
Table 2.2: Summary of advantages and disadvantages of both autograft and allograft 
reconstruction (Amendola & Stolley 2009). 
 
 
2.6.2 Synthetic materials 
Considerable advances have been made with synthetic alternative materials for bone grafts 
over the last 30 years.  Until recently, synthetics were not in favour compared to autografts 
and allografts.  Synthetic bone grafts at most possess only two of the four characteristics of an 
ideal bone graft material (osteointegration, osteoconduction).  Ideally synthetic bone graft 
substitutes should be compatible within the host by showing minimal fibrotic reaction, 
undergo remodelling and support new bone formation.  From a mechanical point of view 
synthetic bone substitutes should have similar strength to that of the bone being replaced.  
This needs to be matched with a similar modulus of elasticity to that of bone in an attempt to 
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prevent stress shielding as well as maintaining adequate toughness to prevent fatigue fracture 
under cyclic loading.  Research continues to seek suitable synthetic biodegradable polymers, 
ceramics, cements and metals to replace the “gold standard” autograft material.  The common 
materials of interest are discussed here; mainly polymers and ceramics. 
 
Table 2.3: Mechanical properties of the synthetic graft materials compared to bone (Moore et 
al.2001). 
 
 
Polymethylmethacrylate (PMMA) 
PMMA is a commonly used non-degradable polymer in medical devices.  It is a self curing 
material through the polymerisation of methylmethacrylate within a short time, which consists 
of repeating homologous chains of methylmethacrylate monomer.  Through the chemical 
manipulation of these properties and modification of the polymer, controlled behaviour 
variations of this material can be achieved.  PMMA is typically used as a filler material (bone 
cement) for joint replacement surgical procedures.  It was originally developed for making 
25 
 
dentures; then in 1950s it was also found to be suitable for stabilizing prostheses, and is still 
used in over 80% of hip and over 90% of knee replacements (Ramakrishna et al. 2001).  
 
Medical grade PMMA preparation necessitates manufacturing conditions limited to the 
clinical situation, which includes lower curing temperatures and pressurization more suitable 
to in vivo applications.  When PMMA bone cement cures in situ, volumetric shrinkage of 
PMMA due to density changes has been calculated and experimentally verified to be between 
5–7% depending on the type of cement and mixing method (Roques et al. 2004).  It was also 
noted that shrinkage of the polymerising cement in vivo, might result in the development of 
porosity, both at the bone-cement and cement-implant in cemented hip replacements (Gilbert  
et al. 2000).  The stresses from the shrinkage of PMMA cement may lead to reduced fatigue 
life of the implant. 
 
Biodegradable polymers 
Biodegradable polymers are materials that will eventually be resorbed and metabolised after 
being introduced into a living organism.  No additional surgery is required to remove the 
implanted material.  Biodegradable polymers are used as temporary scaffolds for 
biomechanical and biochemical support.  As new tissue begins to grow within the 
implantation site, these materials are intended to degrade and leave behind the regenerated 
tissue.   
 
Poly(DL-lactide-co-glycolide) (PLGA) is a biodegradable polymer.  This polymer consists of 
two monomers: polyglycolide (PGA) and poly-lactide (PLA) from the poly(s-hydroxyl acids).  
These polymers have been investigated as porous scaffolds for replacement and regeneration 
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of a variety of tissues and fixation devices for orthopaedic applications (Seal et al. 
2001;Soriano & Evora 2000;Yao et al. 2005).  PLA is more hydrophobic and less crystalline 
than PGA and degrades with a lower degradation rate.  The degradation rate of PLGA can 
thus be easily adjusted by altering the ratio of the two monomers in the formulation.  In 
orthopaedic applications the co-polymer can be exploited to create materials that degrade in 
concert with bone in-growth.  Additionally, porous PLGA is known to support osteoblast 
migration and proliferation, a necessity for bone tissue regeneration (Soriano & Evora 
2000;Wang 2003).  However, such polymers on their own are too weak to be used in load 
bearing situations.   
 
Ceramics  
Research in the field of ceramic materials has been widely increasing in the past 50 years for 
various medical applications, such as hip or knee prosthesis, cardiac valves and dental 
implants.  The bioactive property of ceramic materials has driven most interest in the field of 
hard tissue replacement.  Ceramics provide fixation by osteointegration of the local tissue into 
the implant pores, or onto the implant surface (Hench 1998b;Hench 1998a).   
 
Commercially common ceramics include; alumina and zirconia, which demonstrate inert 
nature, which was the driving force for the popularity of their use in biomaterial applications.  
Alumina increased in popularity due to its loading bearing properties; clinically used as hip 
prostheses and dental implants because of its combination of excellent corrosion resistance, 
good in vivo compatibility, high wear resistance and high strength (Hench 1991). 
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Bioactive glasses and glass-ceramics demonstrate bioactive properties, which mean that they 
are able to bond with bone tissue; ceramics vary in bioactivity, for example some materials 
are able to bone to both soft and hard tissue.  The first bioactive glasses were composed of 
SiO2, Na2O, CaO and P2O5 (reported by Hench in 1970‟s).  Upon implantation the surface is 
modified to form a biologically active hydroxycarbonate apatite (HCA) layer, providing a 
bonding interface with the tissue (Hench 1991); this bonding present adhesion to the extent 
that resists considerable mechanical forces.    
 
A number of biodegradable osteoconductive calcium phosphate ceramic bone graft substitutes 
have received attention as alternatives to autogenous bone but have been used solely as 
osteoconductive bone graft matrices.  Ceramics have the advantage of being compatible with 
the new bone remodelling process required to attain optimal mechanical strength.  A non-
resorbable graft material may hinder remodelling and prolong the strength deficiency of new 
bone, as well as leave permanent stress risers in the fusion mass (Ohura et al. 1996).  Most 
calcium phosphate ceramics used in spinal surgeries are synthetic and are composed of 
hydroxyapatite (Cal0(PO4)6(OH)2; HA), tri-calcium phosphate (Ca3(PO4)2; TCP), or a 
combination of the two.  These biomaterials are produced commercially as porous or non-
porous implants and granular particles with pores and are created with the use of a high-
temperature process called sintering along with high-pressure compaction techniques.  
Calcium phosphate ceramics and their clinical applications are discussed in more detail in 
chapter 3. 
 
For synthetic implants to function in vivo, they must have certain properties: (1) compatibility 
with surrounding tissues, (2) chemical stability in body fluids, (3) compatibility of mechanical 
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and physical properties, (4) ability to be fabricated into functional shapes, (5) ability to 
withstand the sterilisation process, (6) reasonable cost of manufacturing, and (7) reliable 
quality control.  Calcium phosphate ceramics exhibit these properties (Buser et al. 
1991;Z.Schwartz et al. 1996) and have been used successfully as bone graft substitutes in 
dentistry and maxillofacial surgery, in both animals and humans (Klawitter et al. 1977;Lee et 
al. 1976;Nishimura et al. 1993;Schimandle & Boden 1997b;Vaughan 1996).  
 
2.6.3 Ideal graft material properties 
Ideally, a newly designed bone graft substitute should act as bone filling material that initially 
provides space filling with dimensional stability and appropriate porosity in a bone defect.  
The material should then provide an osteoconductive network that degrades at a rate 
appropriate to bone recovery.  Two major concerns in the development of biomaterials are: 
(1) the material must not impinge on its host (the surrounding biological systems) and (2) in 
return, the material must not be affected adversely by its host.  It is therefore essential to have 
a good understanding of biological systems prior to developing new biomaterials.  
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Chapter Three 
Calcium Phosphate Ceramics 
Calcium phosphate is the name given to a family of minerals containing calcium ions (Ca
2+
) 
together with orthophosphates (PO4
3-
), metaphosphates or pyrophosphates (P2O7
4-
) and 
occasionally hydrogen or hydroxide ions.  The bioactive property of ceramic materials has 
received much attention in the field of hard tissue replacement.  Ceramics provide fixation by 
biological in-growth of the local tissue into the implant pores, or onto the implant surface a 
process known as biological fixation (Hench 1998b;Hench 1998a)  through the formation of a 
biologically active hydroxycarbonate apatite layer on their surfaces in vivo. 
 
This chapter presents a review of the calcium phosphate ceramics used for medical 
applications and also reviews current and future clinical applications, as well as focusing on 
the drawbacks of such calcium phosphate based ceramic materials for the use of bone 
replacement applications. 
 
3.1 Characteristics of calcium phosphate ceramics  
The calcium phosphate (CP) ceramics are formed by a process called sintering.  This is a 
process in which high temperatures (1100-1300 °C), and pressures are used to consolidate 
calcium phosphate salts into a monolith.  Many calcium phosphates can be formed by 
sintering precipitated poorly crystalline apatites in highly controlled conditions.  The 
stoichiometry of the precipitate and the sintering conditions enable some control over the final 
calcium phosphate formed.  For example, pure HA is formed by using apatite with a Ca/P 
ratio of 1.7; whereas TCP is formed by using apatite with a Ca/P ratio of 1.5.  When apatites 
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with varying Ca/P ratios are sintered, different amounts of HA and TCP are formed in the 
final ceramic, resulting in biphasic calcium phosphates (BCPs).  Another factor that is 
determined by the sintering parameters is the residual microporosity (Horner 2004).   
 
Table 3.1: Physical properties of various phases of calcium phosphate bioceramics (Groot & 
Wolke 1990;Billottee 2002). 
 
 
CP ceramics are also resistant to microbial attack, pH changes and solvent conditions.  They 
exist in different phases depending on temperature, partial pressure of water and the presence 
of impurities (Groot & Wolke 1990) and (Hench 1998a).  HA, β-TCP, α-TCP, BCP (Wong et 
al. 2002), monocalcium phosphate monohydrate (MCPM) and unsintered apatite are different 
forms of commercially available calcium phosphates currently used in the biomedical 
industry.  Table 3.1 summarises the physical properties of various forms of calcium 
phosphates currently used in the biomedical industry.  Different phases are used in different 
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applications depending upon whether a resorbable or bioactive material is desired (Billottee 
2002).  HA is the ideal phase for application inside human body because of its excellent 
stability above pH 4.3, human blood pH being 7.3.  Table 3.2 presents solubility and pH 
stability of different forms of calcium phosphates in aqueous solution (Guo & Li 2004). 
 
Table 3.2: Solubility & pH stability of different calcium phosphates phases (Guo & Li 2004). 
 
 
Crystallization of various salts of calcium phosphates, like HA and β-TCP depends on; Ca/P 
ratio, presence of water and impurities, and temperature.  For example, in a wet environment 
and at a lower temperature (< 900 °C), the formation of HA is most likely to happen, but in a 
dry atmosphere and at a higher temperature, β-TCP is more likely to form. 
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3.1.1 Structure 
The crystalline structure of sintered calcium phosphate ceramics can be classified as 
microcrystalline or macrocrystalline.  Microcrystalline structures have a reduced space 
arrangement, whereas macrocrystalline materials have a well-ordered crystal structure.  The 
diffraction pattern of the ceramics, as determined by x-ray diffraction, can be compared to 
natural bone, which has a nanocrystalline structure.  The comparison of the diffraction 
patterns provides insight into the resemblance of the crystalline structure of a calcium 
phosphate to natural bone. 
 
3.1.2 Porosity 
Dense and porous ceramics are produced by different sintering techniques.  Dense ceramics 
are produced by compaction under high pressure, resulting in a structure called a green body, 
and is sintered after the compaction process.  Porous ceramics are produced by using 
appropriate-sized naphthalene particles, incorporated in apatite.  After compaction under high 
pressure, removal of naphthalene is accomplished by sublimation which leaves a macroporous 
green body.  The integrity of this macroporous green body is maintained through the sintering 
step.  Another method of producing porous ceramics relies on the decomposition of hydrogen 
peroxide to generate a pore-filled structure (Jarcho 1981).  The porosity of ceramic materials 
enables mesenchymal cell migration, adhesion, proliferation and differentiation into 
osteoblasts within their pores.  This unique structure constitutes their osteoconductive 
characteristics (Spivak & Hasharoni 2001). 
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3.1.3 Solubility 
CP ceramics can dissolve in basic, neutral, or acid solutions, depending on their chemical 
composition.  Particularly in acidic environments CP ceramics dissolve rapidly.  Important for 
the dissolution process is the Ca/P ratio of the ceramic used.  TCP (Ca/P <1.67) dissolves 12.3 
times faster than HA (Ca/P = 1.7) in an acidic medium and 22.3 times faster than HA in a 
basic medium (Hyakuna et al. 2007).  Other properties of the biomaterial, i.e., porosity, 
crystallinity, and impurities of the biomaterial can influence this process (Horner 2004). 
 
The dissolution process results in an increase of the extracellular concentrations of calcium 
((Ca
2+
)e) and phosphate ((PO4
3-
)e). The high (Ca
2+
)e and (PO4
3-
)e results in the precipitation of 
apatites on a substrate ceramic, forming a carbonate-apatite-crystal layer.  The very strong 
interface between the material and bone is believed to be influenced by this crystal layer 
(Horner 2004).  HA has a low dissolution rate which results in almost direct bonding with 
bone and tissue components.  When degradation is extensive, as in the case of β-TCP, the 
dissolution/recrystallization layer is correspondingly wide (Bagambisa et al.1993).  
 
3.2 Hydroxyapatite  
Hydroxyapatite is a naturally occurring form of calcium apatite with the formula 
Ca5(PO4)3(OH), but is usually written Ca10(PO4)6(OH)2 to denote that the crystal unit cell 
comprises two molecules.  It is the main mineral component of bone.  Carbonated-calcium 
deficient hydroxyapatite is the main mineral of which dental enamel and dentin are 
comprised. 
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Highly crystallized HA tends to be stable in vivo and is resorbed at a very slow rate of 5% per 
year via osteoclast activity (Muralithran & Ramesh 2000).  But more soluble forms of HA can 
be produced by reducing crystal size and adding impurities (Ducheyne & Qiu 1999) that 
would reduce its mechanical properties.  HA is generally observed to be non-bioresorbable 
and therefore suitable for long-term surgical procedures.  High porosity HA provides better 
chemical bonding at the implant-tissue interface and allows biological bonding through in-
growth of the host tissues into the implant pores (Ducheyne & Qiu 1999;Ducheyne et al. 
1978).  However, high porosity can give rise to poor mechanical properties.  Also HA is 
generally very brittle and hard, leading to difficulties in reshaping and handling during 
surgical operations (Cao & Hench 1996).   
 
Stoichiometric synthetic HA (Ca10(PO4)6(OH)2), with a Ca/P atomic ratio of 1.67, was 
introduced as a bone-graft substitute because its formula is similar to that of the inorganic 
mineral phase of bone.  Biological HA is calcium deficient and a carbonated apatite (Elliot 
1994).  The bonding mechanism of HA to bone, seems to be due to the attachment at the 
surface of the HA of osteogenically competent cells which differentiate into osteoblasts.  A 
cellular bone matrix is then formed at the surface of the HA.  An amorphous area is present 
between the surface and the bone tissue containing thin apatite crystals.  As maturation 
occurs, this bonding zone shrinks and HA becomes attached to bone through a thin epitaxial 
layer, resulting in a strong interface with no layer of fibrous tissue interposed between the 
bone and HA (Hamadouche & Sedel 2000).  Bone formation grows from the surface of the 
HA towards the centre of the pores (Hench & Wilson 1993). 
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Many researchers have observed that the mechanical strength and fracture toughness of HA 
ceramics can be improved by the use of different sintering techniques.  These include; 
addition of a low melting secondary phase to achieve liquid phase sintering for better 
densification (Lopes et al. 1998) and (Santos et al. 1996); incorporation of sintering additives 
to enhance densification through grain boundary strengthening (Georgiou & Knowles 2001) 
and (Kalita et al. 2002); and use of nano-scale ceramic powders for better densification 
contributed by large surface area to volume ratios of nano-size powders.  It is believed that 
nano-scale HA has the potential to revolutionize the field of biomedical science from bone 
regeneration to drug delivery.  During the past 15 years, much attention has been given to 
nano-structured HA CP ceramic, with major research emphases of production of nano-scale 
powders to improve the mechanical as well as biological properties (Driessens et al. 2002). 
 
Synthetic HA is limited in its use as a biomaterial, primarily due to its low load bearing 
capacity which can be illustrated by the relatively poor mechanical properties compared with 
bone (Rey & Freche 1991).  However, improvements of its mechanical properties have been 
made with the inclusion of soluble phosphate based glasses (P2O5–CaO–Na2O) (Hench & 
Wilson 1993).  Phosphate glasses, when incorporated into HA, melt at a lower temperature 
compared with HA and can act to increase density by enhancing the sintering mechanisms 
which greatly enhances the mechanical properties.  Furthermore, decomposition of HA into 
secondary phases, α- and β-TCP, can occur.  This is related to the compositional effects, in 
particular the Ca/P ratio (Hench & Wilson 1993;Lopes et al. 1998).  It can also be seen as a 
function of sintering temperature (Rey & Freche 1991).  
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The main disadvantages which have limited the clinical application of HA as a bone graft 
substitute are related to the brittle nature and poor tensile strength of the material.  The 
existence of porosity in ceramics considerably affects the mechanical properties (Xu et al. 
2001).  The incorporation of glass in HA acts as a sintering aid, which enhances densification, 
and as a result reduces porosity.  This occurs through a liquid phase sintering mechanism, 
which accelerates inter-particulate diffusion and bonding, thus causing elimination of porosity 
and shrinkage (Santos et al.1996).  However, in this system, it is further complicated by the 
occurrence of decomposition and phase changes that can also have a detrimental or beneficial 
effect on the mechanical properties.  Ultimately, both porosity and phase decomposition are 
influencing factors in the outcome of the mechanical properties. 
 
Santos et al. (1996) concluded that HA undergoes considerable elimination of porosity during 
sintering, predominantly between 1200 °C and 1250 °C.  However, the mechanical properties 
are still relatively poor.  The addition of a glass as a sintering aid significantly improves the 
flexural bending strength.  The majority of the enhancement comes from the decomposition of 
HA to β-TCP with an associated volume change, helping to improve the mechanical 
properties.  At higher firing temperatures, the β-TCP inverts to the high temperature α-TCP 
form.  A relatively small amount of α-TCP can be sustained in the composites.  However, 
large percentages of glass can promote formation of significant amounts of α-TCP with a 
resultant decrease in flexural bend strength. 
 
3.3 TCP  
Tri-calcium phosphate (TCP) is thermodynamically stable only at elevated temperatures 
(1000–1500 °C) (Elliot 1994).  Gibson proved β-TCP to be resorbable in vivo with new bone 
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growth replacing the implanted TCP (Gibson et al. 2000).  Generally β-TCP is resorbed 
within 6 weeks after implantation (Spivak & Hasharoni 2001).  β-TCP and α-TCP are the two 
forms of TCP that are known to exist, β-TCP transforms to α-TCP at around 1200 °C; the 
later phase is stable in the range of 700–1200 °C (Groot & Wolke 1990).  However, α-TCP 
has received little importance in the biomedical field.  The disadvantage for using α-TCP is its 
rapid resorption rate, which limits its usage as a biomaterial (Metsger et al.1999). 
 
TCP would form apatite layer in body environment and has been used for bone repair in the 
form of ceramic blocks or granules.  It is a weak bioceramic and thus cannot be used on its 
own as major load-bearing implants in the human body. 
 
3.3.1 β–TCP 
β-TCP, is a bioresorbable CP ceramic and is a promising material in the field of biomedical 
applications such as orthopaedics.  It has also been observed to have significant biological 
affinity and activity and responds very well to the physiological environments.  Because of its 
slow degradation characteristic, the porous β-TCP is regarded as an ideal material for bone 
substitutes that should degrade by advancing bone growth (Hench & Wilson 1993).  These 
factors give β-TCP an advantage over other biomedical materials when it comes to 
resorbability and replacement of the implanted TCP in vivo by the new bone tissue (Gibson et 
al. 2000).  Since it is well tolerated when implanted into bone β-TCP has great potential to act 
as a scaffold allowing bone regeneration and growth.  X-ray diffraction patterns reveal that β-
TCP has a pure hexagonal crystal structure.  It is reported that the resorbability of β-TCP in 
vivo might be strongly related to the characterization and stability of the β-TCP structure 
(Okazaki & Sato 1990).  
38 
 
 
A number of synthesis methods have been used to produce β-TCP powders.  The 
conventional methods include solid-state process (Bigi et al. 1997) and wet-chemical method 
(Liou & Chen 2002).  The wet-chemical method gives Ca-deficient apatite 
(Ca9(HPO4)(PO4)5(OH), CDHA) with the same molar ratio of Ca/P as that of TCP.  It needs 
to be calcined above 700–800 °C to transform into β-TCP as shown by the following reaction: 
Ca9(HPO4)(PO4)5(OH)→3Ca3(PO4)2 + H2O               (equation 3.1) 
 
3.3.2 α–TCP 
α-TCP has the same composition as β-TCP but is significantly more soluble (-logKsp for α-
TCP = 25.5 compared to β-TCP = 29.5 in distilled water (Elliot 1994)).  α-TCP is metastable 
at normal physiological temperatures (Jillavenkatesa & Condrate 1998), releasing almost 10 
times more calcium than β-TCP under neutral pH conditions (Karlinsey et al. 2010).  α-TCP 
hydrolyses to form a CDHA, this was first reported by Monma and Kanazawa in 1976.  The 
same group later investigated the hydrolysis process as a means to form setting cement; 
however, they found that the hydrolysis reaction proceeded too slowly at a pH higher than 7.5 
to allow setting in a clinically applicable time (Monma et al. 1984).  Although α-TCP-water 
mixtures have been studied extensively for the last 20 years here is still a need for new 
alternatives to increase their injectability and create macropores.   
 
3.4 BCP 
The development of biphasic calcium phosphates (BCP) has drawn considerable attention, 
especially with HA-TCP.  Although HA and TCP are similar in composition, they have very 
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different biological resorption rates; the dense HA ceramics are almost non-resorbable and 
bio-inert when implanted, whereas the porous β-TCP ceramic allow relatively rapid 
degradation following implantation.  When used as a mixture, biodegradable HA-TCP graft 
material has the ability to dissolve, break down and allow new bone formation and 
remodelling required to attain optimal mechanical strength without hindrance.  Several 
authors have produced ceramics using a combination of different phases, combining the 
properties (Jillavenkatesa & Condrate 1998;Kohri et al. 1993a;Kohri et al. 1993b;LeGeros 
2002;Li et al. 2007;Ramay & Zhang 2004;Wang et al. 1998).  Victoria and Gnanam reported 
the production of BCP by a precipitation technique using 1.0 M Ca(OH)2 and H3PO4 (Victoria 
& Gnanam 2002).  The HA and TCP ratio was found to be 70:30. 
 
3.5 Commercially available CP ceramic materials 
A great deal research has been focussed on the formulation CP ceramics in the past thirty 
years and as a consequence there are now several products commerciall available.  Table 3.3 
illustrates many of these commercialised CP ceramic materials.   
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Table 3.3: Illustrates the commercialised CP ceramic materials on the market. 
 
  
3.6 Drawbacks of CP Ceramics 
While a number of commercial CP ceramics are available, they generally have significant 
drawbacks, which has limited their clinical application and stopped them from replacing 
autograft tissue as the gold standard.  Since consolidation into a monolith requires high 
temperature processing, preoperative knowledge of the bone defect site is required, precluding 
use for the repair of bone damage due to trauma.  CP ceramics can be delivered as granules 
that can be pressed into a defect; however, migration from the site of implantation can lead to 
further complication.  The requirement of a high temperature processing step also means that 
it is not possible to incorporate heat sensitive therapeutic molecules into the ceramic during 
manufacture.   Densification of the ceramic during the sintering process results in changes in 
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the ceramic structure this mean that sintered CP ceramics do not closely resemble the calcium 
phosphate phases found in bone.  Sintering results in solid state diffusion between the crystals 
comprising the cement matrix.  While solid state diffusion results in an increase in strength, it 
also causes crystal growth which results in a significant reduction in specific surface area 
which can compromise biological integration.  Calcium phosphate based cements were 
designed with the aim of meeting many of the shortcomings of calcium phosphate ceramics 
that are processed at high temperature.  Following mixing, calcium phosphate cements are an 
injectable paste material used for filling cavities in bone.  This mouldablilty allows the 
material to conform around irregular cavities and harden to form a matrix of hydroxyapatite 
or brushite.  Setting of both materials results in little or no exotherm and since no the 
materials are not heat treated following compaction into the defect, they are microcrystalline 
and so more closely resemble the mineral phase of bone than sintered CP ceramics.  Chapter 
four reviews these cements and their applications in greater detail.   
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Chapter Four 
Calcium Phosphate Cements 
Calcium phosphate ceramics, as mentioned in the previous chapter, are used in bone 
replacement applications, whereby the new bone tissue is able to colonize the implanted 
material (in macroporous foams).  In the case of these porous implants, the interconnected 
porous structure allows the formation of bone tissue growth by osteoblasts that migrate into 
the structure.  In the mid-1980‟s, a new calcium phosphate bone replacement material was 
reported (Brown & Chow 1985) that have the advantages of calcium phosphates, with the 
added advantage of a cement material.  CPCs are formed by the combination of a solid 
powder phase, of calcium phosphate (s), and an aqueous solution.   
 
4.1 Advantages of CPC’s 
  In dentistry calcium phosphate cements play a secondary role at the moment, although they 
often have excellent bone repair properties (Sugama et al. 1992).  The CPCs are able to 
activate the osteoclastic and osteoblastic functions of bone regeneration with the added 
advantage that these cells are able to modify the structure of the cement material so that in 
more closely resembles native bone.  Moreover, they have the advantage over the bioceramics 
as they do not need to be delivered in prefabricated forms (calcium phosphate ceramics are 
commonly applied as granules or blocks), because these self-setting cements can be handled 
by the clinician in paste form and injected into bone cavities.  CPCs can be formulated to be 
mouldable, injectable and thus allow complete filling of a cavity, in situ, within the operating 
theatre.  Cements are of lower crystallinity than ceramics and therefore exhibit a 
comparatively higher specific surface area (cements – 100 m2/g; ceramics – 1 m2/g).  CPCs 
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can produce brushite as the final product by a cement setting reaction; however, brushite 
cannot be sintered like other ceramics because brushite dehydrates at 50 ºC.  For this reason 
heat sensitive therapeutic molecules can also be incorporated into the cement matrix, whereas, 
with ceramics the heat sensitive therapeutic molecules have to be incorporated after 
manufacture.  Other benefits include; initial setting characteristics of the material which gives, 
in an acceptable clinical time, and suitable mechanical strength for a shorter tissue functional 
recovery.   
 
Although there are numerous formulations of CPC, essentially there are only three different 
end products; apatite, brushite and amorphous calcium phosphate.  The only study on 
amorphous calcium phosphate shows that the cement is rapidly converted into apatite 
(Driessens et al. 1996).  For the purposes of these thesis, therefore two main types of cement 
end products are discussed; HA and brushite cements.  Brushite based cements have been the 
focus of much research in the past decade (Bohner 2000a;Grover et al. 2003;Grover et al. 
2006;J.Lu et al. 2002), as the importance of implant resorption has become more apparent.   
 
This chapter presents a review of the calcium phosphate cements used for medical 
applications and also describes the setting, rheological and mechanical properties of HA and 
brushite cements and reviews current and future clinical applications. 
 
4.2 Hydroxyapatite 
4.2.1 Chemistry of setting reactions  
HA setting cements are the most commonly researched CPC, due to HAs compositional 
resemblance to natural bone.  In the last 30 years HA has moved from research to 
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commercialisation (Table 4.1).  The main types of HA based cement system are as follows; 
TTCP (tetracalcium phosphate; Ca4(PO4)2O)/DCPA (monetite; CaHPO4), α-TCP/DCPA, α-
TCP/MCPM (monocalcium phosphate monohydrate; CaH2PO4.H2O) and amorphous calcium 
phosphate cements, which are explored in this chapter. 
 
TTCP/DCPA cement 
The TTCP/DCPA cement is a derivative of Brown and Chow‟s original cement the in which 
an equimolar mixture of TTCP (basic) and DCPA (neutral) is combined with water to form 
apatite (slightly basic) cement paste (Brown & Chow 1986) that sets as: 
Ca4(PO4)2O + CaHPO4 + H2O  Ca5(PO4)3OH + H2O            (equation 4.1) 
This reaction produces a stoichiometric hydroxyapatite (SHA) however, due to the unequal 
dissolution of the two phases it is thought that the cement actually sets to form a calcium 
deficient hydroxyapatite (CDHA) (Ishikawa et al. 1999) in accordance with equation 4.2: 
3Ca4(PO4)2O + 6CaHPO4  2 Ca9(HPO4)(PO4)5OH + H2O           (equation 4.2) 
From equations 4.1 and 4.2 it is very clear that there is no consumption of the liquid phase in 
these setting mechanisms; the presence of water is simply to allow the formation of a 
workable cement paste and aid ion transport.  This “water-less” cement, as it is sometimes 
termed, can be of great advantage allowing the cement reactants to be sterilised as high as 300 
ºC (Elliot 1994). 
 
α-TCP/DCP cement 
Based on the hydrolysis of α-TCP the formation of a CDHA was first reported in 1976 by 
Monma and Kanazawa, the reaction was considered to be far too slow for clinical situations.  
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This led to the addition of DCP, DCPD, PHA or sodium phosphate solution (Na2HPO4 or 
NaH2PO4) to improve reaction kinetics and provide for faster setting harder materials 
exhibiting setting times of less than 30 mins (Driessens et al. 1993a;Durucan & Brown 
2000;Huisen & Brown 1998). 
3 α-Ca3(PO4)2 + H2O  Ca9(HPO4)(PO4)5OH              (equation 4.3) 
The cement is a hydraulic cement system, which means that the HA only forms on 
consumption of water, unlike the TTCP/DCPA formulation.  Hydraulic cements based on 
calcium phosphates offer the advantage of being freely mouldable and adaptable to bone 
defects.   
 
α-TCP/MCPM cement 
In 1995, Constantz et al. added calcium carbonate to CPC to alter the crystallite size of HA in 
the cement, by replacing PO4
3-
 with CO3
2-
.  This improved the degradation speed 
significantly, and results showed excellent clinical treatment effects in bone repair (Constantz 
et al. 1995a).  The dry mixture of α-TCP, MCPM and calcium carbonate mixed with sodium 
phosphate solution resulted in the formation of a hardened matrix of Dahllite: 
Ca8.8(HPO4)0.7(PO4)4.5(CO3)0.7(OH)1.3              (equation 4.4) 
A study on the solubility and dissolution rates of various different commercially available HA 
(Norian CRS and Bonesource) demonstrated an increase in solubility with increasing ionic 
substitutions into the apatite lattice and decreasing crystallinity (Fulmer et al. 2002).  The 
presence of carbonate ions in the lattice of HA have been shown to result in a reduction in 
crystallite size and an increase in the number of lattice defects.   
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Amorphous calcium phosphate cements 
There is only one ACP-based bone cement currently on the market (Biobon in Table 4.1). 
This cement comprises a mixture of ACP (50wt%) and DCPD (50wt%) which is mixed with 
an appropriate amount of aqueous medium (deionised water or saline) with a liquid to solid 
ratio of 0.8 ml/g at room temperature (Tofighi et al. 2001).  An injectable paste is obtained 
which sets in less than 20 min at 37 °C; hydrolysis of the ACP results in the formation of HA, 
as the end product.  After hardening it is constituted of nanocrystalline apatite with crystal 
dimensions close to those of human bone.  This cement setting reaction is endothermic; this 
means that the cement does not set until body temperatures are reached.  This extends 
working time for the paste at room temperature and links setting to implantation; great 
advantages for this cement formulation.  Several authors have experimented to modify 
formulations of this ACP-based cement, including additives with a view to improve and 
control other properties; in particular, setting time and injectability can be optimised for 
different requirements by controlling the amount and nature of additives (Wang et al. 
2007a;Wang et al. 2006).  Van den Vreken et al. studied the influence of ACP when added to 
two cement formulations: an α-TCP-based cement and a TTCP–MCPM-based cement and 
prepared pure ACP cement as a reference (Van den Vreken et al. 2010).  The results 
demonstrated that the addition of ACP to the cement formulations led to a decrease in the 
crystallinity of the end product and was converted to a nanocrystalline CDHA.  Addition of 
ACP to these two CPCs resulted in cements that exhibited good setting times, compressive 
strengths suitable for non-load-bearing applications and demonstrated good cell viability, 
making them suitable candidates for bone substitute materials. 
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4.2.2 Setting properties  
CPC‟s must set slowly enough to provide sufficient time to a surgeon to perform implantation 
but fast enough to prevent delaying the operation.  Good mechanical properties should be 
reached within minutes after initial setting (Bohner 2007).  Gillmore needles have been used 
with success to measure the initial (I) and final (F) setting times of calcium orthophosphate 
cements (Driessens et al. 1993b).  Two different needles are used to measure I and F setting 
times (Appendix 1).  The clinical meaning is that the cement paste should be implanted 
before time I and that the wound can be closed after time F.  The cement should not be 
deformed between times I and F because in that stage of the setting process any deformation 
could induce cracks (Driessens et al. 1998).  Setting times of HA have been reported to be in 
a range between 30 mins (Brown & Chow 1986) to 150 mins (Liu & Shen 1997); this is for 
the same cement system.  However, setting times that exceed 30 mins are clinically limited; 
therefore, much work has been directed towards the use of additives as a means of reducing 
the setting times of these cements. 
 
Accelerators  
It was previously suggested that the presence of a crystal seed could reduce the setting time 
and increase the compressive strength, however Liu and Shen investigated the effect of crystal 
seeding on the hydration of CPC.  They found that the setting time of the CPC with the 
addition of 5wt% low crystallinity hydroxyapatite (used as a crystal seed) was 7 min.  This 
improvement in the setting time was due to HA serving as a substrate for heterogeneous 
nucleation which accelerated nucleation, this meant that the increasing quantity of crystal 
seeding lowered the setting time to a degree, although the extent at which the setting time was 
reduced lessened as the crystal seeding continued to increase (Liu & Shen 1997).  However, 
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they found that the effect of the crystal seeding on the compressive strength of the cement was 
negative; reducing from 60 MPa to 44 MPa (10wt% HA).  The acceleration of the nucleation 
in this reaction means that the growth is limited; this resulted in the formation of smaller sized 
and lower aspect ratio products.  This production of many metastable small particles undergo 
dissolution-reprecipitation during hydration; these particles react and damage the 
microstructure, lowering the strength of the seeded cements (Liu & Shen 1997).   
 
Yang et al. also found that the microstructure was affected by the seed crystals in the cement; 
the presence of the seed crystals (20wt% HA seed crystals) appeared to lengthen the HA 
crystals from “sub-micron” to 1-2 µm (Yang et al. 2002).  This was suggested as the reason 
for the decrease in strength.  Several other studies on crystal seeding demonstrate similar 
results; Brown et al. indicated that HA seeds accelerate the initial setting reactions but did not 
appear to have major long-term effects on the extent of reaction or on the microstructure 
(Brown & Fulmer 1991).  Bermudez et al. found that the compressive strength of the CPC 
based on MCPM–CaO system initially increases with HA seeds content up to 8%, and then 
decreases (Bermudez et al. 1994a).  However, for the α-TCP–MCPM–CaO system, they 
found that the cement setting time decreases with HA seeds content up to 3% and then 
increases (Bermudez et al. 1994b). 
 
Phosphate Solutions  
Another means of reducing the setting times of HA cements is the addition of sodium 
phosphate to the liquid phase.  This addition of phosphate ions causes rapid supersaturation of 
the HA and causes rapid precipitation.  Fernandez et al. refers to the effect of phosphate ions 
on the setting reaction as a “common ion effects” and reported a reduction in the final setting 
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times of the cement composed of α-TCP and DCP.  Both cements exhibited the same common 
ion effect following the addition of 6wt% Na2HPO4 or NaH2PO4.2H2O (instead of water for 
making the cement pastes); where the setting times were reduced by a factor of 10.  However, 
they found this lowered the strength of the cements; the addition of 4wt% Na2HPO4 formed α-
TCP cement with 50% of the original compressive strength of the α-TCP cement made using 
water as the liquid phase.  As means of comparison CaCl2 was also used to reduce setting 
times; however, it was observed that no common ion effect occurred.  This suggests that the 
reduction in setting time was attributed by the lowering of the pH of the cement mix, by the 
acidic phosphate salts (Fernandez et al. 1994). 
 
Ishikawa et al. found that the setting time of a calcium phosphate cement consisting of TTCP 
and DCPA was reduced from 30 to 5 min by use of a cement liquid that contained a 
phosphate concentration of 0.25 mol/l or higher.  The diametral tensile strength and 
conversion to HA during the first 3 h were also significantly increased by the phosphate 
(Ishikawa et al. 1995). 
 
 
Effect of temperature  
It has been demonstrated in various studies that temperature has a marked effect on the setting 
times of HA cements.  An elevation in temperature from 21 ºC to 37 ºC can result in a three-
fold reduction in setting times.  This effect would be advantageous in clinical applications 
where the cement is handled at room temperature, giving the surgeon increased handling time 
with a reduced setting time implanted (in situ).  This was explored by Driessens et al. when a 
cement of powder (P) is mixed with a liquid (L) at a ratio of 3.13 g/ml was produced; 
consisting of α-TCP (64wt%), DCP (27wt%) and HA (9wt%) and with a liquid component of 
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2.5wt% Na2HPO4.  This exhibited setting times of approximately 30 mins at 20 ºC and 10 
mins at 37 ºC, a significant decrease (Driessens et al. 2000).   
 
4.2.3 Rheological properties  
Injectability and cohesion are required for the successful in vivo introduction of CPC‟s.  The 
cement paste is required to be injectable with low resistance; the powder–liquid phase must 
not separate during the injection process, which mainly depends on a suitable rheological 
property of CPC slurry.  In order to prevent wash-out of the cement materials, viscosity 
modifying agents are often added to the cement formulation; this also reduces viscosity and 
minimises the invasive methods of cement application.  
 
Cohesion promoters 
The ability of a hydraulic paste to harden in an aqueous environment without releasing loose 
particles has been termed “cohesion” (Bohner et al. 2006).  From the various parameters that 
may influence the cohesion of the CPC paste were identified both theoretically and tested 
using new methods.  Their results suggested that the two better methods to increase the 
cohesion of a calcium phosphate paste are to decrease the average particle size of the paste 
constituents or in some cases to add a viscosity modifying agen such as xanthan. 
 
An appropriate cohesion is said to be achieved when no disintegration of the cement paste is 
observed in the fluid.  This can be accomplished by keeping a high viscosity for the cement 
paste or using cohesion promoters (e.g. 1% aqueous solution of sodium alginate (Alves et al. 
2008;Bermudez et al. 1993)).  Commercial cements such as, Norian SRS fulfils both criteria, 
but others don‟t necessarily fulfil any of these requirements.  For example, BoneSource and 
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Cementek are not injectable and blood must be kept away from the implanting site until 
setting (Bohner 2000;Bohner 2001).  Also, decohesion of the cement during mixing may lead 
to inflammatory reactions (Miyamot et al. 1999). 
 
Injection of HA cements 
Injectability is the ability to be extruded through the aperture of a hypodermic needle (e.g. 
2 mm diameter and 10 cm length) and for certain applications injectability is a requirement.  
Usually, injectability of a cement paste varies inversely with its viscosity, the P:L ratio, as 
well as the time after starting the mixing of liquid and powder (Khairoun et al. 1998;Serraj et 
al. 2002).  When put under pressure, some CPC‟s demonstrate demixing into a thin paste, 
which is extruded, and a thick mass, which remains inside the syringe; this is called filter-
pressing.  In the case of demixing, the exact composition of the extruded part of the paste 
becomes unknown.  Moreover, due to a deviation from the initial P:L ratio, it becomes 
unclear whether the setting behaviour and the mechanical properties of the extruded part are 
still clinically acceptable.  Therefore, a good cohesion of the paste is necessary in order to 
avoid these problems. 
 
Two examples of workability-improvement agents, which are added to the powder of the 
cement, are polysaccharides and gelatine.  Polysaccharides significantly increase the 
injectability (Lewis 2006) while gelatine was expected to increases the  compressive strength 
and both initial and final setting times, these effects being attributed to a reduction in total 
porosity and achievement of a more compact microstructure (Bigi et al. 2004).  Furthermore, 
gelatine is a commonly used polymer (Chang et al. 2003;Vandelli et al. 2004a;Watase & 
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Nishinari 1980), it is completely resorbable in vivo, and its presence in the cement gives a 
composite material where both the organic and the inorganic phases resemble those of bone. 
 
Gbureck et al. enhanced the injectability of α-TCP-based cement, by adding several fine-
particle-sized fillers, and demonstrated that the use of inert filler can yield significant 
viscosity reduction.  In comparison, the use of tri-sodium citrate as a liquid phase only led to a 
slight decrease of the cement viscosity (Gbureck et al. 2005b).  The study concluded that 
optimization of inter-particle spacing by using inert filler material can yield significant 
strength improvements and viscosity reduction. 
 
4.2.4 Mechanical properties 
During the setting reaction of the cement, calcium phosphate crystals grow and become partly 
interlocked, given the cement the characteristics of mechanical rigidity.  As calcium 
phosphates are brittle, the compressive strength of a CPC is always greater than its tensile 
strength.  Most CPC have a tensile strength of 1–10 MPa, whereas the compression strength 
varies between 10 and 100 MPa.  The mechanical properties of a CPC depend on its 
composition.  The main determining factor is the ratio between the amount of cement powder 
and mixing liquid.  If this P:L ratio is large, the porosity of the CPC is low.  As the 
mechanical properties decrease exponentially as porosity increases, low porosity always 
corresponds to high mechanical properties.  As a rule of thumb, the tensile strength increases 
two-fold with a 10 vol% decrease in porosity.  The mechanical properties reported by CPC 
manufacturers are never documented, so it is difficult to compare CPC. 
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Particle Size Distribution 
The particle size distribution plays a crucial role in the mechanical properties of the cement by 
determining the minimal volume required to form workable cements and also affecting the 
rate and extent of the setting reaction.  Some authors have studied the influence of the particle 
size of the reactants on the final mechanical properties of some cements, such as DCP-TTCP 
based cements or DCPD-TTCP based cements (Otsuka et al. 1995).   
 
A study on the reaction kinetics and the underlying physico-chemical mechanisms responsible 
for the final structure and properties of the cement were investigated by Ginebra et al. The 
particle size of the powder phase is introduced as a variable, in order to determine its 
influence on the final structure of the cement at the micro and nano-scale range (Ginebra et al. 
2004).  It was concluded that the crystallite size of the final product can be strongly reduced 
by increasing the specific surface area of the starting powder; this tailors the developing 
calcium phosphate materials with structures at the micro and nano-scale levels.   
 
Cement Stoichiometry 
The alteration of the stoichiometry of the setting reaction can affect the mechanical properties 
of the cement when two different phases react.  For example, the use of excess TTCP or 
DCPA in the reaction, results in a reduction of mechanical strength.  When equimolar 
amounts of both TTCP and DCPA are mixed at P:L of 4 g/ml a cement exhibiting diametral 
strengths of 13 MPa were produced.  In comparison, when TTCP and DCPA are mixed at 
molar ratios of 2.0 and 0.25 diametral strengths of 6 MPa are exhibited.  This reduction in 
mechanical strengths is a result of a heterogeneous cement matrix caused by the reaction of 
unreacted material (Ishikawa et al. 1999). 
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Compaction  
Reducing the relative porosity can improve the mechanical strength of the cement.  
Compaction (uni- or bi-axial) of the cement setting paste is one technique used to reduce the 
porosity.  However, it is not known whether the compaction of the cement material will alter 
the specific surface area significantly or how the pore size distribution changes with the 
compaction pressure.   
 
Ishikawa and Asaoka showed a linear relation between diametral tensile strength and porosity 
of CPC cement, where porosity was controlled by compaction pressure (up to 173 MPa). 
However, when compaction pressures above; 100 MPa were applied, little decrease in 
porosity was achieved, and diametral tensile strength was not significantly improved 
(Ishikawa & Asaoka 1995).  Thereafter, Barralet et al. explored the effect of compaction 
pressures up to 106 MPa on the mechanical properties in compression and calculated the 
specific surface area of TTCP/DCPA cement (Barralet et al. 2002b).  They concluded that the 
compaction pressure did not alter the specific surface area of the cement, which implies that 
the dissolution of TTCP/DCPA cement would not be affected by porosity changes induced by 
the compaction process. 
 
Following this in 2003, Barralet et al. reported wet compressive strengths of 90 MPa made 
using sodium citrate as the liquid phase; the cement was manually compact, using finger 
pressure.  The addition of sodium salts of α-hydroxy acids with more than one acid group to 
the liquid phase of apatitic cement improved the effectiveness of biaxial compaction (Barralet 
et al. 2003).  By mechanical compaction, using pressures of 200 MPa, the compressive 
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strength of the final cement was increased to 180 MPa; comparable to the strength of cortical 
bone.  This increase of strength widens the range of applications for such cements.   
 
4.2.5 In-vitro ageing  
In-vitro ageing is a means of initially investigating individual parameters that may affect the 
mechanical or degradation properties of the material in-vivo.  The basic requirements that a 
synthetic bone replacement must possesses can be screened by means of in vitro studies. 
 
Effect of ageing times 
HA cement formulated by the mixture of an equimolar powder of TTCP and DCPA with 
water at P:L of 4 g/ml was aged by Ishikawa et al. in a dynamic flow system containing 
simulated blood plasma to investigate the surface changes that CPC‟s undergo in solutions 
that have electrolyte concentrations similar to that of human blood.  The simulated blood 
plasma was comprised of; Na
2+ 
(142 mmol/l), K
+ 
(5 mmol/l), Ca
2+ 
(2.5 mmol/l), HCO3
- 
(4.2 
mmol/l), Mg
2+ 
(1.5 mmol/l), Cl
- 
(148.8 mmol/l), HPO4
2- 
(1 mmol/l) (Ishikawa et al. 1994).  It 
was determined that over the 20 week ageing study the sample had increased in mass by a 
factor of 0.5; this was due to the formation of HA on the surface of the cement.  The benefit 
of this result was an increase in the diametral tensile strength, from 10 MPa at the start of the 
study, prior to ageing to 16 MPa after 20 weeks of ageing.  Phase composition conveyed that 
the bulk composition remained unchanged; this meant the increase of strength was attributed 
by the precipitation of the HA layer.  While the study was aimed to simulate human blood; 
this study did not completely meet the requirements of the conditions entirely.  The simulated 
blood plasma composed of the ions listed above does not contain the protein constituents of 
blood which are known to inhibit the formation of HA on the surfaces of implants.   
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Solubility 
HA is the least soluble calcium phosphate compound in physiological conditions (Nelson 
1981).  It is possible to create a lattice distortion by incorporating different ions into the 
crystal structure and thereby increasing the solubility.  Some ionic substitutions such as 
carbonate have been shown to increase the solubility of apatites, while fluoride substitution 
into the apatite lattice decreases solubility.  In the same way, the degree of crystallinity affects 
the solubility behaviour of apatites; highly crystalline apatites tend to be very insoluble, while 
poorly crystalline apatites have higher relative solubility (Bohner 2001).  Stoichiometric HA 
was found to be the least soluble among the materials tested, compared to the non-
stoichiometric precipitated apatite with high specific surface area and showed higher levels of 
calcium and phosphate release (Fulmer et al. 2002).  Following this, Shellis and Wilson 
studied the apparent solubility distribution of hydroxyapatite at different pH values (Shellis & 
Wilson 2004); experiments were performed at pH 4.5, 5.0, and 5.5.  Results showed a 
tendency to increase slightly with pH but in most cases the 95% confidence intervals 
overlapped, indicating a lack of statistical difference between values. 
 
Chen et al. use the solid-titration method to investigate the solubility of HA, under the 
conditions of minimised excess solid, in order to clarify behaviour (Chen et al. 2004).  The 
solubility for HA in KCl solution, in the absence of CO2 obtained, differs considerably from 
the results of previous solubility studies.  The increase in solubility due to CO2 reported 
earlier was confirmed, while the effect of excess phosphate was found to be to increase the 
apparent solubility of HA, contrary to elementary mass-action expectations. 
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4.2.6 Clinical applications 
Pre-clinical studies   
Although there have been many commercialised products developed over the years, there still 
remains the need to formulate improved cement pastes.  Taking this into consideration, there 
are few studies published on the in vitro cellular response to CPC‟s.  However, there have 
been a large number of in vivo studies on the development and biological response to HA 
providing sufficient evidence to progress the development of these cement formulations to 
allow pre-clinical in vivo studies (Apelt et al. 2004;Barralet et al. 2004;Blokhuis et al. 
2000;Bohner et al. 2005;Constantz et al.1995a;Devlin & Lieberman 2007;Frakenburg et al. 
1998;G.Daculsi et al. 2004;Grynpas et al. 2002a;Joosten et al. 2004;Ohura et al. 
1996;Kozloff et al. 2009;Kurashina et al. 1997;Munting et al. 1993;Penel et al. 
1999;Regsegger & Laib 1998;Spivak & Hasharoni 2001;Taniwaki et al. 2003). 
 
Commercial formulations 
The first commercial CPC products were introduced over 15 years ago for the treatment of 
maxillo-facial defects (Kamerer et al. 1994) and of fracture defects (Constantz et al. 1995b).  
Since then, companies are establishing second-generation cements and are also expanding 
their range to fulfil the various requirements of clinical orthodontics and orthopaedics.  
Several in vitro studies with injectable CPC‟s show their feasibility and mechanical 
effectiveness.  Animal studies confirm their osteoconductivity (Apelt et al. 2004;Chen et al. 
2003;Horstmann et al. 2003;Iooss et al. 2001;Joosten et al. 2004;Kim et al. 2004;Mendez et 
al. 2004;Turner 2002).  An example of these bioactive injectable cements is the commercially 
available self-hardening calcium phosphate composites, Norian® (Stanton et al. 2004), 
consisting of equimolar amounts of TTCP and DCPA, hardens when mixed with water and 
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forms a resorbable HA as the end-product.  This material provides excellent mechanical 
properties and direct bone in-growth ability, but it set in situ after injection.  Table 4.1 
elaborates further on the various commercialized HA cement products. 
 
Table 4.1: Summarizes the commercialised apatite based cement products with their 
composition details (Bohner et al. 2005). 
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4.3 Brushite 
Dicalcium phosphate dihydrate (DCPD) is a mineral, formula CaHPO4·2H2O (brushite); a 
precursor of apatite formation.  Brushite cements are in general weaker and more acidic than 
HA cements, however, their constituents are more soluble in vivo meaning that resorption 
may be aided by dissolution (Elliot 1994).  Subsequently, research rapidly progresses to 
increase the mechanical properties, for example: strength, thus expanding prospective clinical 
application.  Brushite cements are resorbed faster compared to HA cements (Nilsson et al. 
2002) due to the fact that brushite is a meta-stable compound when used under physiological 
conditions (Vereecke & Lemaitre 1990).  The transformation of brushite into apatite after 
implantation, resulting in an increase of the resorption time should be prevented by adding a 
magnesium salt of low solubility (Flautre et al. 1999). 
 
4.3.1 Chemistry of setting reactions 
Brushite cements typically set following the combination of an acidic aqueous source of 
phosphate ions such as MCPM or H3PO4 with β-TCP.  The precipitation of brushite crystals is 
a result of a drop in the pH (lower than 4.2) of the cement slurry following mixing. 
  
β-TCP-MCPM-H2O cement 
The first reported brushite cement by Lemaitre et al. (1987) is a product of β-TCP (slightly 
basic) reacted with MCPM (acidic) and water, to form DCPD (neutral).  The MCPM can 
either be dissolved in the water prior to mixture with the β-TCP or may be combined with β-
TCP prior to the water (Mirtchi et al. 1989). 
β-Ca3(PO4)2 + Ca(H2PO4)2.H2O + 7 H2O  4 CaHPO4.2H2O          (equation 4.5) 
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β-TCP-H3PO4-H2O cement 
The use of orthophosphoric acid to replace MCPM as the acid component in formulating 
brushite cements was demonstrated by Bohner et al. (1995).    
β-Ca3(PO4)2 + H3PO4 + 6 H2O  3 CaHPO4.2H2O            (equation 4.6) 
Bohner et al. (1997) claimed that the cement produced posses several advantages when 
compared to that formed from β-TCP and MCPM, with simpler and faster preparation, easier 
control of the chemical composition and a relatively high tensile strength to the β-TCP and 
MCPM cement. 
 
TTCP-CaO-MCPM cement 
The acidic nature and rapid reactions of MCPM and H3PO4 brushite cements, the quantities of 
the cement components used are often non stoichiometric; resulting in the formation of a 
cement matrix consisting of a proportion of unreacted β-TCP.  Constantz et al. practically 
produced a phase pure brushite matrix following the mixture of TTCP, MCPM and CaO with 
an undisclosed dilute solution (Constantz et al. 1998).   
Ca4(PO4)2O + CaO + Ca(H2PO4)2.H2O  CaHPO4.2H2O           (equation 4.7) 
Nanocrystalline hydroxyapatite-H3PO4 
Barralet et al. reported another brushite cement formation, which set following the mixture of 
nanocrystalline HA with OA (Barralet et al. 2004).   
Ca9(PO4)5(HPO4)OH + H3PO4 + 17 H2O  9 CaHPO4.2H2O          (equation 4.8) 
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Nanocrystalline HA has a higher specific surface area than that of HA produced by thermal 
processes due to smaller crystal size and therefore has greater kinetic solubility; increasing the 
rate of dissolution such that cement formation may occur (Lilley et al. 2005).  The two major 
advantages of this formulation, over the other brushite cements are that; (1) the Ca:P ratio of 
the HA may be lowered so that cement may be produced with lower volume of acidic 
components; and (2) the HA lattice can accommodate for various ion substitutions into the 
crystal lattice; leading to possible changes in properties of the set cements (Barralet et al. 
2004).   
 
4.3.2 Setting properties 
Brushite cements possess extremely rapid setting times; Driessens et al. confirmed the 
nucleation and resulting growth of brushite crystals to be rapid with a pH range of 2-6.5 
(Driessens et al. 1993b).  The cement setting times seem to be approximately 1-2 mins 
(Bohner et al. 2000), which is evidently a limiting factor for clinical applications as it is not 
practical to leave the surgeon so little time to apply the mould the cement correctly.  This has 
led much research in the investigation of various retardants to slow the setting reaction; added 
advantages of improving the mechanical properties of the cement also accompany many of 
these additives. 
 
Retardants 
From previous work it is evident that pyrophosphate ions are most effective at increasing the 
setting times, however, sulphate ions are can simultaneously increase setting times and tensile 
strength, combinations of both of these retarding agents have been used to control cement 
properties (Bohner 2000;Bohner et al. 2000).  The results of the study by Bohner and his co-
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workers, reiterates the fact that these ions are able to inhibit DCPD crystal growth.  With the 
addition of tetrasodium pyrophosphate solution at 33 mM concentration they demonstrated a 
four-fold increase in the final setting time of the brushite cement.  A similar effect of 
pyrophosphate ions was exposed by Mirtchi et al. when they used β-dicalcium pyrophosphate 
(DCPP), with a setting time 5 mins after the addition of DCPP (without DCPP the setting time 
was observed at 30 s) (Mirtchi et al. 1989).  The use of calcium pyrophosphate salts was less 
effective than pyrophosphate solutions since DCPP is relatively insoluble, even at acidic pH 
values (Grover 2005).  Although the addition of pyrophosphate ions retarded the setting 
reaction, there was no net gain in strength. 
 
Ca3(PO4)2 + H4P2O7 + 4 H2O  CaHPO4.2H2O + Ca2P2O7.2H2O           (equation 4.9) 
 
Mirtchi et al. then went on to observe the effects of calcium sulphate hemihydrates (CSH); 
results exhibited setting times to increase to 7 mins (Mirtchi et al. 1989).  Unlike the addition 
of pyrophosphate ions, the CSH not only improved the setting times but also enhanced the 
diametral tensile strength of the cement; from 1 MPa (without CSH) to 2.5 MPa (with 10 wt% 
CSH).  This therefore meant that the cement paste produced demonstrate higher strengths and 
better handling times; the combination of which can widen the applications of such cements.  
More recently, Bohner et al. agreed and reported that the effect of the sulphate ions on the 
setting time is larger below a concentration of 0.1 M.  Above this concentration, CSH crystals 
nucleate and act as nuclei for DCPD crystals, which are the normal product of the setting 
reaction.  This decreases the setting time and decreases the DCPD crystal size, resulting in an 
increase of the tensile strength of the cement (Bohner 1996). 
 
63 
 
Barralet et al. reported a significant improvement of setting times of brushite cements 
consisting of equimolar amounts of β-TCP and MCPM with a liquid phase of 500 mM or 1 M 
solutions of trisodium citrate or citric acid as setting retardants, at P:L of 3.3, 4.0, 4.5 and 5 
g/ml.  Results exhibit an increase in I setting times to 8-12 mins (Barralet et al. 2004).  This 
study demonstrated for the first time the use of ionic modification to produce a low viscosity 
brushite cement paste that was injectable through a hypodermic needle. 
 
4.3.3 Rheological properties   
Previous studies demonstrate the use of carboxylic acids and viscosity enhancing agents on 
the brushite cement cohesion (Alkhraisat et al. 2009;Alkhraisat et al. 2008a).  The cements 
were prepared using a mixture of β-TCP and MCPM, whereas the liquid phase was formed by 
0.5 M citric acid solution modified by the addition of hyaluronic acid of different molecular 
weights.  It was found that medium and high molecular weight hyaluronic acid enhanced the 
cement cohesion and barely affects the cement mechanical properties.  Therefore, hyaluronic 
acid could be applied efficiently to reduce brushite cement disintegration.  However, 
concentrations would have to be at least 0.5 % w/v, any less and the efficiency to prevent the 
cement disintegration is compromised (Alkhraisat et al. 2009).    
 
A more recent study by the same group reports the effect of silica gel on brushite cement 
cohesion.  The cement was prepared using the same method but with the liquid phase 
comprised carboxylic acids silica gel.  This cement presents a shorter final setting time, better 
cohesion and higher amount of unreacted β-TCP than the cement prepared without silica gel 
(Alkhraisat et al. 2010).  The aim was to produce cement that does not disintegration easily.  
The simultaneous use of carboxylic acids and silica gel has resulted in shorter cement final 
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setting time values than those for carboxylic acids alone.  These acids inhibit the growth of 
brushite crystals through the binding of calcium ions by carboxylic groups exposed on the 
brushite surface (Barralet et al. 2005).  The addition of silica gel was highly efficient in 
preventing cement disintegration; this modification could widen their clinical application, by 
reducing surgery time and resisting disintegration. 
 
4.3.4 Mechanical properties  
Brushite cement is too weak to be used in load-bearing areas (Grover et al. 2005a) and many 
studies have been dedicated to improving the mechanical properties of the set cement.  
Retarding the brushite crystal growth rate results in smaller sized crystals allowing them to 
pack more closely together and improving the mechanical properties of brushite cements 
(Grover et al. 2005b).  However, Barralet et al. mentions that the strength improvements 
made by the addition of organic/inorganic additives will be useful for an application of the 
cements in some load-bearing areas, for example in upper spine surgery (vertebroplasty) 
(Barralet et al. 2005). 
 
Pyrophosphate ions, sulphate ions, citrate ions, pyrophosphoric acid and carboxylic acids, 
such as citric, tartaric and glycolic acids have been used to increase the cement setting time 
and improve its mechanical properties (Alkhraisat et al. 2008a;Alkhraisat et al. 
2008b;Barralet et al. 2004;Bohner 1996;Bohner et al. 2000;Grover et al. 2006;Marino et al. 
2007). 
 
Without the addition of additives several authors have again manipulated the formulations of 
the brushite cements.  In once such technique Gbureck et al. produced tailor-made brushite 
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blocks with good mechanical properties have been synthesized using a 3D printing technique.  
This new technique produced cements with compressive strengths of up to 8.7 MPa.  A 
further strength improvement was to hardening of the samples in phosphoric acid for three 
one minute washes, this increased the strength to 22 MPa (Gbureck et al. 2007a); XRD was 
used to determine the phase composition of these samples.  Results proved they mainly 
consisted of brushite with minor phases of unreacted TCP and a lesser amount of DCPA.  
More recently, Hofmann et al. developed brushite cements as strong as 52 MPa in 
compression by adjusting particle size and size distribution of the β-TCP and the MCPM 
powder reactants and also the citric acid concentration, resulting in a decrease of cement 
porosity to 11% (Hofmann et al. 2009).  The cement paste exhibited setting times of 4.5 min, 
which gave a good workable property. 
 
4.3.5 In-vitro ageing 
The major advantage of brushite cements is the higher solubility under physiological 
conditions, such that brushite is dissolved at the implantation site more rapidly than HA 
materials. This property has been demonstrated in vitro (Grover et al. 2003;Xia et al. 2006).  
However, brushite is meta-stable and this means brushite undergoes hydrolysis to form a 
stable HA CPC.  After completing an ageing study of brushite in PBS for over 19 days, 
Constantz et al. demonstrated by that the brushite had completely converted to HA (Constantz 
et al. 1998).   
 
Studies have been published which have investigated the factors that influence the hydrolysis 
of brushite cements both in vitro (Grover et al. 2003) and in vivo (Apelt et al. 2004), 
including implant volume, liquid refreshment rate and media composition.  The study by 
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Grover et al. has shown that the rate of mass loss from brushite cement and the formation of 
HA are affected strongly by the above mentioned factors; this in turn inhibited hydrolysis 
(Grover et al. 2003).   
 
Dehydration of brushite 
Brushite is a hydrated secondary calcium phosphate that upon heating undergoes a 
dehydration process at around 130 ºC accompanied with phase transformation to monetite 
(dicalcium phosphate anhydrous; DCPA) at 160 ºC followed by decomposition of DCPA to 
calcium pyrophosphate at 425 ºC.  It was found that brushite dehydration and DCPA 
decomposition occurred at lower temperatures in cements set with phosphoric acid and water 
(Alkhraisat 2009).  HA started to appear in water and phosphoric acid brushite cements earlier 
than in carboxylic acid brushite cements.  Carboxylic acids are able to inhibit the formation of 
HA and it was proven that the addition of citric acid to β-TCP-MCPM mixtures also 
prevented the formation of monetite. 
 
4.3.6 Clinical applications 
Many in vivo studies (Alkhraisat 2009;Apelt et al. 2004;Bohner et al. 2005;Ohura et al. 
1996;Marino et al. 2006;Munting et al. 1993;Penel et al. 1999;Theiss et al. 2005) have 
demonstrated varied results and authors report incomparable data.  However, a general trend 
shows, using the same animal model, degradation rate decreases as sample size increases, 
along with the brushite hydrolysis to HA. 
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Commercial formulations 
Brushite cements possess relatively poor mechanical properties, therefore limiting their 
clinical applications to non-load bearing bone repair or replacements.  However, there have 
been several cases of commercialisation of the brushite cement for the non-load bearing 
market, which is summarized in Table 4.2. 
 
Table 4.2: Summerizes the commercialised brushite based cement products (Bohner et 
al.2005). 
 
 
 
4.4 Conclusion 
CPC formulations are extremely promising bone replacement materials, which can be applied 
via minimal invasive surgical methods.  The use of CPC‟s has reduced infection rates and 
lessened the aggression (Legeros 1988).  Another advantage of CPC‟s is that the product of 
the reaction, usually apatite, is obtained at low temperature (Hench 1998a).  Therefore, it is 
much more similar to the biological HA than the HA prepared by the conventional high 
temperature sintering methods; it is non-stoichiometric, and it has a low crystallinity and a 
high specific surface area (Ginebra et al. 2004).  These characteristics increase the reactivity 
and resorbability of these materials.  This chapter has evaluated the various advantages and 
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disadvantages that surround the development of CPCs and highlighted the availability of the 
commercialized cement products.  Research in the field of CPCs has been growing at a steady 
pace and will continue to do so until a satisfactory bone replacement material has been 
developed; fulfilling all of the ideal graft material properties mentioned in Chapter 2. 
 
In the following experimental chapters, various material properties have been manipulated to 
meet these ideal material properties mentioned above.  In chapter five we discuss the 
importance of producing monetite based cements by means of manipulating the existing 
brushite cement formulation.  Chapter six discusses the importance of phase separation in 
order to produce self setting or “ready mixed” cement pastes.  Following this the addition of 
antibiotics within the cement matrices and how this affects the mechanical and physical 
structure of the cements is investigated in chapter seven.  Finally chapter eight will explores 
the degradation of the different cement formulations and how porosity affects the degradation 
and hydrolysis of cements. 
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Chapter Five 
Formulation of a monetite based cement  
5. 1 Introduction 
Calcium phosphate cements (CPCs) typically harden following the combination of a powder 
and an aqueous liquid.  The cement paste can initially adapt to the irregular defects (Carey et 
al. 2005), frequently encountered in orthopaedic and craniofacial surgery, and sets to form a 
hardened graft for the replacement of lost or damaged bone (Grover et al. 2005b).  These 
CPCs may be compositionally similar to the mineral phase of bone, and have been shown to 
be non-cytotoxic, osteoconductive, (Kitsugi et al. 1993) and to some extent can be replaced 
by new bone (Chow 1988).  Ripamonti has also reported that CPC materials may exhibit 
some osteoinductive activity (Ripamonti 1996). 
 
5.1.1 Problems with calcium phosphate cements 
Depending on the stoichiometry and pH of the cement slurry, CPCs can set to form a matrix 
consisting of hydroxyapatite (Ca10(PO4)6OH2; HA) at a pH value of >4.2 or brushite 
(CaHPO4.2H2O; DCPD) at a pH value of ≤4.2.  HA has in the past attracted more research as 
it compositionally resembles bone mineral.  Researchers have, however, demonstrated that 
highly crystalline HA is insoluble in physiological conditions (-log Ksp = 58.6 at 37 ºC 
(Grover et al. 2005b)) and is resorbed at only 5% per year via osteoclastic activity 
(Muralithran & Ramesh 2000).  This means the HA cement can remain in vivo for a 
considerable period of time following implantation, posing a risk of catastrophic brittle failure 
(Bohner 2000c).  More soluble forms of HA, however, can be produced by reducing crystal 
size (Ducheyne & Qiu 1999) and incorporating substitutions (e.g. Mg
2+
, CO3
2-
) (Fulmer et al. 
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2002).  Some authors have incorporated high volumes of porosity into HA, to improve 
bonding at the implant-tissue interface by allowing the in-growth of the host tissues into the 
implant pores (Ducheyne & Qiu 1999;Ducheyne et al. 1978), although this has resulted in 
poor mechanical properties until bone integration occurs (Grynpas et al. 2002b;Ryshkewitch 
1953). 
 
5.1.2 Possible solutions 
To address this problem some researchers (Barralet et al. 2002c;Barralet et al. 2004;Gbureck 
et al. 2003;Gbureck et al. 2005c;Grover et al. 2003;Lu et al. 2002;Lemaitre et al. 1987) have 
begun to focus on the production and refinement of brushite cements.  Brushite cements can 
be resorbed faster than HA cements (Nilsson et al. 2002) as brushite is a meta-stable 
compound when used under physiological conditions (Theiss et al. 2005).  Brushite is a 
sparingly soluble calcium phosphate (-log Ksp = 6.63 at 37 ºC (Grover et al. 2005b)) 
therefore can be resorbed both by cell-mediated mechanisms (Xia et al. 2006) and dissolution, 
meaning that they are potentially fully resorbable in the body (Grover et al.2006).   
 
Monetite is the anhydrous form of brushite, (CaHPO4; DCPA) (Elliot 1994); synthesised in 
the same way as brushite by the simultaneous addition of the same phosphate and calcium 
solution to the same phosphate solution at a high temperatures (100 ºC), as opposed to 
ambient temperatures with brushite (Ma et al. 2006) or by the dehydration of brushite, as 
brushite can lose crystal water at high temperatures (>50 °C) (Klammert et al.).  Although 
brushite can be resorbed more rapidly than apatite, hydrolysis occurs converting the meta-
stable brushite into the very stable apatite (Grover et al. 2003).  Recently, Gbureck et al. 
demonstrated that monetite ceramics showed a better degradation profile than brushite when 
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implanted intramuscularly in rats, even though monetite has a lower chemical solubility 
because the low-solubility apatite phase was not formed in the monetite bioceramic (Gbureck 
et al. 2007b).  This was particularly surprising since monetite is less soluble than brushite in 
physiological conditions (-log Ksp = 7.02 at 37 ºC (Grover et al. 2005b)).  On evaluation of 
the retrieved implants, there was no evidence for the formation of HA within the largely 
monetite matrix.  One significant problem with the use of monetite as a bioceramic, however, 
is that to date there are no cement formulations that set directly to form monetite.  Monetite, 
therefore, has to be produced by a process of cement casting and then high-temperature heat 
treatment (>100ºC) (Hsu et al. 1998), which means that preoperative knowledge of the 
grafting site is required and it is not possible to incorporate heat sensitive therapeutic 
molecules into the ceramic matrix.  The reason that monetite is not formed in cement matrices 
is not because it is thermodynamically less stable than brushite, which is actually a less stable 
phase, but because the rate of brushite crystal formation is considerably higher than for 
monetite (Elliot 1994).   
 
Therefore, the hypothesis is to prove if the reaction in equation 4.5 produces brushite cements 
then if the water component is limited we would assum that the reaxction would then result in 
a monetite cemnt.  This would follow the same theory as the dehydration method used to 
produce monetite, without the high temperatures.   
 
5.1.3 Aims 
From the literature it is evident that the formation of a monetite cement, without the use of 
high temperatures (casting, sintering, etc.), may pose to be a difficult task.  However, in this 
study we have manipulated the formulation of the traditional brushite cement system to 
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produce slow setting monetite cement.  Using the MCPM-β-TCP formulation, the powder 
components remain the same, while the liquid phase is replaced by a non-aqueous liquid; thus 
limiting the water component.  The slowing down of the cement reaction, by limiting the 
addition of water, will favour the production of monetite instead of brushite.  The paste must 
exhibit minimal effect on the mechanical properties of the cement to allow clinical usage in 
orthopaedic and/or craniofacial surgeries.  
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5.2 Materials and Methods 
5.2.1 Materials  
β-TCP was synthesised by heating an equimolar mixture of calcium carbonate (Merck, 
Darmstadt, Germany) and dicalcium phosphate anhydrous (CaHPO4, Mallinckrodt Baker, 
Griesham, Germany) at 1400 ºC for 14 h prior to quenching at room temperature.  The 
resulting sinter cake was broken up using a pestle and mortar and then passed through a 160 
μm sieve.  The powder was then milled for a period of 24 h in a centrifugal ball mill (PM400 
Retsch, Germany) using a zirconia container (110 mm diameter) and zirconia charges (10 mm 
diameter).  Monolcalcium phosphate monohydrate (Ca(H2PO4)2.H2O; MCPM, Fluka, Sigma, 
Dorset, UK), monocalcium phosphate anhydrous (Ca(H2PO4)2; MCPA, Sigma, Dorset, UK) 
glycerol (Analytic Reagent grade; Fisher Scientifics, UK), and sodium alginate (viscosity = 
570 MPa/s; Protanal SF200, pharmaceutical grade; FMC BioPolymer, UK) were used as 
received from the suppliers without further modification. 
 
5.2.2 Cement formulation  
The cement powder was formed from an equimolar mixture of β-TCP and MCPM.  The 
powder components were combined and the resulting powder was homogenised using a 
vortex mixer (Fisher brand, UK) for a period of 5 min.  For the monetite cement, the liquid 
component was glycerol containing 2wt% sodium alginate and in the case of the control 
materials double distilled water (dH2O) was used as the liquid component.   
 
Samples were prepared by mixing the powder component with the liquid component at 
powder-to-liquid mass to volume ratio (P:L) of 3 g/mL.  The powder and liquid of the cement 
paste were mixed using a spatula to form a paste that was placed into an open-ended rubber 
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mould of diameter 5 mm and depth 10 mm, the walls of the mould were perforated to allow 
liquid exchange between the samples and the environment.  To induce setting, the samples 
were immersed in phosphate buffered saline (PBS; Sigma, Dorset, UK) at 37 ºC on an orbital 
shaker (HT Infors, Infors UK Ltd, Wigan, UK) at 50 rpm.   In the case of the control material, 
the cement powder was mixed with dH2O at a P: L of 3 g/mL and the resulting paste was cast 
into a PTFE split mould to produce samples of diameter 6 mm and height 12 mm. 
 
5.2.3 Cement paste stability and setting 
The washout resistance was tested by shaping the premixed CPC sample into a small sphere 
(~ 5 mm in diameter) by hand, and then immediately placing it in 5 ml of double distilled 
water (Takagi et al. 2003).  Samples demonstrated washout resistance by maintaining their 
structural integrity after being fully immersed in PBS.  The initial and final setting times of 
the cement were determined using the Gilmore needles.  The cement was considered initially 
set when 35.9 g was loaded on to a needle with a tip diameter of 800 µm (300 KPa) failed to 
make a perceptible indentation on the surface of the cement.  The time measured from the 
powder-liquid mixing to this point was used as the initial setting time for the specimen.  The 
final setting time was determined in the same way except using a 5.3 MPa load.  
 
5.2.4 Cement mechanical properties  
All samples were tested wet following immersion in PBS at 37 ºC for 24 h.  Prior to testing, 
geometrical measurements of the samples were made to allow the subsequent calculation of 
cement porosity using Archimedes principle.  For compression testing, the cement cylinders 
were loaded parallel to the their long axes using a Universal testing machine (Lloyd, 
Southampton, UK) at a constant cross head displacement of 2 mm/min until failure occurred.   
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Cement fragments were collected and dried at 37 ºC for further characterisation.  Platinum 
coated cement fracture surfaces were examined using a field emission gun scanning electron 
microscope (SEM) (JEOL, JSM-7000F. UK).  To determine the influence of storage time on 
the compressive strength (CS) exhibited by the premixed cements, the cement pastes were 
sealed in a universal container and stored at 4 ºC for periods of 3, 7, 14, 28 and 90 days before 
being cast into moulds in ambient conditions and allowed to harden in PBS at 37 ºC. 
 
5.2.5 Perfusion through the cement pastes 
To understand the uptake of water by the samples during the setting reaction, the paste was 
immersed in an aqueous environment; the diffusion of methyl blue, through the cement paste 
was investigated.  The paste was packed into rigid, clear plastic tubing of different lengths, 
10, 15, 20, 25 and 30 mm; the diameter was constant at 8 mm and the wall thickness was 500 
µm.  One end of the tubing was sealed with Para film (Parafilm® M, Structure Probe, Inc. 
USA) to allow the methyl blue to enter through one way and the diffusion was only measured 
in one direction only.  The samples were withdrawn from the solution daily and digital images 
were taken.  Dye penetration was quantified using image analysis (Image J, 1.36b, Wayne 
Rasband, National Institute of Health, USA).   
 
5.2.6 Cement composition 
X-ray powder diffraction data were collected using CuKα1 radiation from a powder 
diffractometer (D5000, Siemens), aligned in transmission mode.  The data set was collected 
from 5 º to 60 º 2θ with a step size of 0.05 º.  A multiphase, whole pattern Rietveld analysis 
was used to determine the crystalline phase compositions of the samples.   
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To determine whether the cement setting is diffusion limited, a cement sample was dissected 
into several layers.  The cement measured a total radius of 5 mm (Figure 5.5A); sections were 
cut using a scalpel shaving off 1 mm through the lenth of the sample for each layer after 
which the cement layers were separately powdered and examined.  Each layer was 
characterized using the X-ray diffractometer and Rietveld refinement, which were compared 
with control samples.  Rietveld refinement is a technique devised for use in the 
characterization of crystalline materials.  The neutron and x-ray diffraction of powder samples 
results in a pattern characterized by peaks in intensity at certain positions.  The height, width 
and position of these peaks can be used to determine many aspects of the materials structure. 
 
Comparisons between the groups were made by the analysis of variance using single factor 
ANOVA.  Differences were determined statistically significant with ρ < 0.05.  Data are 
expressed as mean ± SD. 
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5.3 Results 
The results of the various studies are illustrated below.  The initial study was carried out using 
the glycerol and alginate combination to make the cement paste, made up of the powder 
components of the traditional brushite cement.  Following the initial study various other 
gelling agents were explored to improve the results and determine the reason for the slow 
setting reaction which favoured the formation of monetite cement as the final set cement 
product instead of brushite. 
 
5.3.1 Slow setting monetite cement 
Cement setting and stability in solution 
The incorporation of glycerol and sodium alginate into the brushite cement pastes resulted 
in considerable increases in both the initial and final setting times exhibited by the cement 
pastes.   
 
Table 5.1: The formulations, mechanical and setting properties of the CPCs investigated 
in this study. 
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Following the mixture of the powder and liquid components, the β-TCP–MCPM cement 
paste exhibited an initial setting time of 0.5 ± 0.1 min and a final setting time of 6.9  ± 1.7 
min (Table 5.1).  In comparison the β-TCP–MCPM cement paste combined with glycerol 
and sodium alginate exhibited an initial setting time of 60 min and a final setting time of 
1355 min (Table 5.1).  Although this setting time would be considered too long for a non-
modified cement system, no significant disintegration of the cement paste was noted on 
immersion in dH2O (Figure 5.1) and the cement continued to harden once immersed.  
Table 5.1 also shows a significant decrease in porosity with the addition of glycerol.  
 
 
 Figure 5.1: Image of spheres of the cement paste during immersion in PBS; (A) MCPM 
control cements (β-TCP + MCPM + water) and (B) MCPM cement paste (β-TCP + 
MCPM + glycerol).  Images demonstrate the washout resistance of the paste formulations 
compared to the control samples; no visible degradation of the cement was evident.  
 
To determine how the incorporation of sodium alginate and glycerol into the cement paste 
influenced cement microstructure, the cement fracture surfaces were evaluated using 
SEM.  The control cement microstructure consisted predominantly of „blade-like‟ crystals 
of approx. 50 µm length by 10 µm in width as widely reported in the literature (Figure 
5.2A).  The addition of glycerol to the cement mix resulted in a significant change in 
microstructure, with the formation of irregular sub-micron crystals (Figure 5.2B). 
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Figure 5.2: Scanning electron micrographs of cement fracture surfaces without (A) and 
with (B) the addition of sodium alginate and glycerol.  The addition of the sodium alginate 
and glycerol resulted in a marked change in the morphology of the crystals within the 
cement matrix from predominantly blade-like to irregularly shape.  
 
Mechanical properties with ageing cements 
In order to determine the „shelf-life‟ of the material, the sodium alginate and glycerol 
paste was stored for periods up to 90 days in a hermetically sealed container at 4  °C and 
was subsequently formed into cylindrical samples for testing in compression (Figure 5.3).  
There was an initial statistically significant increase in the mean CS of the hardened 
materials up to 14 days of ageing from 8.6 ± 3.5 MPa to 13.2 ± 1.5 MPa (p<0.05), 
followed by a subsequent deterioration in compression strength (p<0.01) after 90 days of  
ageing (5.8 ± 0.7 MPa) (Figure 5.3).   
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Figure 5.3: Effect of storage, of the paste formulation (at 4 ºC) prior to setting, on the 
compressive strengths exhibited by the hardened material. 
 
The influence of ageing on the microstructure of the cement was determined using SEM 
(Figures 5.4 A-F).  The microstructure of the cement changed little throughout the study, 
and consisted at all timepoints of densley packed and irregularly shaped crystals.  The 
crystals that formed the matrix of the cement contrasted significantly with those 
previously reported to form within the microstructure of monetite ceramics (Prado et al. 
2001), which exhibit a plate-like structure of 400 nm in diameter.  The storage of the 
cement paste in the sealed containers for 90 days did not seem to have a significant 
influence on the microstructure of the hardened material. 
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Figure 5.4: SEM micrographs show microstructure of the fractured surface of the aged 
cement samples.  Samples were aged for 90 days in total; here we can see the minimal effect 
on the microstructure of the monetite cements over the period of time.  Sample A illustrates 
the sample at day 0; sample B at day 3; sample C at day 7; sample D at day 14; sample E at 
day 28 and sample F at day 90. 
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Perfusion of the cement paste 
Since hardening of the cement paste is dependent upon exchange of the glycerol in the 
paste with water, a cylinder of cement of diameter 10 mm was immersed in PBS for a 
period of 20 h in order to determine whether the reaction was diffusion limited.   
 
The resulting hardened structure was dissected into layers of depth 1 mm (Figure 5.5A).  
The phase composition of each layer was determined by means of Rietveld refinement 
phase analysis.  Within the timeframe of the experiment there was little variation in the 
composition of the cement matrix, which in each case was formed principally of monetite 
(Figure 5.5B).  There was a definite increase in the ratio of monetite to brushite toward 
the centre of the sample.  Layer 1 for example consisted of 11 ± 2wt% brushite and 77 ± 
2wt% monetite and layer 5 consisted of 2 ± 2wt% and 83 ± 2wt% of brushite and 
monetite, respectively. 
 
In order to visualise the penetration of the sample by a liquid, cement cylinders were 
immersed in methylene blue.  The only cement samples that were completely saturated 
with the methylene blue stain were the 10 mm and 15 mm samples, which became 
saturated after 4 and 9 days, respectively (Figure 5.6).  As the experiment proceeded, the 
rate of perfusion of the methylene blue through the cement matrix slowed significantly 
and complete penetration of the cement was not noted when the cement paste cylinder was 
of length >20 mm (Figure 5.6A).  However, had the samples been left in the coloured 
solution for longer, the sample >20 mm would have also been fully saturated. 
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Although it is acknowledged that the molecular diameter of methylene blue is in the order 
of six times larger than water (1.35 nm compared with 2.75 Å) and hence may not be 
representative of water penetration, it is evident that cement setting significantly slows 
liquid penetration (Figure 5.6B) and therefore may place an upper limit on the maximum 
size of a paste-like cement material that requires water ingress for hardening to occur. 
 
 
 
Figure 5.5:  A schematic diagram illustrating the sections of cement dissected from the 
hardened cement cylinder (A) following immersion in PBS for a period of 20 h and the 
crystalline phase composition of each corresponding layer (B).  
 
The results from Figure 5.6A and B suggest that during the setting reaction the outer 
layers of the sample set more rapidly than the inner most layers.  X-ray diffraction 
(Figure 5.7) which determined the relative amount of β-TCP and MCPM converted to 
monetite in each layer was used to confirm this theory.  Figure 5.7 reveals the 
relationship between the layers and the relative conversion from β-TCP to monetite. 
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Figure 5.6: There was an upper limit on the distance that the methylene blue solution could 
perfuse the hardening cement paste, with samples of 10 and 15 mm in length being the only 
samples completely perfused (A), the rate of perfusion reduced significantly with time, 
showing that the cement hardening reaction provided a barrier to perfusion.  B) Shows cement 
paste cylinders of 10, 20 and 30 mm of length following 9 days immersion in methylene blue 
solution. 
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Figure 5.7: XRD results of the different layers of the cement paste sample.  Layer 1 = outer 
most layer and layer 5 = inner most layer.  The graph proves that the water-glycerol exchange 
is more efficient near the surface compared to the inner layer.  The various peaks are 
indicative of the composition of the samples; ■ Monetite; ○ Brushite; ● β-tri-calcium 
phosphate (β-TCP); □ Monocalcium phosphate monohydrate (MCPM). 
 
Cement composition 
As expected the X-ray diffraction patterns of the control cements predominately 
consisting of brushite and some unreacted β-TCP (Figure 5.8).  After storage in paste 
form for 24 h at 4 °C, but prior to to immersion in PBS, the modified cement paste was 
shown to consist predominantly of crystalline β-TCP and MCPM.  On immersion in PBS, 
this paste hardened to form a matrix that consisted of monetite and β-TCP alone.  
Relatively little brushite was detected within the hardened cement (Figure 5.8). 
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Figure 5.8: Compares the diffraction patterns of the MCPM control cement (β-TCP + MCPM 
+ water) (bottom) with the paste formulation before (middle) and after (top) the cement paste 
has hardened.  The various peaks are indicative of the composition of the samples; ■ 
Monetite; ○ Brushite; ● β-tri-calcium phosphate (β-TCP); □ Monocalcium phosphate 
monohydrate (MCPM). 
 
To determine whether the formation of monetite was caused by the presence of alginate or 
glycerol within the cement paste, samples were formed using a range of sodium alginate 
concentrations between 0.2wt% and 2wt%, and a sample was made containing glycerol 
alone.  There was little or no change in the relative intensity of the peaks indicative of 
monetite and β-TCP regardless of the quantity of sodium alginate present (Figure 5.9), 
additionally, monetite was shown to form in the cement paste even without the addition of 
sodium alginate.   
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Figure 5.9: Compares the diffraction patterns of the MCPM paste formulation (made using 
glycerol and alginate) with varying amounts of alginate.  The various peaks are indicative of 
the composition of the samples; ■ Monetite; ○ Brushite; ● β-tri-calcium phosphate (β-TCP); 
□ Monocalcium phosphate monohydrate (MCPM). 
 
5.3.2 Comparing gelling agents 
The initial study illustrates the use of alginate as the gelling agent and the results of these are 
found above, in section 5.3.1; the results highlight that the monetite cement is formed by 
slowing down the setting reaction, as the water component is limited.  The cements 
demonstrated slow setting time then the control (brushite) cement and also lower compressive 
strengths.  Consequently, a further study was undertaken to demonstrate whether a change in 
the gelling agent was a means of improved material properties.  Various gelling agents are 
used in this study, for which more details can be found in Appendix 2. 
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Cement setting, stability and mechanical properties 
The various different gelling agents were used in the formulation of the cement pastes and 
mechanically tested; the results are illustrated below in Table 5.2. 
 
 
Table 5.2: The effect of the use of different gelling agents on the mechanical and setting 
properties of the CPCs investigated in this study. 
  
 
Figure 5.10 demonstrates that there is minimal effect when the gelling agent is varied on the 
average compression strengths of the cement paste formulations.  The use of a gelling agent 
with the non-aqueous liquid has a significant effect on the compressive strength, as it is 
reduced by almost 50%, however, between the variations of the gelling agents there is no 
noticeable difference. 
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Figure 5.10: Effect of the variation in gelling agent of the paste formulation on the 
compressive strengths exhibited by the hardened material; all samples were prepared in the 
same manner. 
 
Cement composition 
The XRD pattern in Figure 5.11 illustrates the difference in the composition of the each 
sample, in comparison to the control cement pattern (the pattern shown at the very bottom 
of the graph in Figure 5.18).  The symbols suggest the presence of monetite and brushite 
in the set cement paste samples, compared to the control sample; which shows 
predominately brushite peaks only.  Again the variation in the gelling agent used had no 
effect on the composition at a glance; further phase composition analysis will determine 
the exact quantities of the phases present in watch sample. The SEM images in Figure 
5.12A–F, suggest that there is no difference in morphology of the cements created using 
the various gelling agents. 
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Figure 5.11: Compares the diffraction patterns of the MCPM control cement (β-TCP + 
MCPM + water) (bottom) with the paste formulation after the cement paste has hardened, 
using various different gelling agents.  The various peaks are indicative of the composition of 
the samples; ■ Monetite; ○ Brushite; ● β-tri-calcium phosphate (β-TCP); □ Monocalcium 
phosphate monohydrate (MCPM). 
 
Unlike the monetite shown in the above section 5.3.1, here in Figure 5.12A–F, the traditional 
monetite cement which forms plate-like crystals (Prado et al. 2001) can be seen.  The flat 
plate-like structures are 1.0 μm in width and vary in length from 1.0 – 5.0 μm.  Figures 6.10b, 
c and d, illustrate morphologies more like those demonstrated by brushite crystals, long flat 
needle-like structures (Grover 2005). 
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Figure 5.12: SEM micrographs show microstructure of the fractured surface of the different 
cement samples; each sample is composed using different gelling agent.  Sample A illustrates 
the gelling agent Alginate; sample B uses Agarose; sample C uses Carrageenan; sample D 
uses Chitosan; sample E uses Gellan gum and sample F uses Gelatine.  Here we can see the 
minimal effect on the microstructure of the monetite cements with varying the gelling agent.   
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5.4 Discussion 
In the past ten years there has been a considerable change in the development of calcium 
phosphate based cement materials from those that set to form apatite, which exhibits 
limited resorption in vivo to those that set to form more soluble calcium phosphate phases 
such as brushite (Alkhraisat et al. 2008b;Gorst et al. 2006;Grover et al. 2003;Grover et al. 
2006;Grover et al. 2008;Rousseau et al. 2002;Jinawath et al. 2001;Theiss et al. 2005).  
Due to the considerable refinements of brushite cement formulations they now exhibit a 
similar CS to that of apatite cements and can be delivered in a minimally invasive manner; 
their widespread use has been limited by a an unpredictable degradation rate, which may 
be influenced by implant location, composition or physical properties.  The 
unpredictability of brushite cement degradation is as a result of the meta-stable nature of 
brushite, which when immersed in physiological solutions can hydrolyse to form apatite in 
accordance with Equation 5.1 (Bohner 2000).   
5CaHPO4.2H2O  Ca5(PO4)3OH + 2H3PO4 + 9H2O          (equation 5.1) 
Although several approaches have been investigated to prevent this phase transformation, 
none have been used in a commercially available material.  Recently, Gbureck and co-
workers demonstrated that the dehydrated form of brushite (monetite; CaHPO4), is 
considerably more resistant to hydrolysis and hence may be more rapidly resorbed 
following implantation (Gbureck et al. 2007a).   
 
To date, however, monetite ceramics can only be synthesised using elevated temperatures 
or by storing highly acidic brushite cement formulations at temperatures of >37 °C 
(Jinawath et al. 2001).  The requirement of an additional processing stage means that 
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monetite ceramics cannot currently be delivered in cement form and hence suffer from 
many of the drawbacks associated with other bioceramics that are sintered prior to use, 
such as: difficulty to fit to irregular contours, requirement of preoperative knowledge of 
the defect and the requirement of a high temperature processing stage, which prevents the 
incorporation of temperature sensitive therapeutic molecules.  Therefore, here for the first 
time we report the formation of a cement material that sets to form a matrix consisting of 
monetite without the requirement of an additional heating stage.  The cement was formed 
by the addition of glycerol and sodium alginate to the cement mix rather than water alone.   
 
The formation of monetite within the hardening cement material could be attributed to one 
of three factors: 1) The maintenance of a low pH value within the cement matrix; 2) The 
presence of sodium alginate preventing the incorporation of water into the brushite 
crystal; 3) A change in crystallisation kinetics to favour the formation of monetite rather 
than brushite.  The control cement formulation hardened to form a matrix that consisted 
predominantly of brushite (Figure 5.8), this suggestes that the formation of monetite 
within the cement matrix could not be attributed to the acidic nature of the cement matrix, 
that has previously been shown to result in monetite formation within brushite cements  
(Bohner et al. 2003).   
 
It has previously been reported that the addition of sodium alginate to a precipitation 
reaction resulted in the precipitation of monetite, which increased in a monotonic manner 
with the addition of increasing quantities of the sodium alginate hydrocolloid  (Lima et al. 
2006).  This change in composition was attributed to the ability of alginate to chelate 
calcium ions in the newly forming crystals and hence prevent the incorporation of layers 
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of water into the monetite crystal lattice.  While this mechanism could go some way 
toward explaining the compositional changes that occured within the cement matrix, here 
we demonstrated that there was no relationship between the quantity of sodium alginate 
added to the cement mix and the amount of monetite forming within the cement matrix.  
Indeed, monetite formed within the cement matrix in the absence of sodium alginate  
(Figure 5.9).  This suggests that the addition of glycerol was critical to the formation of 
monetite within the cement.  The presence of glycerol could have favoured the 
precipitation of monetite rather than brushite since mass transport throught the glycerol 
would have been hindered in comparison to water.  As a consequence, the rate of crystal 
formation would have been reduced significantly (Figure 5.2).  Since brushite is actually 
less thermodynamically stable than monetite and forms only because its rate of 
crystallisation is an order of magnitude faster than monetite (3.32 X 10
-4 
mol DCPD min
-1
 
m
-2
 (Elliot 1994)), reducing the rate of crystal formation within the cement so drastically 
could have favoured the formation of monetite within the cement rather than brushite.  
Indeed, the earliest report of purely synthesized monetite required that the precursor 
calcium nitrate and ammonium phosphate were adjusted to a pH value of 3 and then 
interdiffused through nitric acid prior to washing with acetone (Louati et al. 2005).  The 
conditions in this study would have been very similar, with a low pH value within the 
cement paste and the limited interdiffusion of the reactants through the media.   
 
The slow perfusion of liquid throught the cement paste was shown by the relatively slow 
penetration of methylene blue dye through the hardening material (Figure 5.6).  As setting 
proceeded, the rate at which dye penetration slowed significantly and in the case of cylinders 
of diameter 10 mm and length >10 mm, perfusion through the setting paste stopped 
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altogether.  This suggests that with cementitious materials which require the exchange of 
water with a non-aqueous solvent such as glycerol, there is an upper limit to the size of 
implant that can be applied and will set to form a homogeneous matrix (Figure 5.5).  Figure 
5.7 shows that the inner most layers of the cement pastes have a relatively lower β-TCP to 
monetite conversion, compared to the outer most layers.  This means that if the diffusion 
distance is kept small the setting time would be shorter and therefore, producing stronger 
cement.  The formation of an implant that is homogeneous is particularly important to 
cement used for biomedical applications since a heterogeneous matrix results in the 
formation of a material with poor mechanical properties and a large proportion of 
unreacted acidic or basic compounds that could cause long-term complications in vivo.  
Efforts have previously been made to develop premixed cement pastes that set to form 
matrices of apatite (Carey et al. 2005;Takagi et al. 2003) or brushite (Han et al. 2009).  
While these studies demonstrated the efficacy of each premixed cement, none evaluated 
the homogeneity of the setting reaction throughout the matrix, and although Han et al. did 
report the formation of some monetite, it was as an impurity phase rather than the 
predominant product of the setting reaction.  One reason for this could be that Han et al. 
used very small samples (diameter 6mm and height 3mm) and as such water penetration 
into the matrix would not have been limited by sample size (Figure 5.6).   
 
Han et al. also stated the importance of washout resistance of the cement material 
following implantation.   Previously, Carey et al. observed that small particles of a TTCP-
DCPA cement pastes elicited into the elute as the samples were setting even though the 
samples were not placed under agitation (Carey et al. 2005).  The release of small debris 
could potentially cause a severe inflammatory response if implanted (Miyamoto et al. 
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1999).  As such, sodium alginate has previously been incorporated into calcium phosphate 
cement to prevent the production such debris with significant success.  The incorporation 
of sodium alginate here also prevented the generation of particulate material as a result of 
wash-out (Figure 5.1).  The setting times exhibited by the premixed cement material were 
considerably longer than for the control cement (Table 5.1).  While a final setting time of 
more than 20 h is inappropriate for traditional cement materials formed from the 
combination of a powder and liquid phase prior to implantation, in the case of this 
formulation where setting proceeded following immersion, the cement is not required to 
fully set before the surgeon closes the implant site.   
 
The mechanical strength of any bioceramic cement is an important parameter as the cement 
requires having some load-bearing ability.  The CS of monetite are demonstrated as 2.05 ± 0.2 
MPa according to a recent study (Desai et al.2008), which is relevant for bone replacement as 
human trabecular bone has compressive strengths of 2–10 MPa.  The CS results exhibited 
here  (Table 5.1 and 5.2) are comparable to previous work with brushite cements (Charriere et 
al. 2001).  Control cement exhibited 15.6 ± 5.8 MPa which reduced to 8.6 ± 3.5 MPa with the 
addition of the sodium alginate.  Figure 5.3 illustrates the changes in CS of the stored cement 
pastes over time; exhibiting initial average CS for MCPM was 8.1 ± 2.2 MPa.    The data 
collected in this study shows that in the first 3 days the CS increased from 8.1 ± 2.2 MPa to 
10.6 ± 2.0 MPa.  There was a statistically insignificant decrease between day 3 and 7 (day 7 = 
9.8 ± 1.6 MPa) and then an increasing to 13.2 ± 1.5 MPa.  By 90 days the CS exhibited was 
5.7 ± 0.7 MPa.  This suggests that the CS decreases over time however after 3 months the CS 
was reduced by 38% of the initial CS measured and by 63% of the highest CS value of the 
monetite sample.   
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Further work was then undertaken to compare the use of various other gelling agents, such as 
Agarose, Chitosan (Carey et al. 2005).  These gelling agents conveyed comparable results to 
that of Alginate.  The gelling agents had average CSs from as low as 6.8 ± 3.2 MPa, using 
chitosan to 9.3 ± 2.2 MPa, and using gellan gun.  There were several other gels which produce 
cements with compressive strengths around 8 MPa (Table 5.2 and Figure 5.10).  The 
composition of the cement pastes when other gelling agents were used are illustrated in 
Figure 5.11.  It is clear that the hardened cement pastes are composed predominately of 
monetite, with some peaks which represent brushite (Figure 5.11).  This means that limiting 
water component in this setting reaction is the key to the formation of monetite, and possibly 
where water in present in abundance there is a chance of brushite formation, hence there is the 
presence of both crystals in the final set cement paste.  SEM micrographs (Figure 5.19A–F) 
show the typical structure of monetite cement, in the form of plate-like crystals (Prado et al. 
2001).  However, samples which may consist of some brushite are also demonstrated on the 
SEM micrographs; the presences of flat plate-like crystals and flat needle-like structures, 
representing monetite and brushite, respectively (Figure 5.19A–F). 
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5.5 Conclusions 
Here we have reported the first cement system that sets to form a matrix predominantly of 
monetite.  The formation of monetite rather than brushite was attributed to the limited 
perfusion of the hardening cement paste with water during setting.  Incomplete penetration 
of the cement by methylene blue has demonstrated the importance of sample volume on 
the formation of the set cement phase. i.e. too small volumes would set quickly and in the 
case of Han et al. produce a brushite phase as water is not limited sufficiently; large 
volumes, as demonstrated in this study, indicates that the perfusion will stop once this 
limit is reached. 
 
Form this study; it was found that many different gelling agents can be used in the 
formulation of the paste cement.  However, regardless of which gelling agent was used, the 
average material properties were similar.  This indicates that the gelling agent is not the main 
influence of strength or structure here.  The formation of monetite was possible due to the 
slowing down of the setting reaction, which was possible by limiting the water component.   
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Chapter Six 
Controlled-setting cement pastes using polymer encapsulation 
6.1 Introduction 
In clinical situations, the surgeon‟s ability to accurately mix the cement and then to place the 
cement paste in the defect within the prescribed time is a critical factor in achieving optimum 
results (Takagi et al. 2003).  The requirement for on-site powder–liquid mixing increases the 
surgical time (Carey et al. 2005).  It may also result in insufficient and heterogeneous mixing 
thus compromising the implant strength, and inconsistencies between operators causing 
unpredictable variations in graft performance.  Thus, it would be desirable to have a ready 
mixed cement paste that is stable in the package and hardens only after being placed in the 
defect. 
 
One way to enable controlled setting would be to separate the cement components from one 
another in a polymeric micro-capsule that breaks down and releases a reactive component 
following the application of an appropriate stimulus.  This section describes the use of an 
emulsion or double emulsion system to encapsulate orthophosphoric or pyrophosphoric acid 
and then incorporate the spheres into a ready-mixed paste consisting of β-TCP and water.  
The formed spheres were designed so that they would breakdown in response to pH, 
temperature (Eudragit) or the application of shear (poly(caprolactone)).   
 
6.1.1. Microencapsulation 
Microencapsulation is an extensively used technique to capsulate food flavourings (Kim et al. 
1996), cosmetics (Miyazawa 2000), drugs (Mi et al. 2009;Sugawara et al. 1994;Wan et al. 
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1992), protein (Calvo 1997), antigens (Cleland 1998;Singh & O'Hagan 1998), cells (Mi 
1999), and enzymes (Tiourina & Sukhorukov 2002).  In biotechnology, microencapsulation of 
biologically active materials like living cells and enzymes may increase biological half-life.  
In the pharmaceutical industry, the reasons for microencapsulating a drug are to improve its 
stability, e.g. protection of vaccines from gastric acid, to reduce side effects or mask 
unpleasant taste, to reduce dosing frequency and total dosing amount, to obtain better 
pharmacological activity, and for sustained (long-lasting) release. 
 
Microcapsules can be of the regular shape (e.g. spherical, tubular and oval) or irregular shape.  
The spherical form of microcapsules is the most common form in controlled release systems 
as release from a sphere should be more predictable than from an irregular shape.  As 
illustrated in Figure 6.1, the typical forms of spherical microcapsules include matrix, single-
wall (or single-layered), multi-wall (or multi-layered) and multi-core (Hua-Jiang Huang, Xiao 
Dong Chen, & Wei-Kang Yuan 2006).  For easy administration of microencapsulated 
component, loaded microparticles can be further designed into tablets, capsules, and 
microparticle suspensions in a solution, which can be injected when their particle size is small 
enough. 
 
The most common methods of microencapsulation are extrusion, solvent evaporation, phase 
separation, interfacial polymerization, spray drying and ionotropic gelation (Huang et al. 
2006).  Extrusion involves forming droplets by forcing a solution or suspension of active 
(core) material and wall material through a syringe, a coaxial needle or a nozzle (Breitenbach 
2002); this is difficult for use in large-scale production, and the beads obtained are large.  
Spray drying has been widely utilized in the food industry.  With the conventional spray 
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drying technique, the particles obtained can be small but the size distribution is very wide 
(Poncelet 1999).  Interfacial polymerization always involves using many organic solvents and 
potentially cytotoxic wall materials (Ji et al. 2001).   
 
Figure 6.1: Typical forms of spherical microcapsules, which are made by various different 
methods, depending on the application.  Matrix and single-wall are typically relatively easy to 
manufacture, compared to multi-wall and multi-core, which require more complex processing 
methods. 
 
Solvent evaporation also involves using relatively more organic solvents.  The substances 
encapsulated by these means may have more side effects after oral administration as they 
contain more non-biodegradable wall materials or residual solvents.  Phase separation and 
ionotropic gelation involves less organic solvents, so substances microencapsulated pose less 
of a risk to the health of an individual exposed to them (Poncelet 1999).  As emulsification 
appears to be a more straightforward way to obtain small droplets with relatively narrow size 
distribution, the following will focus on the emulsification based techniques, coupled with 
solvent evaporation, ionotropic gelation, phase separation and spray drying. 
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6.1.2 Emulsions 
An emulsion is a mixture of two immiscible substances; one substance (the dispersed phase) 
is dispersed in the other (the continuous phase).  Examples of emulsions include butter and 
margarine, espresso, mayonnaise, the photo-sensitive side of photographic film, and cutting 
fluid for metalworking.  Emulsions tend to have a cloudy appearance, because the many phase 
interfaces (the boundary between the phases is called the interface) scatter light that passes 
through the emulsion (Chern 2006).  Emulsions are unstable and do not form spontaneously; 
energy input through shaking, stirring, homogenizers, or spray processes are needed to form 
an emulsion.  Over time, emulsions tend to revert to the stable state of oil separated from 
water (van der Graaf et al. 2005).  Surface active substances (surfactants) can increase the 
kinetic stability of emulsions greatly so that, once formed, the emulsion does not change 
significantly over years of storage (Chern 2006).   
 
Emulsions are part of a more general class of two-phase systems of matter called colloids.  
Although the terms colloid and emulsion are sometimes used interchangeably, emulsion tends 
to imply that both the dispersed and the continuous phase are liquid.  There are three types of 
emulsion instability: flocculation, where the particles form clumps; creaming, where the 
particles concentrate towards the surface of the mixture while staying separated; and breaking, 
where the particles coalesce and form a layer of liquid (Antin & Salager 1986).  Whether an 
emulsion turns into a water-in-oil emulsion or an oil-in-water emulsion depends on the 
volume fraction of both phases and on the type of emulsifier.   
 
Double emulsions have significant promise for the production of multi-compartment 
microspheres.  Although a certain measure of controlled instability is desired in some cases, 
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such as for a drug delivery systems, generally the stability of double emulsions is low and 
poorly controllable and therefore a main problem with regard to shelf life of a product (van 
der Graaf et al. 2005). The instability usually leads to a significant part of the internal phase 
being lost during the production of the double emulsion.  A double emulsion is an emulsion in 
an emulsion; two main types of double emulsions can be distinguished: (1) water-in-oil-in-
water (W/O/W) emulsions (Okochi & Nakano 2000), in which a W/O emulsion is dispersed 
as droplets in an aqueous phase, and (2) oil-in-water-in-oil (O/W/O) emulsions, in which an 
O/W emulsion is dispersed in an oil phase. W/O/W emulsions are more common than O/W/O 
emulsions.  Double emulsions contain more interfaces and are even more thermodynamically 
unstable than single emulsions (Antin & Salager 1986). 
 
The most important conventional emulsification devices are stirring apparatuses, rotor–stator 
systems and high-pressure homogenizers.  Stirrers are the earliest type of equipment that has 
been used for emulsification.  The dispersed phase is broken up by the shear stresses of the 
turbulence; the energy consumption is usually large.  For the production of double emulsions, 
it is important not to use high-shear stresses to prevent disruption of the internal emulsions 
and coalescence with the external phase (van der Graaf et al. 2005). 
 
6.1.3 Materials 
Poly-caprolactone (PCL) 
PCL is biodegradable polymer suitable for controlled release due to a high permeability 
(Wang et al. 2007b).  Biodegradation of PCL is very slow in comparison to other polymers, 
so it is most suitable for long-term delivery extending over a period of more than one year 
meaning that it should retain ortho- and pyrophosphoric acid for long enough to allow for 
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manufacture, storage and delivery.  A selection of drugs encapsulated in microspheres have 
exhibited a faster dissolution rate than pure drug due to an increase in surface porosity of 
microspheres (Kim et al. 2004).  The release rate of drug from PCL depends on type of 
formulation, method of film preparation, PCL content, size and percent of drug loaded in the 
microcapsules (Miyai et al. 2008).   
 
Eudragit® 
Eudragit
®
 polymers are copolymers derived from esters of acrylic and methacrylic acid, 
whose physicochemical properties are determined by the different functional groups attached 
to them Figure 6.2 (Rohm Pharma 2003).   
The two grades of Eudragit® used in this thesis were: 
 Eudragit S100 is an anionic polymer of methacrylic acid and methacrylates with a -
COOH group, which is designed to dissolve at pH values > 7.0 for release at the 
implantation site, usually for targeted delivery in the ileum between pH 6.0–7.5 (Li 
2005;Zahirul et al. 2000).  
 Eudragit RS has a low content in quaternary ammonium groups compared with other 
types of Eudragit (Rohm Pharma 2003).  The ammonium groups, present as salts, 
make the polymer permeable under certain conditions.  This property was utilised to 
make temperature sensitive polymer matrices (Fujimori et al. 2002). 
 
 
Therefore, the hypothesis is to prove whether a novle CPC can be formulated that can set post 
operatively upon a change of environment, such as temperature or pH. 
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Figure 6.2: The chemical structures of  Eudragit RS 100 (A) and Eudragit S100 (B) (Reproduced from 
(Rohm Pharma 2003)). 
 
 
6.1.4 Aims 
This chapter investigates the separation of the two cement components during the production, 
packaging, storage and transportation of the cement by using Eudragit
®
 polymers, and 
demonstrate how the cement paste is able to set on demand when exposed to a change in 
temperature or pH.   
 
The initial study involves the encapsulation of the traditional brushite cement by the 
formulation in Equation 4.6 (β-TCP-H3PO4-H2O cement); this determined whether this 
method was viable.  From these results, once the method of microsphere production had been 
refined the new modified brushite cement was tested; encapsulating pyrophosphoric acid 
(PPA) instead of H3PO4 (orthophosphoric acid, OA). 
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6.2 Materials and Methods  
Eudragit
®
 polymers are copolymers derived from esters of acrylic and methacrylic acid, 
whose physicochemical properties are determined by the different functional groups attached 
to them (Rohm Pharma Polymers, 2003).  The two grades of Eudragit
®
 used were; Eudragit 
S100 (pH sensitive) and Eudragit RS (thermo-sensitive).  
 
6.2.1 Production of Microspheres 
Most methods of producing microspheres are modifications of three basic techniques (Freitas 
et al. 2005); Solvent extraction/evaporation; Phase separation; Spray drying.  Here solvent 
extraction evaporation methods have been used.  The process consisted of four steps: (i) 
dissolution or dispersion of the substance to be encapsulated in an organic solvent containing 
the polymer (ii) emulsification of this organic phase in a second continuous phase immiscible 
with the first one (iii) solvent extraction into the continuous phase, and evaporation of the 
solvent, transforming the droplets into solid microspheres (iv) harvesting and drying (Freitas 
et al. 2005).  
 
Eudragit®-PEG blend 
Thermo-sensitive polymer matrices consisting of Eudragit
®
 RS (Rohm Pharm, Darmstadt, 
Germany) and PEG 400 (polyethylene glycol with a low molecular weight) (Sigma Aldrich); 
polymers were produced by the solvent casting method (Fujimori et al. 2002).  They were 
dissolved at 13% PEG to Eudragit
®
 weight ratio in ethanol at 10 w/v% of total polymer 
concentration.  Different amounts of 4 M orthophosphoric acid (0.5ml, 1ml, 1.5ml) were 
added to this polymer solution.  This solution was then either cast into a rubber tube (10 mm 
diameter) cut in half along its length, or cast into Teflon coated dishes approximately 4 cm in 
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diameter.  The solvent was allowed to evaporate at 40 °C for 48 h in an incubator (New 
Brunswick Scientific, U.S.A).  The produced matrices were then removed and cut into 1 cm 
long pieces and stored in a silica gel desiccator. 
 
Eudragit® S100 
The pH threshold for Eudragit® S100 is 7.0; allowing 1 g of Eudragit
®
 S100 to dissolve in 7 g 
methanol, ethanol, in aqueous isopropyl alcohol or acetone (containing approx. 3% water), as 
well as in 1 N sodium hydroxide to give clear to slightly cloudy solutions.  Eudragit S100 
microspheres where prepared by the solvent evaporation method in water-in-oil-in-water 
double emulsions.  Eudragit S100 (600 mg) was dissolved in 10 ml of a mixed solvent system 
of dichloromethane (DCM)/ethanol/isopropyl alcohol in a ratio of 5:6:4 to form the organic 
phase (O).  The internal aqueous phase (W1) was made up of 2ml, 1.5ml, 1ml and 0.5ml of 
4M orthophosphoric acid along with polysorbate 20 (Sigma Aldrich) solutions (3% v/v).  W1 
was emulsified with the above organic phase for 2 minutes using an ultrasonic bath (Grant, 
XB6) in a 4 ºC ice bath which formed the primary emulsion (W1/O).  The primary emulsion 
was added drop by drop using a syringe with a needle diameter of 0.45 mm to a 50 ml 
external aqueous phase (W2) of 2wt% PVA (polyvinyl alcohol) (MW 23,000-70,000, Sigma 
Aldrich) solution by using a high speed homogeniser (Silverson L4RT, England) at the speed 
of 2,000 rpm for 4 minutes to form a “multiple emulsion” (W1/O/W2).  The resulting 
W1/O/W2 emulsion was stirred at room temperature overnight with a magnetic stirrer to 
evaporate the residual organic solvent. Samples were centrifuged (MSE High Speed 18, 
England) at 10,000g for 10 min and washed three times with distilled water to remove 
residual PVA.  The microspheres were then resuspended in distilled water and freeze dried 
(Edwards, EF03) for 24 h. The final product was then stored in a desiccator at 4 ºC.  
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Eudragit® RL 
Microspheres were prepared by the solvent evaporation method using an acetone/liquid 
paraffin system (Azarmi et al. 2002;Oth & Mos 1989).  Eudragit® RL (3 g) was dissolved in 
27 ml of acetone using a magnetic stirrer.  The PPA (1 g) and magnesium stearate (100 mg) 
were dispersed in the polymer solution.  The resulting dispersion was then poured into a 
vessel of 1000 ml containing the mixture of 270 ml liquid paraffin and 30 ml n-hexane while 
stirring.  A cylindrical vessel (10 cm inside diameter and 14 cm height) and a mechanical 
stirrer with a blade (6 cm diameter) were used.  Stirring was continued for an hour, until the 
acetone evaporated completely.  The polymer: acid ratio (3:1, w/w) and stirring rate (500 and 
750 rpm) of the system were changed to obtain spherical particles.  After evaporation of 
acetone, the microspheres formed were collected by filtration in a vacuum, washed 4–5 times 
with 50 ml n-hexane each and dried at room temperature for 24 h (Figure 6.3).   
 
PCL microspheres 
PCL microcapsules in this study were prepared using a simple emulsion solvent evaporation 
technique with a slight modification.  The PCL (1.5 g) was dissolved in 50 ml 
dichloromethane, to which 1 ml of the PPA was added and stirred well; this formed the 
organic phase of the emulsion.  This mixture was then emulsified into 500 ml of 2% w/v 
polyvinyl alcohol (PVA).  The emulsion was placed under a high speed homogeniser 
(SILVERSON, machine serial No.V5100) for 3 min at 7,000 rpm.  This emulsion was then 
magnetically stirred at 500 rpm followed by addition of 200 ml of distilled water, for 6 h, or 
until the dichloromethane had evaporated.  This increased the diffusion of organic solvent into 
the external aqueous phase to promote microsphere hardening.   
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Figure 6.3: Illustration of the production of Microspheres by the solvent evaporation method 
using the acetone/liquid paraffin system (Azarmi et al. 2002;Oth & Mos 1989).   
 
After completion of solvent evaporation, the microspheres were collected by centrifugation, at 
2,500 rpm for 10 minutes.  The solutions were evenly distributed into the centrifuge tubes and 
the excess solution was discarded, then the microspheres were washed out using distilled 
water about 3-4 times each, this ensured that the PVA has been washed off the surface of the 
microspheres.  The samples were collected and freeze dried and stored between 10-15 ºC.  
Microspheres dried at room temperature were then weighed and the yield was calculated 
using equation 6.1: 
 
          
                                      
                                                  
              (equation 6.1) 
 
110 
 
Table 6.1: The physicochemical properties of the poly(caprolactone) used in this study.  
 
 
6.2.2 Release study  
The release of acid from both temperature-sensitive matrices and pH-responsive microspheres 
was detected and quantified using the same method.  The encapsulated polymer (Eudragit 
(RL, S100 or E-PEG) or PCL) were weighed; half used as control.  The encapsulated 
polymers were immersed in 200 ml of distilled water for the release.  With the thermo-
sensitive matrices half were placed in an incubator and the other half in a refrigerator for the 
control (at 4 ºC).  A constant temperature of 37 ºC was maintained within the incubator for the 
thermo-sensitive matrices, and the control setup did not reach above 8 ºC in the refrigerator.  
For the pH-sensitive polymer matrixes, the control was kept at pH 4 and the rest was tested in 
a solution at pH 7.  Thereafter, 300 μl of sample was collected every hour from both the 
experiment and the control for 7 h and was analysed for the presence of phosphate ions. 
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The technique that was used to quantify phosphate ion release was described by Chen et al. 
(Chen et al. 1956).  Released solutions (300 μl) were mixed with 3.7 ml of distilled water and 
added to 4 ml of Reagent C.  Reagent C was made by mixing 2 volumes of distilled water, 1 
volume of 3 M sulphuric acid (Sigma Aldrich), 1 volume of 2.5% ammonium molybdate 
(Sigma Aldrich) solution and 1 volume of 10% ascorbic acid solution (Sigma Aldrich).  The 
mixture of sample solution and Reagent C was kept at 37 °C in an incubator for 1.5–2 h, 
followed by the reading of the optical density which was measured at 620 nm using a 
spectrophotometer (Cecil CE 1020).  The calibration curve for this experiment was made 
using different concentrations of a 2 M solution of potassium dihydrogen phosphate (Sigma 
Aldrich).  
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6.3 Results 
6.3.1 Release from Eudragit microspheres 
Various different combinations of Eudragit microspheres have been demonstrated in the 
literature; here we used two of the most common ones; temperature and pH sensitive, and also 
a mixed blend using other polymers. 
 
Eudragit®-PEG blend (temperature sensitive) 
The release of the encapsulated orthophosphoric acid (OA) from temperature sensitive 13% 
E-PEG matrices was investigated.  Four batches of the matrix encapsulating 1 ml of a 4 M 
OA solution were made.   
   
However, release studies were carried out on samples produced with OA as the encapsulation 
acid.  Figure 6.4 shows the percentage of the encapsulated acid released from the E-PEG 
matrix with respect to time.  It can be seen that more than 90% of the encapsulated acid is 
released by the end of the seventh hour at 37 ºC while the control has released only around 
15%.  Also, the curve is indicative of a higher percentage of release in the first four h 
(releasing more than two-thirds of the encapsulated acid) than in the last 4 h of the 
experiments.  This method was not used to produce cements with PPA as the samples produce 
were not microspheres; pellet-like rods were created.  This method produced a sticky mixture 
that had to be poured into a mould and allow for the polymer blend to cure.  
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Figure 6.4: The graph illustrates the cumulative release, in percentage, of OA released 
against time in hours, over an 8 h period at the different temperatures; at 37 ºC the thermo-
sensitive polymer releases the encapsulated content; at 4 ºC the content should remain 
encapsulated.  The graph illustrates the mean values of the data points from all the batches 
produced (error bars are also indicated). 
 
Eudragit® S100 (pH sensitive) 
The average size of the microspheres prepared using the double emulsion technique (Jain et 
al. 2005) falls in the micron range, so scanning electron microscopy was used to observe 
them.  The SEM micrographs clearly demonstrate the fragile nature of the microspheres 
(Figure 6.5); majority of the spheres appear to be broken, even though samples were handled 
with care.  The size of the microspheres can also be observed from the SEM and range 
between 10–200 µm; this variation may be due to the deficiency in controlling the stirring 
speed, which is the main factor influencing the particle size. 
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Figure 6.5: SEM micrographs of Eudragit S100 microspheres at 200 x magnifications (A) 
and (B).  The morphology illustrated in the SEM micrographs clearly shows all of spheres to 
be broken. At 5,000 x magnifications (C) it can be seen that the microspheres do produce a 
hollow sphere, with a relatively smooth surface.  Cracks or wrinkled-like surface of the 
microspheres may be attributed to the heat created by the high voltage of the electron beam. 
 
An attempt was made to produce pH-sensitive Eudragit
®
 S100 microspheres encapsulating 
OA.  Four batches of microspheres, containing 2 ml, 1.5 ml, 1 ml and 0.5 ml of 4 M OA as 
their Internal Aqueous Phases (IAP) were prepared.  The percentage of encapsulated OA 
released, assuming all the OA was encapsulated, is shown in Figure 6.6.  It can be seen that 
no greater than 10% of the encapsulated acid maintained at pH 7–7.5 was released at the end 
of the 7 h period.  This is likely to be because only a fraction of the acid was actually 
encapsulated, indicating that the technique used may not be the best for this application. 
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Figure 6.6: The graph illustrates the cumulative release, in percentage, of OA released 
against time in hours, over an 8 h period at the different pH; at pH7.4 the pH-sensitive 
polymer releases the encapsulated content; at pH 4 the content should remain encapsulated.  
The graph illustrates the mean values of the data points from all the batches produced (error 
bars are also indicated). 
 
From previous investigations, it was clear that although the Eudragit S100 microspheres were 
manufactured using the double emulsion technique (Jain et al. 2005) (Figure 6.5), they 
appeared to break very easily.  Taking this into consideration a solvent evaporation method 
was used (Figure 6.3).  Figure 6.7 shows that it was not possible to produce microspheres 
using this method. 
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Figure 6.7: Eudragit S100 prepared by solvent evaporation method using acetone/liquid 
paraffin system (Figure 6.3).  The micrograph shows the fragments of the microspheres, the 
fluffy flake-like structure created by this method does not allow the encapsulation of OA (A) 
and PPA (B).  
 
Subsequently as it can be seen from Figure 6.8, where both the release at pH 7 and pH 4 
show similar release profiles, this method would clearly not be suitable for encapsulation of 
the OA and PPA.  The Eudragit
®
 S100 is unstable when formulated into microspheres with 
the solvent evaporation method using acetone/liquid paraffin system.   
 
 
Figure 6.8: The graph illustrates the cumulative release in percentage of OA (A) and PPA (B) 
released against time in hours, at the different pHs;  pH7 the pH-sensitive polymer releases 
the encapsulated content; at pH 4 the content should remain encapsulated, however results 
show total release of microsphere content.  The graph illustrates the mean values of the data 
points from all the batches produced (error bars are also indicated).  Eudragit S100 prepared 
by solvent evaporation method using acetone/liquid paraffin system (Figure 6.3). 
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Eudragit® RL 
Figures 6.9 illustrate the morphology of the microspheres produced using the solvent 
evaporation method.  The microspheres were generally smooth, spherical and regular; 
however, they exhibited a wide particle size distribution from 10–150 μm in diameter, which 
may be due to a variation in flow during stirring.  The microspheres also seem to be fused 
together in clumps.  From Figure 6.9B it is clear that these clumps are bound together so if 
broken or separated it is likely to release the encapsulated content.   
 
 
 
Figure 6.9: (A) Eudragit
®
 RL microspheres without any encapsulated acids.  Microspheres 
were prepared by solvent evaporation method using acetone/liquid paraffin system (Figure 
6.3).  (B) and (C) Higher magnification of the microspheres to emphasize the binding of the 
microspheres.  
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Figure 6.10: Eudragit
®
 RL microspheres with OA (A and B) and PPA (C and D) 
encapsulated.  Microspheres were prepared by solvent evaporation method (Figure 6.3).  
Micrographs show the difference in morphology of the two microspheres; with OA 
encapsulated the surface is smooth, with a porous interior structure; with the PPA the 
microspheres exhibited a porous surface, on closer inspection the interior was hollow or 
porous within the same batch. 
 
Although from the study using Eudragit S100 microspheres it was apparent that majority of 
the microspheres produced were broken, however a small quantity of the samples were 
collected that had kept their structural integrity allowing the measure of the particle size 
distribution and compare with the Eudragit RL microspheres.  Accordingly, Figure 6.11 the 
particle size distribution of the microspheres was large ranging between 10 and 100 μm.  The 
particle size distribution was not congruent with the previous observations made using SEM, 
suggesting that the particles were agglomerating in solution, this is also suggested by the 
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observed differences between the particle size distributions of different batches produced 
under the same conditions.  When the homogeniser was set at speeds of less than 5,000 rpm, 
the spheres were not formed, illustrating the importance of effective force to create a stable 
emulsion.  
 
 
Figure 6.11: The graph illustrates the particle size distribution of the two microspheres 
produced; Eudragit S100 (A) and Eudragit RL (B), using the two different methods. 
 
Release profiles for the microspheres producing using the solvent evaporation method using 
acetone/liquid paraffin system (Figure 6.3) are shown in Figure 6.12.  The release was 
carried out over a 24 h period, to ensure maximum release was recorded; both phosphate and 
pyrophosphate release were calculated from the results and are illustrated in Figure 6.12A.  
The release from the control sample at 4 ºC was carried out for 8 h only; as no further release 
was measured after 3 h. 
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Figure 6.12: Illustrates the cumulative release (%) of OA and PPA over, (A) 24 h period at 37 
ºC; (B) OA and (C) PPA release over an 8 h period at the different temperatures; 37 ºC the 
thermo-sensitive polymer releases the encapsulated content; at 4 ºC the content remain 
encapsulated.  Illustrating the mean values of the data points from all the batches produced 
(error bars are also indicated). 
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It can be seen that the microspheres are releasing the phosphate steadily (Figure 6.12).  The 
control (at 4 ºC), however, also shows a degree of release which could be attributed to the 
release of surface bound acid.  The continued release suggests that the temperature of the 
distilled water, in which the microspheres release, may not have been low enough (may not 
have reached 4 ºC).  This demonstrates that the thermo-sensitive Eudragit RL can be used to 
manufacture microspheres that are temperature sensitive.  
 
Figure 6.13 demonstrates the effect of concentration of the acid on the conversion of β-TCP 
to brushite.  It can be seen from the peak representing brushite that it increases in height with 
an increasing ratio of OA to β-TCP.  This shows conclusively that the brushite crystals are 
formed within the cement mix.  The peaks also confirm that the released acid is in fact OA, 
since no other component of the microsphere formulation can react with β-TCP to form 
brushite (Pflugrath 1999). 
 
Microspheres were manufactured to encapsulate the acid component of the cement reactants; 
this was achieved and it was demonstrated that the release acid component was able to 
recreate the reaction with the cement powder components and form the cement matrix 
(Figure 6.13).  Following this, the microspheres were mixed with the powder components 
and water at 37 ºC (using the Eudragit RL) to initialise the reaction.  XRD patterns in Figure 
6.14 illustrate the resultant cement composition. 
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Figure 6.13: Compares the diffraction patterns of the control cement (β-TCP + OA+ water) 
with the varying concentrations of OA paste formulations using microspheres staggered on 
top.  The various peaks are indicative of the composition of the samples; ○ Brushite; ● β-tri-
calcium phosphate (β-TCP). 
 
6.3.2 Cement composition 
Once it was determined that Eudragit microspheres could be produced reproducibly; 
calculations using the stoichiometry equation determined the amount of microspheres are 
required to enable the powdered components to fully react to produce brushite cement.  The 
correct amount of acid encapsulated Eudragit microspheres were then mixed with the β-TCP 
and placed in the incubator at 37 ºC overnight to allow the cement to harden.  The set cements 
were then tested and compositions were compared to the control samples in the case of both 
OA and PPA cements. 
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The results from the XRD shown in Figure 6.14 show the compositions of two cement 
formulations.  The cements made using the microspheres to encapsulate the orthophosphoric 
acid and made without encapsulation formed brushite as the end product.  The XRD patterns 
in Figure 6.14A exhibit very little change in composition, suggesting a complete reaction of 
β-TCP.  Both the control pyrophosphate modified brushite cement, formed using a liquid 
phase of water and PPA, and the Eudragit pyrophosphate modified brushite cement, formed 
using the PPA component encapsulated within the microspheres, demonstrate that there is 
very little β-TCP remaining in the cement, suggesting almost complete reaction (Figure 
6.14B).  Importantly, no MCPM was formed within the cement matrix, which can occur if the 
pH value of the cement paste drops significantly below pH 4.2 in localised regions within the 
cement paste.  The apparent similarity in composition between the cement formed using the 
PPA free and encapsulated in Eudragit is very important as it demonstrates that the presence 
of the polymer has little or no influence on the final composition of the material.  
 
SEM micrographs of the fracture surfaces of the Eudragit cement are shown in Figure 6.15.  
The micrographs show the effect of encapsulating the OA and PPA in the Eudragit 
microspheres instead of using it directly during mixing.  The images illustrate the size and 
shapes of the brushite crystals; Figure 6.15 confirms the composition of the cement produced 
due to the presence of blade-like crystals, representative of brushite.  On examination at 
higher magnifications, the length of the blade-like structures ranged from 15–50 μm in length 
and from 2–10 μm in width.   
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Figure 6.14: Compares the diffraction patterns of the control cement (β-TCP + OA (A) or 
PPA (B) + water) with the paste formulations using Eudragit RL microspheres with the 
encapsulated OA (A) or PPA (B).  The various peaks are indicative of the composition of the 
samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP). 
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Figure 6.15: (A) SEM micrographs of the fracture surface of the set cement produced using 
Eudragit RL microspheres to encapsulate the OA component (500 X magnified); (B) A higher 
magnification (1,000 X) of the cements needle-like microstructure; and (C) the surface of the 
cement at 1,500 X magnifications that shows both brushite crystals and Eudragit RL 
microspheres.  Eudragit
®
 RL microspheres were prepared by solvent evaporation method 
using acetone/liquid paraffin system (Figure 6.3).   
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Figure 6.16: (A) SEM micrographs of the fracture surface of the set cement produced using 
Eudragit RL microspheres to encapsulate the PPA component (500 X magnified); (B) A 
higher magnification (1,000 X) of the cements needle-like microstructure; and (C) the surface 
of the cement at 1,500 X magnifications that shows both brushite crystals and Eudragit RL 
microspheres fused together; small amounts of degraded polymer is visible, which appears to 
be fusing the brushite crystal together in some areas.  Eudragit
®
 RL microspheres were 
prepared by solvent evaporation method using acetone/liquid paraffin system (Figure 6.3).   
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6.3.3 Storage of microsphere-cement pastes 
It is evident from Figures 6.14–6.16 that the Eudragit encapsulated acid is able to be released, 
as a result of a change in surrounding conditions, and react with the powder component of the 
cement; forming a hardened brushite cement as the end product.  The preservation of the 
paste-like nature of the material is shown in Figure 6.17. 
 
 
Figures 6.17: The images show the effect of storage at 4 ºC with the use of microspheres 
S100 (A) and RL100 (B). 
 
The initial results were promising, illustrating that the cement paste could be stored without 
setting for 28 days (Figure 6.17).  The final samples were removed from storage at 4 ºC after 
90 days appear to remain unset. However, when exposed to a change in temperature the 
microspheres released their content and allowed the cement paste to harden, producing set 
cement phase compositions comparable to the control samples (Figure 6.18).  The fact that 
the cement remains as a paste for such a long period in the sealed containers suggests that the 
microspheres have not „leaked‟ their load of PPA into the cement paste.  This confirms the 
efficacy of the temperature dependent materials on storing PPA in these conditions for an 
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extended period of time.  Unfortunately, the materials produced using the pH responsive 
polymer hardened after only one day of storage at 4ºC, this excludes the further use of this 
system and consequently we are investigating other polymer (e.g. poly(caprolactone)) for the 
production of a „shear-activated‟ cement system. 
 
 
Figures 6.18: Illustrates that similarity in the composition of the control pyrophosphate 
modified brushite cement (bottom) and the Eudragit encapsulated PPA cement after being in 
storage at 4 ºC for 90 days then; heated to 37 ºC to allow hardening (middle) and without 
being exposed to a change in the environment to allow hardening (top).  The various peaks are 
indicative of the composition of the samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP). 
 
6.3.4 PCL microspheres 
The results show that the PSD, again similar to the Eudragit microspheres, have a large range.  
The particles exhibit diameters from 0.4 μm to 3000 μm.  Impeller speed did not influence the 
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mean particle size; the peaks were also broader as the speed was increased.  ESEM images 
illustrate that the particles produced using the double emulsion method for PCL produced 
microspheres of diameter 0.5–1 µm; very small compared to Eudragit.  Similar to Eudragit, 
there is a large variation in the size of the microspheres (Figure 7.19).  The EDS results in 
Table 6.2 quantify the amount of the elements that are present in each spectrum, which relates 
to the box in Figure 6.20.  
 
Figure 6.19: Shows the particle size distribution of the microspheres produced using PCL; 
the speed at which there were produced had a large effect on the PSD: 6,000 rpm (A); 3,000 
rpm (B); 1,500 rpm (C); and 750 rpm (D). 
 
Table 6.2: Shows EDS results of the microspheres produced using PCL, with the table which 
shows the elements present. 
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Figure 6.20: Shows the ESEM micrographs of the microspheres produced using PCL; (A) 
shows spectrum 1 – outer layer of the microsphere, (B) shows spectrum 2 – the inside of the 
microsphere, both relate to the EDS analysis in Table 6.2. 
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Here in Figure 6.21 it is evident that the PCL microsphere released the encapsulated PPA 
without a stimulus.  The PCL beads were dispersed into 37 ºC distilled water and elutes were 
taken every 10 minutes for a total of 90 minutes, the results demonstrate that PCL 
microspheres leak. 
 
 
Figure 6.21: The graph illustrates the cumulative release, in percentage, of PPA released 
against time in hours, for a total of 2 h at room temperature of 22 ºC the content should 
remain encapsulated, however, here the contrary is demonstrated.  The graph illustrates the 
mean values of the data points from all the batches produced (error bars are also indicated). 
 
6.3.5 Mechanical properties of microsphere-cements 
The resulting cements from the above successful cement formulations were compared to 
determine the most efficient method and polymer for the encapsulation of the acid component 
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of the cement.  The results in Figure 6.22 demonstrate that the strength of the cements 
produced is dependent on the speed of the homogeniser used.  The slower the speed of the 
homogeniser the larger the microspheres, with more acid loaded, which mean the cement 
formulated is less porous as there is less degrading polymer.   
 
From the results it is evident that the mechanical properties are directed related to the stirring 
rate.  The faster the stirring rate the weaker the final cement is, due to the increased porosity.  
Microspheres produced at speeds of 6,000 rpm and mixed with the cement powders produce 
cements with strengths of 446 KPa and 403 KPa for Pyro and ortho brushite cements, 
respectively with similar porosity levels (16-17%).  At the lower stirring speeds of 750 rpm 
(lowest speed the microspheres are able to be produced at) pyro brushite cement exhibits 
strengths of 767 KPa with porosities of 23%, whereas ortho brushite cements exhibit lower 
strengths of 662 KPa with higher porosities of 35%.  This higher strength of the pyro cement 
may be attributed to the fusion of the brushite crystals with degrading Eudragit polymer 
(Figure 6.16).  In comparison Figure 6.15 demonstrates the brushite crystals not fused 
together, and also shows the presents of the Eudragit polymer spheres between the brushite 
crystals, which may be the reason for the poor mechanical strengths. 
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Figure 6.22: The graph illustrates the compressive strengths (A) of the cements compared to 
the relative porosities (B) at each homogeniser speed (750, 1500, 3000, 6000 rpm). 
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6.4 Discussion 
Polymer matrices and microspheres were selected to be employed as temperature- and pH- 
sensitive encapsulation systems.  Since there was no previously published work on the 
concept of using encapsulation techniques to delay CPC formation, different such methods 
were trialled during the first half of the project to see if the morphologies of the produced 
microspheres and matrices would be affected on encapsulating OA.  
 
Eudragit®-PEG blend  
The matrices, produced using a simple solvent casting technique had comparable 
morphologies to those obtained in previous studies (Fujimori et al. 2002) whose method was 
used in this work to encapsulate OA.  The results of release studies carried out on temperature 
sensitive matrices have shown that there is a greater amount of the encapsulated OA released 
at around body temperature in contrast to the control (maintained at 4ºC), which released only 
small amounts of OA.  As can be seen in Figure 6.4, during the first hour of the experiment 
an average of 50% of the encapsulated OA was released, while the control released only 
around 8%.  In the second hour, close to 65% of the encapsulated amount was released in the 
experiment while the control released very little after the first hour.  By 4 h of release, over 
90% of the OA was released in the experiment while only a maximum of 15% was released in 
the control.  After reaching a total release of over 90%, the curve plateaus showing on average 
greater than 95% release of the encapsulated amount by the end of the experiment.  In 
contrast, the control curve, also demonstrated a plateau, but from the initial hour, shows only 
an average of 15% release by end. 
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The results obtained from these studies are similar to those obtained by Fujimori et al (2002) 
whose work involved quantifying the percentage of release of the drug acetaminophen from 
EPG matrices (Fujimori et al. 2002).  They obtained an 80% release of a solution containing 
acetaminophen from 13% EPG matrices by end of a release study lasting 6 h. The cause of the 
much higher release of acid at 37 ºC could be attributed to the fact that 13% EPG matrices 
have a glass transition temperature at around that temperature making them more permeable 
than at 4 ºC.  The results show in positive light that it would be possible to develop 
temperature-sensitive EPG matrices into an encapsulation system for use in CPC 
formulations.  However, the morphology of these matrices would not be able to be 
incorporated within the cement components.  Therefore, before they can be incorporated into 
a CPC formulation as a workable encapsulation system, they must be produced in micro-size.  
The formations of these micro-sized spheres were then carried out using different methods.    
 
Eudragit® S100 
The microspheres prepared by the double emulsion solvent evaporation method, using water-
in-oil-in-water double emulsions (Jain et al. 2005), had regular morphologies, and were 
relatively spherical, as can be seen in the SEM pictures Figure 6.5.  However, the 
microspheres appeared to be broken and damaged, therefore this was another method that was 
not of choice for producing microspheres for subsequent release studies.  The release studies 
of pH-responsive microspheres have, contrary to expectation failed to show that a cement 
paste could be formulated without triggering setting and cement formation at a lower pH.  It 
was found that in the first hour, there was a release of around 7% of the encapsulated amount 
in the experiment maintained at pH 7.4 (Figure 6.6).  This was less than three times that of 
the control, which released in the same time, nearly 2.5% at pH 4; the low pH release also 
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demonstrated large errors (almost ± 1.0%).  This shows that the microspheres are only slightly 
sensitive to pH, and that storing a cement mix at low pH such as 4 would result in conversion 
of at least half of the β-TCP into brushite.  Furthermore the amount released did not increase 
by more than 1% in the following 6 h in both experimental and control release profiles.  
Therefore, not only was there an average release of only 7% of the entire encapsulated content 
of acid, but the microspheres did not show much sensitivity to pH.  These results are in 
contrast to those obtained by Jain et al. (2005) who produced Eudragit S100 microspheres 
loaded with insulin, and obtained a release of nearly 50% by the end of a 6 h release study 
(Jain et al. 2005). 
 
Two reasons could be attributed to the failure of the experiment with pH-responsive 
microspheres.  One reason for the relatively poor pH-sensitivity seen in the control could be 
that not all of the acid was encapsulated within the microspheres.  A considerable quantity of 
OA may have been deposited on the microsphere surface, thereby not releasing it as such, but 
washing off the surface attached acid, upon contact with water.  Another reason could be that 
the microspheres incurred considerable damage during preparation since making double 
emulsions is a relatively complex procedure involving a high-shear homogenisation step and 
an extreme temperature freeze-drying step.  The another method described previously 
(Haznedar & Dortunc 2004) was originally intended for the production of Eudragit RS; used 
on Eudragit S100 as an alternative.  The method did not produced microspheres, instead 
clumps of highly irregular flake-like structures was formed, as apparent from SEM analysis 
(Figure 6.7).  The subsequent release profile of these polymer flakes was demonstrated in 
Figure 6.8; this was considered a failure.  Again the flake-like structure probably bound much 
137 
 
of the acid on the surface, which washed off during the release study exhibiting release of 
phosphate regardless of a change in pH. 
 
Eudragit® RL 
The temperature sensitive microspheres were produced by a method (Azarmi et al. 2002) 
previously used for the encapsulation of drugs in to microspheres, such as insulin.  The 
originally intended method for Eudragit
®
 RS/RL polymers was used and produced regular 
bead like morphology.  Initially, however, the microspheres were highly clumped together.  
Encapsulation was possible with the solvent evaporation method using the acetone/liquid 
paraffin system (Figure 6.9–10).  Consequently, the release profiles of these microspheres 
exhibited an initial burst and then plateaus after 60% of the total phosphate had been released 
(after 7 h).  On comparing the control sample (at 4 ºC) to the increased temperature (37 ºC) 
sample release profile (Figure 6.12) it was obvious that this method was successful in 
producing a temperature sensitive microcapsule that would release on demand.  
 
X-ray diffraction analysis was carried out on the cement mix obtained by mixing the released 
OA from the temperature-sensitive microspheres with increasing amounts of β-TCP.  It 
showed that a small amount of the β-TCP was converted to brushite (Figure 6.13).  This was 
both conclusive evidence for cement formation as well as confirmation of the fact that the 
released content from the temperature-sensitive matrices was indeed OA and not any other 
substance.  The reason for the small peaks representing brushite is likely due to the relatively 
small amounts of acid encapsulated (no more than 1 ml), and also due to dilution of OA 
samples when they were released (in 200 ml of water).   
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SEM micrographs of the fracture surfaces of the Eudragit cement are shown in Figure 6.15; 
the micrographs show the effect of encapsulating the PPA in the Eudragit microspheres 
instead of using it directly during mixing.  The images illustrate the size and shapes of the 
brushite crystals which form blade-like crystals to indicate the presence of brushite.  On 
examination at higher magnifications, the length of the blade-like structures ranged from 15–
50 μm in length and from 2–10 μm in width.   These sizes are consistent with the control 
pyrophosphate modified brushite cements made previously.  Figure 6.14 confirms the 
composition of the cement produced using XRD analysis which exhibits peaks for β-TCP and 
brushite.  However, the presence of blade-like crystals in the pyro-modified brushite cement is 
not typical of the structure, as Grover et al. demonstrated the mixture of β-TCP-PPA-OA 
presented prismatic crystals 2–4 mm in length and 1–2 mm in width instead of the blade-like 
microstructure (Grover et al. 2005a).  The presence of the brushite crystals here may be 
explained by the hydrolysis of the PPA to form OA.  Grover et al. reported the presence of an 
unexpected amount of brushite in a study based on α-TCP-PPA-OA and suggested that when 
the cement is immersed in water, the P-O-P bond in a pyrophosphate ion could be hydrolyzed 
to form two orthophosphate ions, as shown in the equation 6.2, this may be the reason for the 
blade-like crystals present in the pyro-modified brushite cement: 
H4P2O7 + H2O  2H3PO4                    (equation 6.2) 
Storage of microspheres 
To determine the influence of storage time on the composition of the cement pastes 
formulated using microspheres, the cement powder and the microspheres were mixed using 
the quantities calculated from Equation 6.1, mixed with the adequate amount of distilled 
water and stored in a sealed universal container at 4 ºC for periods of 3, 7, 14, 28 and 90 days 
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before being cast into moulds in ambient conditions and allowed to harden in at various 
different conditions, as mentioned above.  The initial results were promising; presenting the 
cement paste could be stored without setting for 28 days (Figure 6.17).  The final samples 
were removed from refrigeration after 90 days of storage and the consistency was analysed.  
The cement pastes that remain in a paste form, for such length of time, in the sealed 
containers suggests that the microspheres have not leaked their load of acid into the cement 
paste.  This confirms the efficacy of the temperature dependent materials on storing the acid 
component in these conditions for an extended period of time.  Unfortunately, the materials 
produced using the pH responsive polymer hardened after only one day of storage at 4 ºC 
therefore not useful for this investigation.   
 
For the cement pastes that did not set, due the leakage of the microspheres, were then mixed 
under 37 ºC and allowed to set.  This set cement was diffracted and results are explained 
using Figure 6.18 show that brushite is the phase present in the final set cement, post 
hardening.  It is also clear from the XRD patterns that the paste formulation remains as β-TCP 
and the acid kept separate from the powder not allowing the cement reactants to mix and set.  
The set cement consists predominately of brushite peaks with high intensities and a few, low 
intensity β-TCP peaks; comparable to control pyro-modified brushite cements.  
 
PCL microspheres 
As expected Figure 6.19 shows that there is a variation in size with speed, as the speed was 
increased the microspheres reduced in size.  However, as speed was increased, the 
microspheres exhibited a broader particle size distribution.  This meant that the increase in 
speed was not stable, at lower speeds the microspheres seemed to be more stable, e.g. at 
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750rpm, the particle size distribution is of high intensity.    The ESEM micrographs also 
confirm this results, Figure 6.20 directly shows the variation in size.  The spectrum boxes 
marked on the micrographs are analysed by the EDS and the results are shown in Table 6.2.  
The results quantify the elemental content of each spectrum taken; e.g. in spectrum 1 we 
expect to see the presences of everything that are components of the PCL microspheres only.  
From spectrum 2 we expected the same, however, with the presence of phosphorus which 
would indicate that the PPA was encapsulated.  However, this was not the case.  Both 
spectrums demonstrated no phosphorus presence.  This could possibly be due to the small 
amount encapsulated or that the particular microsphere broken and analysed with the EDS 
was not recently broken.  Figure 6.21 illustrates the initial cumulative release of the acid 
released at room temperature (22 ºC); the  content of the microsphere should remain 
encapsulated, however, it is the total opposite; total uncontrolled release was observed.  The 
reason for this remains known; it may be due to the instability of the microspheres and the 
strength of the acid content.   
 
Mechanical properties of the cements produced following the encapsulation of the acid 
component remains to be generally weak (Figure 6.22) compared to the control cements.  
This is no doubt due to the addition of the polymer microspheres that the acids were 
encapsulated in.  At high speeds the microspheres produced were smaller; this means when 
mixed with the powder component of the cement matrix there is a higher ratio of polymeric 
material after release, due to the larger surface area in total.  This in turn causes greater 
porosity in the hardened cement, as the polymer degrades and departs the cement matrix, 
leaving a highly porous scaffold.  However, one method of overcoming this was to produce 
larger microspheres to maximise loading and minimise the polymer-to-cement ratio.  
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However, the continual production of larger microspheres can be difficult; microspheres were  
not easily fabricated below 750 rpm using the method by Azarmi et al.; although many 
methods suggest otherwise (Gao et al. 2006;Haznedar & Dortunc 2004;Kim et al. 2002;Sipos 
et al. 2005;Tamber et al. 2005;Wu et al. 2003).  In the preparation of the microspheres, the 
selection of the appropriate solvent is of major importance.  The ideal organic solvent has low 
toxicity and diffuses quickly into the external aqueous phase, thereby ensuring uniform 
solidification of the polymer.  Rapid solidification of the globules is a key step, because this 
avoids coalescence of the droplets and drug outflow from them, especially at such low speeds.  
Acetonitrile, methanol, methyl ethyl ketone, acetone, ethyl acetate and also their mixtures are 
widely used as polymer carriers; these solvents are less toxic and their use can result in a 
slightly increased particle size (Ruan et al. 2002).  Most of the research on polymer 
microsphere production is focussed around drug delivery, and optimising the encapsulation of 
drugs into the smallest particle size.  However, here in this study we are looking at increasing 
at particle size to maximise the loading and minimising the amount of the polymer in the 
cement formulation.  Figures 6.22 demonstrate that producing larger microspheres can result 
in stronger cements, exhibiting 767 KPa at speeds of 750 rpm with an average porosity of 
16% (n = 3).  These cements demonstrated significantly greater strengths than the cements 
with microspheres produced at 6000 rpm (ρ < 0.05). 
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6.5 Conclusion 
Using a Eudragit® RS-PEG 400 blend polymer, temperature-sensitive matrices were 
produced that successfully encapsulated OA.  They were studied for release of the acid and it 
was found that almost all of it was released it at 37 ºC and only very little at 4 ºC showing the 
responsiveness of the matrices to different temperatures.  X-ray diffraction then showed that 
the OA released from the polymer could cause hardening in the brushite cement.  
 
The temperature-sensitive matrices can be tested further for increased capacity to encapsulate 
OA. When more information from different batches is available, the exact amount of polymer 
required to obtain a certain amount of brushite can be calculated and feasibility studies can be 
conducted for application in vivo.  The temperature-sensitive matrices could be tested for the 
possibility of producing an injectable pre-mixed brushite CPC paste by mixing appropriate 
quantities of the ground or crushed OA-encapsulating matrices, β-TCP and water. Storing the 
paste at low temperatures such as 4 or 8 ºC would prevent the release of OA from within the 
polymer matrix and thus ensure that significant cement formation will only occur once 
implanted wherein the temperature of the CPC paste will be raised to around 37 ºC. 
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Chapter Seven 
Calcium Phosphate Cements For Drug Delivery 
7.1 Introduction 
Postoperative infections are one of the largest problems associated with orthopaedic surgery 
and such infections often lead to severe pain, loss of bone tissue and possibly removal of 
implants, which requires secondary operations (Harris & Sledge 1990;Lew & Waldvogel 
2004a;Ruchholtz et al. 2004).  These orthopaedic-related infections are largely caused by 
Gram-positive bacteria such as Staphylococcus aureus, epidermidis, and Streptococci 
(Moojen et al. 2007).  These bacteria are treated using various regimes of antibiotic 
administration and for this reason, an increasing number of these bacteria have become 
resistant to antibiotics.  Especially methicillin-resistant S. aureus, which are commonly found 
in infections caused by orthopaedic surgery (Dion et al. 2005;Penner et al. 1996).   
 
Often intramuscular or intravenous administration of an antibiotic does not allow sufficient 
concentrations of the drug to reach the area of infection, as blood circulation is limited and/or 
uncertain.   Therefore, one current method of treatment is the localized delivery of antibiotics.  
One way of enabling localised delivery is to encapsulate the drug of choice into poly(methyl 
methacrylate) (PMMA) beads (Alt et al. 2004;Bohner et al. 1997), which are pressed into the 
defect or mixed with CPC (Itokazu et al. 1998).  PMMA beads are, however, not resorbable 
(Penner et al. 1996) and require surgical removal after which they may be replaced either by 
new beads to prolong the antibiotic therapy or an alternative bone graft.  Therefore, much 
research has focussed on the impregnation of antibiotics within resorbable materials such as 
CPCs (Anttipoika et al. 1990;Barralet et al. 2002a;Bohner et al. 1997;Dion et al. 2005;Frutos 
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et al. 2002;Ginebra et al. 2006;Jiang et al. 2008;Penner et al. 1996;Gitelis & Brebach 
2002;Schnieders et al. 2006).  The possibility to use CPCs, not only as bone substitutes, but 
also as carriers for local and controlled supply of drugs is very attractive. They have been 
used for the regeneration of bone defects caused by the resection of bone tumours, 
osteoporosis or osteomyelitis and can provide a prophylactic dose of antibiotics to prevent 
further infection.  Unlike calcium phosphate ceramics employed as drug delivery systems, 
where the drugs are usually absorbed on the surface, in CPCs the drugs can be incorporated 
throughout the whole material volume, by adding them into one of the two cement phases, 
thus enabling more prolonged delivery of the therapeutic molecule of choice.  Drugs can be 
introduced either in the liquid phase or in the powder phase of the CPC matrices.  During 
cement setting, dissolution of calcium phosphates from the powder phase takes place, and it 
can be assumed that the drug is dispersed in the matrix formed by the set cement.   
 
The hypothesis, therefore, must prove how CPC’s can be formulated to exhibit properties of 
both a cement material scaffold and also is able to deliver antibiotics to the site of infection. 
 
7.1.1  Aim 
This chapter provides an insight in the application of CPC’s as matrices for controlled drug 
release.  Various formulations of the CPC’s that have been previously studied are used here 
and have been manipulated by incorporating active molecules such as, Vancomycin 
Hydrochloride (VH) and Gentamicin Sulphate (GS).  The principal objective of this 
investigation was to determine the effectiveness of the antibiotics which have been 
incorporated into the cement matrices by means of measuring the release and culturing 
microorganisms and determining inhibition zones. 
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7.2 Materials and Methods 
 
7.2.1 Matrix preparation for CPC comparison study 
The CPC’s considered for the release study included two brushite cements and HA as a 
comparison.  Firstly, HA cement consisted of an equimolar mixture of TTCP and DCPA 
which was mixed with water at a P: L of 3.5 g/mL.  The setting reaction proceeded in 
accordance with Equation 7.1.   
Ca4(PO4)2O + CaHPO4 + H2O  Ca5(PO4)3OH + H2O            (equation 7.1) 
The orthophosphate brushite cement consisted of β-TCP with a liquid component made up of 
4 M orthophosphoric acid with 10 mM citric acid, as a retardant.  The powder and liquid 
components were mixed at a P: L of 2.5 g/mL, the cement set in accordance with Equation 
4.6.  Finally, the pyrophosphate modified brushite cement consisted of β-TCP and a liquid 
mixture of distilled water combined with PPA with a water-to-PPA ratio of 1.37:1, both 
phases were mixed together at a P: L of 2.5 g/mL, and hardened in accordance with Equation 
4.9.  The VH (Sigma–Adrich, St. Louis, MO) was mixed with the cement powder at a 
concentration of 50 mg/g, prior to combination with the liquid phases in each case.  All the 
cement matrices were poured into a PTFE split mould to produce set cylindrical samples of 
12 mm (height) by 6 mm (diameter) and samples were allowed to harden for a period of 24 h 
in ambient conditions before further study.   
 
7.2.2 Sample Elution 
The CPC samples were immersed in 5 mL of pH 7.4 PBS stirred at 100 rpm and incubated at 
37 °C.  At regular time intervals 5 mL was withdrawn from each sample and assayed for 
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GS/VH content by a colourimetric method.  Antibiotic release was monitored by measuring 
the absorbance of the elution medium at 280 nm and 246 nm (for VH and GS, respectively) 
using a UV–visible spectrophotometer (UVIKON 922, Northstar Scientific, Potton, UK). 
Antibiotic concentrations were determined from the average of three absorbance readings 
using corresponding calibration curves (Appendix 3).   
 
7.2.3 Microbiological activity assay 
Staphylococcus aureus (ATCC 25923, NCIMB, Aberdeen,UK) and Staphylococcus 
epidermidis (ATCC 12228, NCIMB, Aberdeen,UK) were aerobically cultured on nutrient 
agar plates, with antibiotic loaded CPC samples of known masses (approximately 2.0 g, 1.0 g, 
0.5 g and 0.25 g) placed in the centre of each Petri dish for 24 h at 37 °C.  The same was done 
for the samples used in the release experiment; this was thought to determine the potency of 
the cement samples following a release experiment lasting 24 days in total.  The inhibition 
zones of the samples were determined by measuring the diameter of the inhibited area at three 
points.  This zone also included the sample in the middle; the reason for this was that the 
samples varied in size.  The effectiveness of the VH loaded cements was also measured by 
means of observing the broth culture turbidly with an inoculation of S. aureus (1 × 10
6
 cfu/ 
mL) grown in Müeller Hinton broth for 24 h at 37 °C.  A VH-containing sample was added 
into the Müeller-Hinton broth with S. aureus at a 1:1 ratio.  A bijou containing 500 mL of 
Müeller-Hinton broth with S. aureus served as a positive control, and 500 mL of none 
inoculated Müeller-Hinton broth served as a negative control.  All samples were incubated at 
37 °C for 16–24 h.  Antibacterial activity assays were conducted for both control calcium 
phosphate cements and calcium phosphate cements–loaded VH samples at each time point. 
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7.2.4 Mechanical Testing 
The ultimate compressive strength (UCS) was measured using a Universal Testing Machine 
(Lloyd Instruments LTD, 6000R, Southampton, UK) at a crosshead speed of 2 mm/ min.  The 
samples were tested before and after the 24 day release.  Hardened cement samples were 
broken to provide fracture surfaces for observation, both before immersing in PBS to measure 
the release and after the release experiment had been terminated (after 24 days).  The samples 
were coated with platinum before analysis in a field emission scanning electron microscope 
(SEM) (JEOL, JSM-7000F, UK).   
 
7.2.5 Physicochemical characterisation 
The crystalline compositions of the cement matrices were determined using XRD; Fourier 
transform infrared spectroscopy (FTIR) was also use to characterise the samples.  The 
powdered samples were placed onto the diamond window on the stage of a smart orbit FTIR 
(NICOLET 380, Thermo Electron, Madison, WI), and the spectra were recorded at a 
resolution of 4 cm
-1
  and 32 scans.  X-ray powder diffraction data were collected using 
CuKα1 radiation from a powder diffractometer (D5000, Siemens), aligned in transmission 
mode.  The data set was collected from 5˚ to 60˚ 2θ with a step size of 0.05˚.   
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7.3 Results 
Initial work carried out on the antibiotics VH and GS using characterisations methods, such as 
SEM, XRD and FTIR.  This was to identify and characterise key properties the antibiotics 
prior to incorporation with the cement, to determine any factors which may influence the 
cement properties after mixing within the cement. 
 
7.3.1 Comparison of CPCs  
In the case of both the brushite cements, a burst release of VH was observed during the first 
24 h of the stud (Figure 7.1).  Following the initial burst, the rate of release reduced 
significantly, and after 11 days, both cements had released 75-80% of their loaded VH.  In 
comparison the HA cements released only 20% of the VH within the first 24 hours, however, 
by day 4 the total percentage released increased to 40%, this trend continued until day 7 and 
carried on increasing until day 7 when the release reached 80%, after which it plateaued.   
 
Figure 7.1: The concentration of the drug in the eluent per day, of VH from the three cement 
matrices; two brushite based cements are compared to the traditional HA cement, with the 
MIC line. 
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Figure 7.2 (A) illustrates the diameters of the inhibition zone formed around each cement 
sample when placed onto a culture of S. aureus.  All the cement matrices exhibit similar 
inhibition zones ranging from 15–21 mm, interestingly, the HA cement not loaded with VH 
also demonstrates a bactericidal effect on the S. aureus comparable to that of the cements 
loaded with VH.  The digital images in Figure 7.2 (B) give a visual representation of our 
findings. 
Figure 7.2: Illustration of the inhibition zone around the cements in both loaded and unloaded 
cement matrices (A); the digital images of the inhibition zones (B). 
 
Table 7.1 shows the antimicrobial activities of the S. aureus in the broth; organisms were 
grown aerobically at an agitation of 100 spm at 37 °C, then VH eluted solutions were added to 
the broth dilutions.  In the case of the two brushite based cements, sufficient antibiotic was 
released from the cement matrix to have an inhibitory effect on the S. aureus culture.  On the 
other hand, the apatite cement did not release sufficient active drug to inhibit the growth of 
the organism.   
9 mm  
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Table 7.1: A summary of the results obtained from the antimicrobial assays performed using 
the VH eluted from each cement sample.  
 
 
The microstructures exhibited by the brushite and HA based cements are shown in Figure 
7.3.  The brushite based cement material consisted of large plate-like crystal of 20 to 50 μm in 
length typical of a brushite cement microstructure.  The HA based cement material was 
formed of submicron crystals that were considerably more densely packed than in the brushite 
cement. 
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Figure 7.3: SEM images of the microstructure of (A) typical brushite structure, illustrates 
needle-like thin ling crystals and (B) HA cement, characterised by flat densely packed 
crystals. 
 
 
Figure 7.4: Compares the diffraction patterns of the samples as shown in the SEM 
micrographs of the various cement formulations.  The various peaks are indicative of the 
composition of the samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP); * Tetracalcium 
phosphate (TTCP), which remained in small amount in the HA cement (at 28˚ and 29˚ 2θ). 
152 
 
 
The chemical characteristic of the cements were compared by XRD analysis (Figure 7.4); the 
HA cement exhibited apatitic phases at approximately 32º 2θ and also exhibited some 
unreacted TTCP at 28˚ and 29˚ 2θ.  The brushite phases were present in both orthophosphoric 
and pyrophosphoric brushite cements, with small amounts of unreacted β-TCP.  FTIR was 
also used to characterise the cements (Figure 7.5). 
 
 
Figure 7.5: FTIR spectra of the apatite cement and brushite cements (both OA and PPA 
brushite cements).  The spectra of all CaP based materials indicated the presence of phosphate 
groups at the range of 1070-1140 cm 
-1
.  In addition, the peak at 872 cm 
-1
 of the brushite 
cements was indicative of the presence of HPO4
2-
 groups.    
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7.3.2 Brushite cements  
Cement setting times 
The initial setting time for the control cements was 5 mins, as expected.  The addition of GS 
reduced the setting time, but did not have a significant (ρ ≥ than 0.05) effect on the setting 
time.  However, the addition of VH increased the setting time to a greater extent, as shown in 
Table 7.2 and 7.3. 
 
Table 7.2: Compares the average setting times and the UCS (MPa) for the cements 
formulated using β-TCP + OA with the addition of antibiotics (GS and VH). 
 
 
Table 7.3: Compares the average setting times and the UCS (MPa) for the cements 
formulated using β-TCP + PPA with the addition of antibiotics (GS and VH). 
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Release of drugs 
The concentration of the antibiotics, GS and VH released from the CPCs is shown in Figure 
7.6, which illustrate the concentration of the released antibiotics from the CPC produced 
using of β-TCP + OA, over a period of 24 days.  The concentration of VH initially released 
(with in 24 h) was somewhat higher than that of GS, at 8.5 mg/ mL in the first 24 h compared 
to 1 mg/ mL of GS.  This may have been due to the poor washout resistance, as there was 
more visible degradation than the GS and control cements.  The VH cement only increased a 
small amount thereafter, the highest concentration reached was 9.5 mg/ mL by 264 h.   
 
 
Figure 7.6: Illustrates the concentration of the antibiotic – gentamicin sulphate  and 
vancomycin hydrochloride released from the β-TCP + OA cement, stored in PBS with at an 
agitation of 100 spm at 37 °C over a period of 24 days. 
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The concentration of the antibiotics, GS and VH released from the CPC produced using the 
same for the β-TCP + PPA cement is shown in Figure 7.7, over a period of 24 days; 
demonstrating an initial burst release which then plateaud very quickly.  However, the amount 
released was very small (1.3 mg/ mL) with GS in the first 3 h compared to that released from 
the other cements.  Once the release amount reached 1.9 mg/ mL by 96 h, the release rate 
decreased.  The cement only released 0.06 mg/ mL from 96–288 h, after which not GS was 
released (10 days).  VH shows a similar release pattern to that of GS; just releasing higher 
concentrations in the same time.  The initial burst release took place within 18 h of immersion 
reaching 11 mg/ mL.  The concentration reached 11.49 mg/ mL by 240 h (10 days), after 
which no more VH was released. 
 
 
Figure 7.7: Illustrates the concentration of the antibiotic – gentamicin sulphate and 
vancomycin hydrochloride released from the β-TCP + PPA cement, stored in PBS with at an 
agitation of 100 spm at 37 °C over a period of 24 days. 
 
156 
 
Morphology of cements 
SEM images (Figures 7.8–7.13) show the fracture surfaces of the cements before and after 24 
days immersion in PBS.  Figure 7.10 shows the formation of needle like crystals of ~ 3–5 μm 
in length on the surface of the β-TCP once mixed with GS.  The use of VH had a similar 
effect on the surface of β-TCP; however, the VH crystals were much larger in size (~ 10 μm) 
GS and also present large plate like structures. 
 
 
Figure 7.8: SEM images of the control OA cement sample; (A) illustrates small short 
brushite-like structure before and (B) demonstrates fused needle-like structures to create 
irregular globular structures, after being immersed in PBS for 24 days. 
 
 
Figure 7.9: SEM images of the control PPA cement sample; (A) exhibits obvious needle-like 
structures indicating presence of brushite, before and (B) illustrates irregular globular 
structures, after being immersed in PBS for 24 h. 
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Figure 7.10: SEM images of the GS loaded OA cement sample; (A) before and (B) after 
being immersed in PBS for 24 days.  Sharp defined fine need-like structures, 3–5 μm in 
length indicative of presence of brushite; no change in morphology indicated here. 
 
 
Figure 7.11: SEM images of the GS loaded PPA cement sample; (A) illustrates some 
brushite-like structure before and (B) demonstrates fused needle-like structures to create flat 
planes (10 μm in length), after being immersed in PBS for 24 days. 
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Figure 7.12: SEM images of the VH loaded OA cement sample, (A) before and (B) after 
being immersed in PBS for 24 days.  Smooth flat plates over 10 μm in length; slightly needle-
like indicating presence of brushite with larger crystals; no change in morphology indicated. 
 
 
Figure 7.13: SEM images of the VH loaded PPA cement sample; (A) before and (B) after 
being immersed in PBS for 24 days.  Sharp defined need-like structures, 3–7 μm in length 
indicative of presence of brushite; no change in morphology indicated here. 
 
Inhibition of bacterial growth 
Figure 7.14 and 7.15 compares the inhibition zones produced by the samples before and after 
the release experiment.  Samples were aerobically cultured on S. aureus (ATCC 25923) over 
night at 37 °C.  No valid inhibition zone measurements were obtained from the cultures with 
S. epidermidis, as the organism did not grow very well in the presence of the cements.   
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Results show that there was a significant (ρ < than 0.05) reduction in the inhibition zones 
produced before and after releasing of the antibiotics for 24 days with both cements.  With 
OA cements, GS reduced from 18.5 mm to 3.1 mm and VH reduced from 16.6 mm to 2.5 
mm.  The control cement produced an inhibition zone, before and after the release but did not 
reduce significantly.   
 
 
Figure 7.14: Average inhibition zones produced by OA cements grown on; S. aureus 
samples, after 48 h at 37 °C (A) and S. epidermidis samples, after 48 h at 37 °C (B).  The 
control cement illustrates some low antimicrobial activity.  
 
 
Figure 7.15: Average inhibition zones produced by PPA cements grown on; S. aureus 
samples, after 48 h at 37 °C (A), and (B) average inhibition zones of S. epidermidis samples, 
after 48 h at 37 °C.  The control cement illustrates some low antimicrobial activity. 
 
(a) 
(a) 
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The PPA cement samples grown on S. aureus exhibited inhibition zones of 7.1 mm and 8.9 
mm on average, after the encapsulation of GS and VH, respectively.  After release 
experiments, the GS samples produced an inhibition zone 0.7 mm radius but the VH sample 
was unable to inhibit the growth of S. aureus.  Growth on S. epidermidis follows the same 
pattern.  The images in Figures 7.16 and 7.17 illustrate the antimicrobial strength of the 
cements when loaded with GS (a), VH (b) and cements not loaded with any antibiotics (c) on 
a lawn of S. aureus; these results are represented quantitatively in Figure 7.14 and 7.15.  The 
results show that the inhibition zones were significantly (ρ < 0.05) reduced in the control 
cements and the VH loaded cements after the release of the antibiotics. 
 
 
 
Figure 7.16: Images of the Inhibition Zones exhibited by GS (A) and VH (B) loaded OA 
cements compared with the inhibition zone produced by control OA cement (C), which 
indicates that the control cement illustrates some low antimicrobial activity.  
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Figure 7.17: Images of the Inhibition Zones exhibited by GS (A) and VH (B) loaded PPA 
cements compared with the inhibition zone produced by control PPA cement (C), which 
indicates that the control cement illustrates some low antimicrobial activity.  
 
Figure 7.14–7.17 illustrates the inhibition zones of standard sample sizes made in a PTFE 
mould (diameter 12 mm and height 6 mm).  However, although these samples have been 
compared in the figures the actual comparison of each antibiotic cannot be made, as the 
cement mass varies from one sample to another.  To determine which antibiotic is better at 
inhibiting the growth of the bacteria the same mass of each sample was measured and used to 
compare the exhibited zone of inhibition (mm) with an increase in mass (g) (Figure 7.18). 
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Figure 7.18: Inhibition Zones exhibited by the cements compared to the mass of cement 
samples placed in the centre of the lawn of culture; OA cement (A) and PPA cement (B). 
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Compression strengths 
The ultimate compression strengths of the cements reduced significantly (ρ < 0.05) after the 
release in the case of both cements.  Tables 7.4 show the effects of the addition of antibiotics. 
 
Table 7.4: Average ultimate compression strengths of the cements before and after being 
placed in PBS for 24 days at an agitation of 100 spm at 37 °C. 
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7.4 Discussion 
In the development of medical devices, there has been a growing need for materials that have 
antimicrobial properties in order to prevent infections (Christof et al. 2005).  The gold standard 
treatment for the prevention of bone infections are PMMA beads (Kim et al. 2004) loaded with 
antibiotics, such as vancomycin (Shinsako et al. 2008) or gentamicin (Neut et al. 2001).  These 
antibiotics are specifically used against S. aureus in the treatment of bone related infections 
such as osteomyelitis (Lew & Waldvogel 2004a).  However, in order to achieve the desired 
antibacterial effect, it is necessary to supply a relatively high dose for example, 500 mg to 5 g 
(Korkusuz et al. 1993), which can lead to other complications.  A local drug delivery system 
is advantageous because it is thought to decrease the systemic toxicity and it may also 
improve efficacy by delivering higher drug concentrations to infected bone (Frutos et al. 
2002;Penner et al. 1996).  The release of drugs from any drug delivery device depends on 
different factors such as the microstructure, the drug solubility, the type of bond between the 
drug and the matrix which holds it (Mathiowitz 1999), and the mechanism of degradation of 
the matrix (Ratner et al. 2004).   
 
Calcium phosphate based materials such as HA, β-TCP, and brushite in particular, have 
shown promise in their ability to locally deliver a therapeutic dose of bactericidal drugs 
(Bohner et al. 1997;Dion et al. 2005).  The reasons for this are owed to the ambient setting 
temperatures of these ceramics, which mean that active molecules can be incorporated into 
the matrices during manufacture; as a result the distribution of active molecules throughout 
the cement matrix is homogeneous.  CPC’s are also used as diffusion-controlled devices, 
where the drug is incorporated into a non-biodegradable matrix, through which it should 
diffuse.  Although some CPCs are resorbable, in most of the CPC studied as drug-carriers, the 
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rate of matrix degradation is much lower than the rate of drug liberation.  For that reason it is 
possible to assume that the drug release is mainly controlled by the process of diffusion 
through the cement matrix and not by the degradation of the same.  Therefore, much research 
has been driven towards the impregnation of antibiotics within degradable materials such as 
CPC’s (Anttipoika et al. 1990;Barralet et al. 2002a;Bohner et al. 1997;Dion et al. 2005;Frutos 
et al. 2002;Ginebra et al. 2006;Jiang et al. 2008;Penner et al. 1996;Gitelis & Brebach 
2002;Schnieders et al. 2006).   
 
Although, in most cases it can be considered that CPC do not degrade while drug is released, 
some authors have shown certain degree of degradation of CPC during drug liberation.  For 
example, a study in Japan (Otsuka et al. 1997) showed an increase of porosity in a carbonated 
hydroxyapatite cement during the release of indomethacin, which was attributed to the cement 
degradation.  In this case, the higher resorption rate of the cement was explained by the fact 
that the addition of different amounts of NaHCO3 to TTCP/DCPD cement resulted in a 
carbonated apatite more soluble than the stoichiometric HA used in previous studies.  
Resorption of carbonated HA with time produced an increase of porosity, which increased the 
drug release rate (Chung & Park 2007).  Consequently, if porosity does not remain constant, 
drug release kinetics does not follow Higuchi's law, and the drug diffusion through the CPC 
matrix is not the only mechanism which controls drug liberation.  In any case, during release 
of drugs, the speed of resorption of the CPC matrix depends on various factors, such as 
chemical composition, microstructure and crystallinity of the cement.  In the case of brushite 
cements, the degradation rate is much higher than that of apatite cements, and therefore is 
more important to consider these phenomena (Ginebra et al. 2006).  
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The setting reaction of the CPC can be affected or modified by introducing a drug either to the 
powder phase or to its liquid phase and, as a consequence, the physico-chemical (Ratier et al. 
2001) and mechanical properties can change (Takechi et al. 1998).  In general, in apatitic 
cements antibiotics tend to increase their setting times and reduce the mechanical strength.  
Takechi et al. studied the effect of incorporating flomoxef sodium in different concentrations 
(up to 10%) to the solid phase of cement formed by TTCP and DCPA.  Since this antibiotic is 
very soluble, it was assumed that it dissolved fast in the cement liquid phase.  The authors 
noticed a strong reduction of mechanical strength when the amount of antibiotic added 
increased.  This decrease of mechanical strength was attributed to increased porosity and to 
some inhibition of the setting reaction, as suggested by the presence of certain amount of 
reactants when the antibiotic quantity increased.  The drug release followed the kinetics 
typical for these types of materials, and after 72 h the total amount of liberated antibiotic was 
between 55% and 60%.  In other cases, the modification of the CPC properties can be due to 
some chemical interactions between the antibiotic and the cement.    
 
In comparison of the two main CPC’s (brushite and HA) the results of this study reveal that 
HA exhibited different release kinetics compared to brushite cements (Figure 7.1).  HA 
rapidly released 90% of the encapsulated VH within 7 days, whereas, both the brushite 
cements steadily released the same amount over 11 days.  Rapid release from both brushite 
cements suggests a link between the release profiles and the cement microstructure; both 
brushite cements follow a very close pattern with almost indistinguishable proportions of the 
VH released from the cement matrix at days 1 and day 11 (Figure 7.1), respectively.  This is 
highly likely since drugs are typically delivered from ceramic matrices by a process of simple 
diffusion.  The HA cement had a slower initial release following a burst and plateaus by day 
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7, however, all the cements resulted with approximately 75% released by day 11.   One 
explanation in the difference in release profiles may be the variation in microstructure (Figure 
7.2), which has an effect on the degradation of the cements (chapter 8 explains further).  
Additionally, the cement material contains a basic component (TTCP) that is likely to have 
caused transformation of the VH to its insoluble isoform, as a result inhibiting dissolution of 
the VH until the highly basic TTCP had either been reacted away or dissolved from the 
cement matrix.  In addition, it is evident from the degradation study (Chapter 8) that there is 
a noticeable difference in the degradation of the cements with a difference in composition.  
The slower degradation of the HA may have provided an additional barrier to the release of 
VH from the cement matrix.  As mentioned earlier, the residual unreacted TTCP (dissolution 
releasing of hydroxyl ions) may have been responsible for the bactericidal properties of the 
HA cement that was not loaded with VH (Figure 7.2).  Producing inhibition zone of 
comparable to the loaded HA cements; this mechanism has previously been exploited to 
develop antibacterial calcium phosphate cements from potassium substituted calcium 
phosphates (Gbureck et al. 2005a). 
 
The antibiotic release kinetics of brushite cements, more resorbable than apatitic cements, was 
analysed by adding gentamicin sulphate both in powder form and as a solution (Bohner et al. 
1997).  The reactants used for the cement were MCPM and β-TCP.  Once again the 
rheological and mechanical properties of the cement changed by antibiotic addition, but in the 
opposite direction of that reported by Takechi et al.  They observed an increase of the setting 
time, which was initially too short, as well as an increase of mechanical strength, that was 
ascribed to the presence of sulphate ions in the antibiotic (Takechi et al. 1998).   
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The results illustrate the concentration of the released antibiotics (GS or VH) from the CPC 
produced using of β-TCP + OA (Figure 7.6) and β-TCP + PPA (Figure 7.7), over a period of 
24 days.  The initial concentration of the released GS is lower than that of VH; within 24 h the 
cement releases 1 mg/ mL and releases 0.9 mg/ mL during the next 120 h.  Thereafter a burst 
release occurs between 120–264 h.  On the other hand, VH cements produced an initial burst 
release of 8.5 mg/ mL in the first 24 h, after which there was a very slow release for the next 
24 days.  The final concentration reached at the end of 24 days was 9.5 mg/ mL.  In Figure 
7.7 the release from VH demonstrates an initial burst release.  However, the amount released 
is very small (1.3 mg/ mL) compared to that released from the OA cement (12 mg/ mL).  
Release stopped after reaching 1.96 mg/ mL in 12 days.  This could be due to the very slow 
degradation of the PPA cement in vitro.  The GS release curve shows a similar pattern, with a 
burst release followed by no release after 10 days.  However, the release concentration of VH 
is much higher (maximum released concentration = 11.49 mg/ mL).  Both the cements 
demonstrated that after the first 10–15 days the cement stops releasing the antibiotics.  The 
reason for the pause in release may be because the antibiotics on the surface of the cement 
samples have been released.  Therefore, if the cement was left to degrade the antibiotic release 
would continue.   
 
The control cement provided a weak antimicrobial potency with a maximum inhibition zone 
of 1.5 mm, with a sample mass of approximately 0.1 g (Figure 7.16).  The reason for this 
antimicrobial activity in the control cement originates from the release of hydroxyl ions which 
raise the pH value of the surrounding environment to approximately 12–12.5 (Gbureck et al. 
2005a) after dissolution.  This high pH value may destroy bacteria by damaging the 
cytoplasmic membrane and DNA and denaturing proteins.  In contrast, the inhibition zones 
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around the GS and VH loaded cements were larger with values of approx. 44 mm and 37 mm, 
respectively.  The antimicrobial potency of the GS containing cements had a significant 
difference (ρ > 0.05) after the sample was placed in solution to release antibiotics for 24 days.  
This means that the potency of the antibiotic reduces and antibiotics are eluted in the solutions 
during the release experiment.  The compression results (Table 7.4) shows that the release has 
a significant effect (ρ < 0.05) on the UCS of the cements.  Consequently, this means the 
addition of antibiotics reduces the strength, which may be due to the change in crystal 
structure or the dissolution of antibiotics to leave pores as shown in the SEM micrographs of 
brushite using OA and PPA (Figure 7.8–7.13). 
 
Although CPC’s therapies show good results, a risk of establishing bacterial resistance due to 
low continual doses remains a threat (Durbhakula et al. 2004;Hendriks et al. 2004;Pitto & 
Spika 2004).  In order to reduce the incidence of implant-associated infections, several 
biomaterial surface treatments have been proposed.  One such study (Hamanishi et al. 1996) 
examined the incorporation of vancomycin to a CPC formed by TTCP and DCPD for treating 
osteomyelitis caused by MRSA.  In an in vitro investigation they observed an effective release 
of vancomycin within 2 weeks, in the case of CPCs containing 1% vancomycin, and within 
9 weeks for CPCs containing a higher content (5% vancomycin).  In both cases, the released 
concentrations were higher than the effective concentration against different types of MRSA, 
which suggests that the dosage is high enough not to create bacterial resistance due to such 
treatment methods. 
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7.5 Conclusion 
Incorporation of antibiotics within the cements has been demonstrated to release sufficient 
dosage, therefore reducing or even eliminating the risk of post-operative infections after major 
orthopaedic surgeries.  We have demonstrated that VH can be delivered from brushite and HA 
cements, both the brushite matrices demonstrate similar release profiles.  However, the HA 
cements damage the antibiotic effectiveness when VH was incorporated due to the high pH of 
TTCP; causing deamidation of VH.  The release mechanism of VH from HA cements 
indicates more than one types of mechanism was involved.  
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Chapter Eight 
Degradation of calcium phosphate cements 
8.1 Introduction 
Resorption of bone is a natural phenomenon that occurs during bone remodelling (details of 
the bone remodelling mechanisms are mentioned in Chapter 2).   Ideally bone replacement 
materials should exhibit a similar resorption rate to natural bone, to ensure optimum 
osteoconduction and osteointegration once replaced with a synthetic material (Gupta et al. 
2006).  For this reason, much research has been driven towards alternative cements rather 
than HA; as HA is almost insoluble in physiological conditions, which means slow resorption 
rates.  This in turn may eventually lead to catastrophic brittle failure. 
 
8.1.1 Problems with CPC’s 
There are a number of problems associated with the use of calcium phosphate bone cements 
such as a very low resorption rate.  There is some in vivo evidence to suggest that dissolution 
and cell mediated resorption occurs initially, it then slows down, as a result the cement may 
be stable for over 12 months after implantation (Legeros 1993).  Previous work suggest that 
liquid to cement volume ratio (LCVR) does have an effect on the dissolution of the cements, 
higher LCVR allows more dissolution (Grover et al. 2006).  Several other studies also show 
how the resorption of the various cements vary (Bohner & Baumgart 2004;Grover et al. 
2006;Theiss et al. 2005); these studies all demonstrate that the more recently researched 
brushite cement exhibits faster resorption, compared to the traditional HA cement (Nilsson et 
al. 2002), this is due to the fact that brushite is sparingly soluble in physiological conditions.  
However, the transformation of brushite into apatite after implantation, results in an increase 
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of the resorption time (Constanz et al. 1998).  This can be prevented by adding a magnesium 
salt of low solubility (Rousseau et al. 2003;Rousseau et al. 2002), they concluded that the 
presence of Mg in brushite cements affected their working characteristics significantly.   
Setting times, ultimate degree of conversion and mechanical performances were all altered as 
a result of the addition of magnesium phosphate.  These effects depend largely on the nature 
of hydro-soluble polymers dissolved in the mixing liquid; specific interactions were suggested 
to exist between magnesium and hyaluronic acid.  
 
8.1.2 Macroporosity of CPC’s 
Previous studies have shown that macropores can be introduced into cement by mixing the 
CPC with a pore-making agent that will be removed later.  The pore-making agents that have 
been used by other researchers include hydrophobic liquid (Bohner 2000), degradable organic 
particles (Link et al. 2006), and NaHCO3 (del Real et al. 2002).  However, it is hard to control 
the particle or liquid drop size of these pore-making agents, consequently, making it difficult 
to manage the pore size of the macroporous cement; so the alginate beads were given more 
attention.  The size of alginate beads can be controlled by using different needle size’s, when 
produced using a needle technique.  Alginate is the most frequently used polysaccharide 
system for protein encapsulation as it is readily available and inexpensive (details on structure 
and properties are found in Appendix 2).  Sodium alginate hydrogels are widely used as 
thickeners in the food industry and in biotechnological applications, including cell 
encapsulation, protein delivery, and tissue engineering (Alves et al. 2008;Chan et al. 2002; 
Lima et al. 2006;Ishikawa et al. 1996;Serge et al. 2009).  Moreover, sodium alginate 
microspheres were shown to exhibit bioadhesive properties, which can be exploited for site-
specific drug delivery to mucosal tissues (Salgado et al. 2004). 
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The hypothesis must prove that CPC structure can be modified to allow the degradation to be 
controlled; this in turn should allow the brushite cement to chemically remain as brushite and 
not hydrolyse to HA. 
 
8.1.3 Aim 
CPC’s have been widely used as a bone tissue engineering scaffold material due to its 
excellent osteoconductivity, however, in vivo resorption and tissue in growth is slow.  To 
address these issues, calcium alginate beads can be introduced, which will create 
macroporosity in the system.  The goal of this study was to investigate the handling properties 
and degradation characteristics of calcium phosphate cement containing calcium alginate 
beads.  Alginate beads are non-toxic and very simple to make and the size of the alginate 
beads can be controlled by choosing the appropriate needle size.  An in vitro degradation 
study was carried out in which cylindrical scaffolds were placed in PBS.  Samples were 
assayed on mass, compression strength, and morphology; this study focuses on the effects of 
porosity on degradation.  To enhance the rate of the degradation different amounts of calcium 
alginate beads were incorporated within the matrix.  Micro CT was used to visually determine 
the effects and changes in porosity and pore size during degradation. 
 
An in vitro ageing experiment in simulated physiological conditions (using PBS and serum) 
has been undertaken, with the aim of understanding the long term in vivo degradation of 
pyrophosphate modified brushite cements.  The main purpose of this investigation was to 
monitor the degradation of the CPC in different solutions.   
174 
 
8.2 Methods and Materials 
8.2.1 Materials 
Calcium chloride dihydrate, tri-sodium citrate, ethanol, orthophosphoric acid and acetic acid 
were purchased from Fisher (Loughborough, UK), citric acid from BDH Laboratory Supplies 
(Poole, England), and sodium alginate, low-viscosity (3.7 mPas of 1% solution) alginate 
powder and high-viscosity (824 mPas of 1% solution) alginate powder from Sigma (UK).  
CPC’s were synthesized in the laboratory.      
 
8.2.2 Calcium phosphate cement synthesis 
β-Tricalcium phosphate (β-TCP) was synthesized by heating a mixture of CaCO3 (Merck, 
Germany) and CaHPO4 (Mallinckrodt-Backer, Germany) to 1050 ºC for 24 h followed with 
quenching to room temperature in a desiccator. In this reaction the theoretical calcium to 
phosphate ratio (Ca: P) is 1.5.  The sintered cake was crushed and passed through a 355 μm 
sieve.  The purity of the solid phase was then detected by X-ray diffraction (XRD; D5000, 
Siemens, Munich, Germany). 
 
8.2.3 Preparation of calcium-alginate beads  
A calcium chloride solution of 100 mM and a sodium alginate solution of 2% w/v were 
prepared in distilled water.  The cross-linked alginate beads were prepared by the ‘drop wise’ 
addition of 20 mL of sodium alginate solution into 100 mL of calcium chloride solution 
through steel hypodermic needles with different internal size such as 19, 21, 25 and 26 
gauges, while being stirred.  The beads were kept in calcium chloride solution for 2 h to allow 
hardening, and then separated from the solution by a funnel before washing with 600 µM 
calcium chloride.  The beads were stored in the 600 µM calcium chloride at 4 ºC (Figure 8.1).   
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Figure 8.1:  Illustrates the set-up of the set up of the calcium alginate bead production by 
means of a digital image.  The smaller image on the bottom left indicates the final alginate 
product.   The alginate beads are dried and separated by size, due the variance in the 
production (obvious non-homogenous bead production). 
 
8.2.4 Macroporous cement  
Orthophosphate brushite cement 
A 4.5 M orthophosphoric acid solution containing citric acid at a concentration of 250 mM 
was prepared for mixture with the synthesized cement powder.  A cylindrical tube of height to 
diameter aspect ratio 2:1 was prepared as a mould to form a cylindrical structure of porous 
cement.  The beads were mixed with the cement powder, the cement: bead (C: B) mass ratios 
were ∞, 4, 2.3, 1.5 and 1.  The samples were packed them into the prepared tubes and allowed 
to harden at 37 ºC for 12 h.  Once removed from the moulds the beads were dissolved to be 
the porous cement structure by using a 10 mM tri-sodium citrate solution for 5 h on the shaker 
(100 rev/ min, 25 ºC, 86 Gallenkamp, Serial No. 5A 2658, cooled orbital incubator).  Then the 
wet porous cement scaffolds remained at 37 ºC for an additional 12 h. 
 
100 mm  
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Pyrophosphate brushite cement 
The pyrophosphate modified brushite cements were produced as described in chapter 6, 
however, with the addition of the calcium alginate beads to the powdered component (β-
TCP).  The different beads to cement ratios investigated were ∞, 4, 2.3, 1.5 and 1; and the P: 
L ratios of the paste were 2 g/ml.  The cement samples were casted into rubber moulds with 
fixed height and diameter (ratio is 2:1).  The cement filled moulds were then left in the 
incubators at 37 ºC for 12 h.  After the 12 h, the samples were taken out of the moulds and 
then immersed into 10 mM tri-sodium citrate solution at 100 rpm at 37 ºC.  This allowed the 
beads to be dissolved, leaving porous samples, which were then placed into the incubator at 
37 ºC for an additional 12 h.   
 
8.2.5 Mechanical studies 
The compressive strength of the cements was determined using A Lloyd Material Testing 
Machine (Lloyd Instruments, 6000R, UK) was employed with a load cell of 30 kN to 
compress on the samples, with a cross-head displacement rate of 1 mm/min.  
 
8.2.6 Characterization of macroporous cement scaffold 
Measurements of diameter of the beads were calculated using digital images; a large batch of 
beads (30–50) were analysed using an image analysis software package (Image J 1.36b, 
National Institute of Health, USA). 
 
Porosity  
The different porosities in the cements could be observed by using computer micro-
tomography (Micro CT; Skyscan 1072, Skyscan, Belgium) at the source of 100 kV/98 µA.  
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Micro CT has been previously proved to be a useful method to examine the microstructure in 
tissue engineering.  The samples were set by the programme ‘SKYSCAN-1172’ and obtain 
the images with a cross-section pixel size of 8.468179 µm, Optical Axis line was 518.  The 
scanning speed was set to 0.9 º/step of total 180 º rotation angle.  It allows a complete 
reconstruction of a 3D object from a series of cross-sectional 2D images.  The Micro CT 
software produced results of the pore sizes and percentage of porosity of the samples.    
 
Phase composition 
XRD (D5000, Siemans, Munich, Germany) was employed to determine the degree of 
reaction.  Diffraction data was collected for 2θ ranging from 10 ° to 50 ° with a step size of 
0.02 ° and a normalized count time of 0.3 s/step.  The whole pattern analysis was employed to 
determine the crystalline phase compositions.  The detection was carried out on cements 
incorporating 1 ± 0.83 mm alginate beads incorporated in brushite cement with C: B = ∞ and 
C: B = 1. 
 
8.2.7 Degradation 
The degradation study is based on the mass loss of the cement.  The pyrophosphoric modified 
brushite cement samples are made using the same method as in previous work; β-TCP mixed 
with pyrophosphoric acid (PPA) and distilled water.   The dry, hardened samples were then 
immersed in 20 ml PBS solution (at pH 7.4).  The PBS solution was refreshed three times a 
week to simulate the dynamic environment of an implanted sample.  The degradation is 
measured by mass lost in weight of the samples.  At all allocated time points the samples were 
imaged with the use of the Micro CT.   
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8.3 Results 
8.3.1 Comparing CPC degradation   
In this initial study we compare the degradation properties of both commonly used CPC’s; 
HA and brushite using these as comparisons for the recently developed pyrophosphate 
modified brushite cement (Figure 8.2).  It is obvious from this study that HA exhibits slower 
degradation then brushite cements which conforms to previous research; and therefore HA is 
used as a means of comparison in this study to determine the relative degree of degradation. 
 
 
Figure 8.2: Graphs illustrate the degradation of cements over a period of 90 days. Two 
brushite cements were compared to the HA cement. 
 
The HA cement demonstrated an initial increase in mass by day 2 of immersion in PBS, this 
may be due to the porous nature of the cement, which may have absorbed much of the PBS 
within the pores, demonstrating a mass increase upon measuring, as this was also apparent in 
the orthophosphate cement to a greater extent due to the larger amount of porosity (Figure 
8.3).  However, the orthophosphate cement was exhibited a drop in mass of almost over 2wt% 
by day 7 and then steadily degraded over the 90 days to a final mass reduction of over 25wt%.  
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HA exhibited a reduction in mass of 10wt% over the same length of time and also 
demonstrated at various time points a gain in mass.  In the case of the pyrophosphate cement 
there was a steady reduction in the mass of the cement throughout the 90 days of immersion 
in PBS with the cement losing approximately 15wt% of mass in this period of time.  No 
obvious mass gain was noted; however interestingly there was a discrepancy in the results 
between days 20–27, where the results demonstrate an unstable degradation of the mass of all 
three samples.  As this inconsistency with obvious for all three samples there may have been a 
malfunction or an irregularity of the equipment used to calculate the mass. 
 
The SEM micrographs illustrate the microstructure of the cement samples (Figure 8.3); HA 
demonstrates a smooth and fine fracture surface, with small globular structures of 1–2 µm, 
this may be the reason for the high relative porosity.  Brushite cements demonstrate needle-
like surfaces of 5–7 µm in length and approximately 1 µm in width, which is typical of 
brushite cement.  Pyrophosphate modified brushite cement samples demonstrate similar 
needle-like structures with greater thickness (2–3 µm in width) packed around irregular 
particles of 1–2 µm; not typical of this cement, as previously suggested this may be attributed 
to the hydrolysis of the pyrophosphate to orthophosphate.  Table 8.1 indicates the key 
material properties to allow caparison of the samples. 
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Figure 8.3: SEM micrographs illustrate the microstructure of the cements investigated; HA 
cement (A), orthophosphate brushite cement (B) and pyrophosphate brushite cement (C). 
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Table 8.1: Summarises the key properties of the cements; HA cement, orthophosphate 
brushite cement and pyrophosphate brushite cement.  Comparing the porosity with the 
strength of the cements and how this affects the degradation rate. 
 
 
8.3.2 Addition of macroporosity 
In chapter 4 discussed the chemistry of the CPC’s in detail and mentions that depending on 
the stoichiometry and pH of the cement slurry CPCs can set to form a matrix consisting of 
HA (pH value of >4.2) or brushite (pH value of ≤4.2).  Due to the long term stability of HA, 
brushite (a sparingly soluble CPC) is considered as an alternative.  However as studies has 
shown brushite can hydrolyse to HA.  Here we use a method of incorporating macroporosity 
to overcome such long term stability and hydrolysis, by increasing the rate of cement 
degradation.  
 
The incorporation of the calcium alginate beads (1.1 ± 0.2 mm in diameter) into the cement 
paste resulted in the formation of macroporosity in the cement without significantly 
influencing the cement setting reaction (Table 8.2).  In the absence of the beads (cement: 
bead ∞) the porosity contained within the pure cement was 25% and this increased with the 
addition of calcium alginate beads to a maximum of 57% at a cement: bead ratio of 1 (Figure 
8.4).  The combination of calcium alginate beads even at a cement: bead ratio of six resulted 
in a reduction in compression strength from 48 ± 12 MPa with the addition of no beads to 12 
182 
 
± 1 MPa (Figure 8.4).  When the cement was mixed with the calcium alginate beads at a 
cement: bead ratio of 1 the cement exhibited a compression strength of 4 ± 0.2 MPa. 
 
 
Figure 8.4:  The influence of cement:bead mass ratio on the porosity contained within 
brushite cement and the compression strength exhibited by the hardened material.  
 
The degradation profiles of the macroporous and non-macroporous brushite cements aged in 
PBS are shown in Figure 8.5.  In the case of the non-macroporous brushite cement there was 
a steady reduction in the mass of the cement during the first 14 days of immersion in PBS 
with the cement losing approximately 10wt% of its mass in this time.  After 14 days of ageing 
the rate at which the cement lost mass reduced significantly so that following 28 days of 
ageing the cement lost only a further 2wt% of its original mass.  The macroporous brushite 
cement, in contrast, lost mass at a steady rate throughout the study so that after 28 days the 
cement had lost 60wt% of its original mass (Figure 8.5).  
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Figure 8.5: Illustrates the degradation profiles of macroporous and non-macroporous brushite 
cements. 
 
There was a steady reduction in the proportion of the cement formed from brushite, after a 
period of 14 days of ageing HA was detected in the cement matrix (Table 8.2), which 
corresponded to the reduction in the rate at which mass was lost from the cement material.  In 
the case of the macroporous brushite cement aged in identical conditions, HA was not formed 
at any point during the study and interestingly, following 14 days of ageing, neither brushite 
nor HA was detected in the cement matrix (Table 8.2).  Figure 8.6 demonstrates clearly that 
the phase composition prior to ageing of the brushite cement does not change with the 
addition of the alginate beads; XRD patterns are almost identical. 
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Table 8.2: Compares the composition of the macroporous brushite and non-macroporous 
brushite cement following immersion in daily refreshed PBS. 
 
 
 
Figure 8.6: Compares the diffraction patterns of the control brushite cement (bottom) with 
and macroporous brushite cement (top).  The various peaks are indicative of the composition 
of the samples; ○ Brushite; ● β-tri-calcium phosphate (β-TCP).  
 
Following this different amounts of porosity were then added to the cement; 0, 20, 30, 40 and 
50% porosity samples were produced.  The amount of porosity was referenced to the amount 
of beads added to the cement powder, for example, if cement powder to bead ratio was 1:1 
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then the cement sample was considered to be 50%.  This was the maximum amount of beads 
that could be added to produce a set cement scaffold.  Figure 8.7 illustrates the degradation of 
the various samples, which were ages over 90 days.  Porosity was not able to be artificially 
added to the pyrophosphate brushite cement in the same manner as the beads did not mix 
homogeneously throughout the cement sample; beads were mixed, however during the setting 
reaction the beads where pushed to the top end of the mould.  This may have been due to the 
density of the beads compared with the cement. 
 
 
Figure 8.7: A 3D reconstruction of the control brushite cement (A) and macroporous brushite 
cement (B) with 50% beads.   
 
8.3.3 Long term degradation of brushite cements  
Long term degradation of orthophosphate cement samples with macroporosity of 20, 30, 40 
and 50% beads are illustrated in Figure 8.8.  The sample with 0% beads refers to the non 
porous cement.  The degradation results clearly demonstrate the effect of the addition of 
porosity in the cement slurry.  The results indicate that with the addition of 20 and 30% of 
beads of the total mass of the cement powder the cement degradation does not vary 
significantly.  However, with the addition of over 40% of beads the degradation rate changes 
significantly (ρ < 0.05).  The results from Figure 8.9 demonstrates the results of compression 
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strengths of samples at the various time points after being allowed to degrade for a maximum 
period of 730 days (note that no results are exhibited for beyond day 365 due to lack of 
structural form).   
 
 
Figure 8.8: Graphs illustrate the degradation of cements over a period of 730 days.  No 
results were recorded for day 545 and 730, as the samples had degraded too far to be 
measured using the same conditions; most samples beyond days 365 remained in particulate 
form.  
 
The samples of PPA cement was degraded in two different solutions to demonstrate a 
biological environment serum was used and compared to the generic PBS solution used for 
the results in this chapter.  It is clear from the results that serum aids the rate of degradation, 
however, Figure 8.10 also exhibits a larger standard deviation for the samples degraded in 
serum, especially as the samples are aged for longer periods of time. 
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Figure 8.9: Graphs illustrate the degradation of the non porous orthophosphate brushite 
cements over a period of 730 days (2 years).  The graph is plotted using common logs to 
allow a clear view of the compressive strengths over this long period of time (n = 6).  No 
results were recorded for day 545 and 730, as the samples had degraded too far to be 
measured using the same conditions; most samples beyond days 365 remained in particulate 
form. 
 
Figure 8.10: Graphs illustrate the degradation of cements over a period of 730 days.  No 
results were recorded beyond day 340 (545 and 730), as the samples had degraded too far to 
be measured using the same conditions; most samples beyond days 365 remained in 
particulate form.  Black plots demonstrate the PPA cement in PBS and the grey plot illustrates 
the degradation of PPA in serum solution. 
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8.4 Discussion 
Brushite cements have considerable promise as new bone replacement materials as they are 
more soluble than HA in physiological conditions and could therefore be more rapidly 
resorbed than HA based materials in vivo.  Although more soluble than HA cements, brushite 
is metastable and can hydrolyse to form HA which results in a reduction of pH at the implant 
site (equation 8.1) and ultimately results in the long term stability of the material (Fulmer & 
Brown 1998).  A key factor affecting the dissolution of brushite is the concentration of 
calcium ions; an increase in concentrations results in a decrease in the rate of brushite 
dissolution (Kumar et al. 1999).  This factor is directly connected to the method of ageing 
experiment; whether the ageing method is dynamic or static the resulting mass loss will differ 
due to the saturation of the ageing medium.  The PBS used, here in this chapter, as an ageing 
medium contained no calcium ions.  Consequently once the cement was immersed in the 
ageing solution, brushite dissolution began and an increase in calcium and phosphate ion 
concentration, as a result slowing the rate of dissolution.  Therefore, to maintain a higher rate 
of dissolution the PBS ageing medium needs to be refreshed daily (using a dynamic ageing 
method).   
 
A number of studies have been undertaken to elucidate the factors that can affect the 
hydrolysis reaction including, implant volume, media refreshment rate and media composition 
(Grover et al. 2006).   
3 CaHPO4.2H2O + 2 Ca
2+
  Ca5(PO4)3OH + 5H2O + 3 H
+
           (equation 8.1) 
Some authors have attempted to prevent this reaction from occurring by the incorporation of 
salts capable of preventing hydroxyapatite formation including magnesium phosphates and 
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calcium pyrophosphate into the cement (Grover et al. 2003).  In this study, it has been 
demonstrated that the hydrolysis of the brushite can also be influenced by the porosity of the 
cement material.  By increasing the rate of brushite dissolution, it is possible to prevent HA 
formation from occurring, thereby allowing continued degradation of the material.  The more 
rapid dissolution of brushite from the cement may be due to the improved mass transport 
away from the cement in the presence of a network of macropores. 
 
This study was undertaken to explore the effects of porosity on the degradation patterns and 
relationships of calcium phosphate cements.  Here, in this study a novel idea was discovered 
to manipulate the degradation of these cements by introducing sodium alginate beads.  The 
alginate beads manufactured by the needle technique using a simple process produced sizes 1-
2 mm in diameter; these beads leave a suitable pore sizes for cell to be cultured in.  Having 
analysed the cement produced by the formulation C: B = 2, the pore size was measured and 
was found to be near enough the same size as the diameter of the alginate beads, before 
addition.  Interestingly, the macroporous cement consisted only of β-TCP by the end of the 
study.  This is interesting as brushite is widely thought of as the phase that effectively binds 
the cement together.  It is possible that another amorphous or poorly crystalline phase is 
present in the cement which cannot be detected using X-ray diffraction.   
 
Figure 8.7 illustrates the three dimensional Micro CT images of the brushite cement sample, 
which demonstrates the effect of the addition of beads to the porosity of the samples.  As the 
sample is aged, the highly soluble brushite cement is degraded and the pores are seen to 
increase in size over time.  New pores are also formed as the sample is aged, this could be the 
weakening or expanding of an adjacent pore wall due to dissolution.  This is exhibited in 
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Figure 8.8, which shows the degradation rates of several samples of different porosities. 
Collective with Figure 8.9 the effect of this porosity on the compressive strength of the 
samples is, as expected, decreasing with time.  This evidently suggests that the cement 
porosity can be manipulated to control the degradation of the implant for a wider application.   
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8.5 Conclusion 
The new method to manufacture the macroporous cement has been exposed here in this study 
and this method possesses many advantages. The procedure is easy to reproduce just at room 
temperature, reducing manufacturing costs. The macropores are fabricated by mixing the non-
toxic sodium alginate beads with the brushite cement; this enables pore size to be easily 
controlled within the cement by using different sizes of the beads. The pore sizes created in 
the cement does not affect the porosity significantly, but the samples that possessed a large 
pore size were stronger than those with a smaller pore sizes.  The strengths of the 
macroporous CPC cement were generally low compared to dense cements; however, these 
macroporous cement can be applied in the bone tissue engineering.  The degradation rate can 
be controlled by different porosities through using different amount of beads.  
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Chapter Nine 
Thesis conclusions 
Calcium phosphate cements have been investigated for several decades and here in this study 
we have manipulated the formulations to produce various ideas for the development of and 
enhancement of the material properties of CPC’s. 
 
9.1 Formulation of Monetite cement  
We have reported the formulation of the first cement system that sets to form a matrix that is 
formed predominantly of monetite.  The formation of monetite rather than brushite was 
attributed to the limited perfusion of the hardening cement paste with water during setting.  
Incomplete penetration of the cement by methylene blue has demonstrated the importance of 
sample volume on the formation of the set cement phase. i.e. too small volumes would set 
quickly, and in the case of Han et al. produce a brushite phase as water is not limited 
sufficiently; large volumes, as demonstrated in this study, indicates that the perfusion will 
stop once this limit is reached. 
 
9.2 Controlled setting paste cement formulations 
For good bone healing initial stabilisation is a prime factor.  Injectable bone substitutes are 
good alternatives to allografts and calcium phosphate blocks because they may exactly fill the 
defect shape.  Another important advantage with injectable calcium phosphate bone 
substitutes is their resorption rate.  Since a material is unable to adapt, proliferate and remodel 
according to its’ own overall biomechanical situation it is of great interest for most 
applications to replace the material within years.  These ready mixed CPCs: (1) avoid the 
powder–liquid mixing in surgery thus cutting down the surgical time; (2) allow the paste to be 
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mixed in advance under controlled conditions therefore avoiding inadequate and 
inhomogeneous mixing; (3) will not harden in the package or in a syringe, and will harden 
rapidly in aqueous environment; and (4) eliminate the requirement for the surgeon to mix and 
finish the placement into the defect within a set time before the paste hardens.  They may also 
allow for the pre-processing of the cement paste using processes such as high-shear mixing 
improving mechanical performance.   
 
The cement paste formulations here have shown to be very promising; the results are evident 
of the successful use of the Eudragit microspheres to encapsulate PPA, which are then used to 
formulate the cement that has also shown to harden to form brushite.  Future work will seek to 
evaluate the mechanical and setting characteristics of the pyrophosphate based cement formed 
using Eudragit comparing them with those exhibited by the non-encapsulated PPA.  The 
cement pastes produced using the microencapsulation technique allow setting when the 
cement paste is exposed to a change in conditions.  This is only true for the temperature 
sensitive microcapsules, as the pH sensitive microcapsules leak their load of PPA in a short 
period of time.  To overcome this issue, the use of shear forces as a means to initiate the 
reaction as opposed to temperature or pH was investigated, though, the results were 
disappointing.  The PCL microspheres were unable to carry the phosphorus; the ESEM 
spectrums demonstrated no phosphorus presence.  This could possibly be due to the small 
amount encapsulated.  
 
9.3 Calcium phosphate cements as drug delivery matrices 
Incorporation of antibiotics within the cements has been demonstrated to burst release.  The 
results conclude that the addition of GS allows better conservation of the original cement 
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strength compared to the addition of VH.  Therefore, GS incorporated cements are suitable 
form of supplying drugs to areas where intravenous drug delivery is unsuitable or incapable of 
reaching the infected site.  We also demonstrated, from another study, that sufficient VH can 
be delivered from three distinct CPC matrices at sufficient concentrations to exceed the MIC 
for S. aureus for 168 h.  Importantly, the pH in the ceramic matrix during processing is a very 
important consideration in the effectiveness of the released drug against the bacteria.  The 
findings of this study illustrate the importance of evaluating the antibacterial efficacy of drugs 
loaded into material for in vivo drug release, rather than simply monitoring release. 
 
9.4 Degradation of calcium phosphate cements 
Degradation of the cements does depend on the composition as is evident from the results.  
From the studies here has confirmed the literature that HA is more stable in vitro than 
brushite.  The hydrolysis of brushite in calcium phosphate cement can be influenced by the 
porosity of the implant.  By manipulating implant porosity through the addition of calcium 
alginate beads to the brushite cement during mixing, it may be possible to effectively tailoring 
the rate of in vivo degradation rate in clinical applications.  We have demonstrated that the 
addition of porosity within the cement matrices it is feasible to regulate the cement scaffold’s 
degradation rates.  However, this study also found that the size of the beads does not have a 
substantial effect on the degradation.  The data collected, does suggest that there is a 
relationship between the degradation patterns and the rate of degradation.  
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Chapter Ten 
Future work 
 
10.1 Formulation of Monetite cement 
We have demonstrated that many different gelling agents can be used to add viscosity to the 
non-aqueous liquid used for the formulation of the monetite cements.  However, we have only 
used one such non-aqueous liquid (glycerol); the use of other possibilities can open this novel 
idea to a vast range of applications. Several other possible non-aqueous liquids that may be 
considered: 
- Propylene glycol (1,2-propanediol or propane-1,2-diol) - used in food, medicine,  
pharmaceuticals, emulsification agent, moisturizer in medicines, cosmetics, food, 
toothpaste, mouth wash, and tobacco products. 
- Ethylene glycol (ethane-1,2-diol) - used in chilled water air conditioning systems. 
- Triethylene glycol (TEG, or triglycol) - used by the oil and gas industry to "dehydrate" 
natural gas. 
- Diethylene glycol (DEG) - a component brake fluid, lubricants, wallpaper strippers, 
artificial fog solutions, and heating/cooling fuel. 
- Silicone oils - primary uses are as lubricants or hydraulic fluids. 
 
The use of acceleration agents within the formulation and the effects of these on the phase 
composition would be interesting to study.  In this study we have demonstrated that the 
setting of the monetite paste cement varies between 15–20 h, an accelerating agent would 
reduce that time dramatically.  Following this in vivo studies into the compatibility of the 
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cement with cell adhesion and growth is an additional work that would require an in depth 
investigation; following some of the work on additives, mentioned in chapter 4. 
 
10.2 Controlled setting paste cements using microspheres 
Working on the formulation of this investigation and deriving methods to optimise the 
loading of the microspheres to get maximum acid to polymer ratio.  Investigations on blend 
polymers and various other degradable polymer materials can be utilised for the manufacture 
of such capsules. Also the use of liposomes as an alternative to polymers would widen the 
applications of such technologies. 
 
10.3 Drug delivery 
Using the CPC as drug delivery matrix for a large range of antibiotics and selecting the 
optimum drugs for this versatile delivery matrix.  These methods of incorporating drugs into 
cements can be used for commercial products such as, dental cements, root canal filling 
materials, etc.   
 
10.4 CPC degradation studies 
Continuing long term degradation studies to determine the effects of different environments 
would be the next stage of this investigation.  Formulating a continuous degradation unit, in 
which the sample can remain and measurements of loss of mass and dimensions can be made 
without altering the surrounds and affecting the experimental conditions. 
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Appendix One  
Methods of Cement Characterisation 
Material characterisation is an important part of development for a new material.  
Characterisation aids the comparison of materials and establishes area’s where improvements 
can be made to existing materials; increased osteointegration and osteoconduction, higher 
strengths, better handling and improved outcomes. 
 
1.1 Cement characteristics 
Cement materials are constantly developing; materials characterisation is a means of 
standardising and comparing each material to maximise its potential.  When developing bone 
replacement materials the characteristics are comparable to natural bone; material 
characterisation allows quantification of the various parameters.  In this thesis we take HA 
characteristics as a means of comparison, as HA is commercially available for clinical use. 
 
1.1.1 Setting characterisation 
Calcium orthophosphates which either can be formed by precipitation at room or body 
temperatures are formulations of cements containing at least one or more acidic components 
and one or more basic components which react when the powder is mixed with water.  
Several combinations of reactants are possible in the systems of calcium phosphates and even 
combinations with calcium phosphates containing sodium, potassium, magnesium, zinc, 
carbonate or chloride are thought to be useful.  In addition, other compounds can be added as 
accelerators or retarders of the setting reaction or as promoters of bone in-growth.   
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The Gilmore needle technique 
Gillmore Needles is an American Standard Test Method (ASTM C266−89) (ASTM 1993), 
used for the determination of the setting times for hydraulic-cement pastes.  The Gillmore 
Needles instrument consists of two different needles: one with a weight of 113 g ± 0.5 g and a 
tip diameter of 2.12 mm ± 0.05 mm giving a static pressure of 0.3 MPa used for the initial 
setting time and the other one with a weight of 453.6 ± 0.5 g and a tip diameter of 1.06 ± 0.05 
mm giving a static pressure of 5 MPa used for the final setting time.  The setting times were 
measured by applying the weight to the surface of a cement cylinder held in a ring (cement 
parameters: 16mm diameter, 8mm height) at 30 second intervals and left for 10 seconds.  The 
initial setting time is the time required for the test specimen to bear the initial Gillmore needle 
without leaving an impression on the surface, while the time required for the test specimen to 
bear the final Gillmore needle without leaving any mark is the final setting time.   
 
The practical value of the initial setting time is that it defines the time during which the mate-
rial must not be manipulated to avoid the solid structure, which is being formed during the 
setting, being destroyed (Driessens et al. 1993b).  The practical value of the final setting time 
is that the material now has hardened, but maximum strength for some materials has not been 
achieved.  In a study where over 100 formulations were tested on their ability to set upon 
mixing with water (Driessens et al. 1993b), the initial and final setting times were measured 
with Gilmore needles.  The Gillmore needles technique is operator dependent, many 
researchers have reported varying final setting times for the same commercial cements 
(Grover et al. 2005b).  For this reason interpretation of literature that quotes the setting times 
using the Gillmore technique must be considered subjectively. 
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1.1.2 Mechanical characterisation 
In weight bearing structures such as the human skeleton, every newly developed biomaterial 
needs to be mechanically tested to ensure its functionality, consistency and reliability.  For 
bio-cements, measurement of their multiaxial mechanical properties is more difficult, given 
that their behaviour depends heavily on the microstructural defects associated with the 
manufacturing process (Charriere et al. 2001).  When bone is loaded, it undergoes a 
deformation; the amount of deformation is quantified by the amount of strain.  Strain is 
defined as a change in length per unit of length (van Eijden 2000).  This deformation cause’s 
tension to occur in the bone tissue; quantified by the amount of stress, which is defined as 
force per unit area.  The stress can be classified as compressive, tensile, or shear depending on 
how the load is applied. 
 
Figure A1.1: Illustration of the different types of strain for three forms of stress; 
compression, tension, and shear (van Eijden 2000). 
 
Strength is a critically important mechanical feature of a bone replacement material.  The 
yield strength is defined as the stress at the yield point, beyond which deformation causes 
tissue damage (van Eijden 2000).  Beyond the yield point, the bone replacement tissue will 
not return to its original shape when the load is released.  The ultimate strength is the 
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maximally sustainable stress; the breaking strength is the stress at which the material will 
break.  The value of the ultimate strength of bone depends on the type of stress; typically bone 
is weaker in shear and in tension than in compression (van Eijden 2000).  Brittleness is 
characterized by strongly differing tensile and compressive strengths, appreciable size effect, 
and high scatter of test data (Hoffman 1967). 
 
Compressive strength  
The mechanical properties of the bone substitutes were defined by compression testing.  The 
samples used for the compression test should be cylindrical with the height-to-diameter ratio 
(H/D) equal to 2, to avoid bending.  Samples were compressed at 1 mm per minute along their 
long axis until failure.  Load and actuator displacement were recorded at a rate of 0.2 kHz and 
stored.  The maximum load was used to calculate the compressive strength.  The compressive 
strength is a measure of the maximum compressive force the material can withstand per unit 
area.  During compression (Figure A.2) the compressive forces (C) generate tensile forces (T) 
in the centre of the specimen acting perpendicular to the vertical axis.  These forces will tear 
the sample apart when the strength limit of the material is exceeded. 
 
Figure A1.2: Compression Testing: the compressive forces (C) generate tensile forces (T) in 
the centre of the specimen acting perpendicular to the vertical axis. 
 
1.1.3 Porosity characterisation 
Surface area and porosity are important parameters regarding applications and performance of 
many materials; porosity has a marked influence on the mechanical properties of the material.  
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With regards to pore there are three main different types of pores: Micropores < 2.0 µm; 
Mesopores 2.0–50 µm; and Macropores > 50 µm (Thielmann & Burnett 2000).  In order to 
gain a better understanding of how different pores can affect product properties knowledge of 
the pore size distribution is required.  A standard method for the determination of micro- and 
mesopores size distributions is volumetric nitrogen adsorption measurements at 77 K (Murray 
et al. 1999).  Macroporosity is not measurable by gas sorption and is usually obtained from 
mercury porosimetry (Portsmouth & Gladden 1991).  An alternative to nitrogen adsorption at 
77 K is dynamic sorption at ambient conditions using non-polar organic vapours.  This 
approach has several benefits, especially for organic solids such as pharmaceutical and food 
materials (Thielmann & Burnett 2000). 
 
Mercury porosimeter  
Mercury intrusion porosimetry (MIP) is based on the principle that a non-wetting liquid (one 
having a contact angle greater than 90°) will only intrude capillaries under pressure (Abell et 
al. 1999).  The relationship between the pressure and capillary diameter is described as; 
P = -4γcosθ / d                (equation A.1) 
where P is the pressure; g is the surface tension of the liquid; q is the contact angle of the 
liquid and d is the diameter of the capillary. 
 
Mercury must be forced using pressure into the pores of a material.  The pore size distribution 
is determined from the volume intruded at each pressure increment.  Total porosity is 
determined from the total volume intruded.  The MIP technique is widely used because of its 
ease and simplicity.  However, it does not measure the true distribution of sizes for pore 
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geometries found in cement-based materials (Chatzis & Dullien 2005).  For these systems, 
large internal pores are accessible by very narrow throats.  The MIP technique misrepresents 
the size of these pores as having the diameter of their throats.  Mercury intrusion is a 
penetration process, whereas nitrogen desorption is a phase equilibrium process.  
Consequently, the mercury intrusion curve measures the accessibility of the pore network to a 
meniscus of a particular size (Androutsopoulos & Mann 1979).  The conventional nitrogen 
desorption isotherm is time-consuming to measure, typically taking from 6 to 12 h depending 
on the sample (Murray et al. 1999).  Therefore it would be convenient to acquire the same 
structural data using a quicker and simpler technique.  A possible alternative to the desorption 
isotherm is the mercury intrusion curve, which can typically be measured in about 1 h.   
 
Calculation of density  
According to Archimedes Principle when an object is immersed in a fluid, the fluid exerts on 
the object a force whose magnitude is equal to the weight of the displaced fluid and whose 
direction is opposite the force of gravity (Hughes 2006).  Consider the specific case of an 
object suspended from a string while being immersed in a container of water.   
 
Helium Pycnometer measures the density or more accurately the volume of solids, be they 
regularly shaped, porous or non-porous, monolithic, powdered, granular or in some way 
comminuted, employing some method of gas displacement and the volume to pressure 
relationship known as Boyle's Law.  The Helium pycnometer works by the Archimedes’ 
principle; consisting of two chambers, one to hold the sample and a second chamber of fixed, 
known internal volume.  The device additionally comprises a valve to admit a gas under 
pressure to one of the chambers, a pressure measuring device connected to the first chamber, a 
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pathway connecting the two chambers, and a vent from one of the chambers.  The working 
equation of a Helium pycnometer where the sample chamber is pressurized first is as follows; 
Vs= Vc + Vr / 1- (P1/P2)              (equation A.2) 
where Vs is the sample volume, Vc is the volume of the empty sample chamber (cell), Vr is the 
volume of the reference volume, P1 is the first pressure and P2 is the second pressure after 
expansion of the gas into the combined volumes of sample chamber and reference chamber.  
 
Figure A1.3: The Helium Pycnometer; automatic density analyzer that performs volume and 
density measurements. 
 
DVS  
Dynamic vapour sorption (DVS) is a well-established method for the determination of vapour 
sorption isotherms.  The DVS-1 instrument, Figure A.4 illustrates schematic diagram, used 
for these studies measures the uptake and loss of vapour gravimetrically using a Cahn D200 
recording ultra-microbalance with a mass resolution of ± 0.1 μg.  The high mass resolution 
and excellent baseline stability allow the instrument to measure the adsorption and desorption 
of very small amounts of probe molecule.  The vapour partial pressure around the sample is 
controlled by mixing saturated and dry carrier gas streams using electronic mass flow 
controllers.  The temperature is maintained constant ± 0.1 °C, by enclosing the entire system 
in a temperature-controlled incubator (Thielmann & Burnett 2000). 
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Figure A1.4: Schematic of Dynamic Vapour Sorption (Thielmann & Burnett 2000). 
 
X-ray computed microtomography (Micro CT)  
Conventional methods for evaluating osseointegration of tissue engineered scaffolds are based 
on 2D histological and radiographical techniques and in some cases mechanical testing.  To 
further the development of optimal scaffold architectures and to characterise precisely the 
growth of bone into scaffolds a fast and non-destructive technique to measure the 3D 
properties of scaffold composites during growth is required.  More recently, micro CT has 
been applied in bone engineering studies (Verna et al. 2002).  In Micro CT analyses, it is 
crucial that the scan data is to be processed by the built-in programs of the microtomographic 
scanner used (Skyscan). The 3D reconstruction works by firstly creating a series of images of 
the sample using a 2-dimensional x-ray detector and an electronic x-ray source. 
 
This method allows the investigation of the interconnectivity of the pores within a scaffold 
structure in a more quantitative manner then the traditional estimations made using SEM and 
other imaging techniques.  This non-invasive techniques, allow non-destructive visualization, 
reconstruction and quantification in 3D with minimal sample preparation.  Many researchers 
have found the use of Micro CT to be an improvement in the study of bone degeneration and 
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disease, especially when analysing the morphology of the trabeculae (Gielkens et al. 
2008;Parkinson & Sasov 2008;Regsegger & Laib 1998;Tuan & Hutmacher 2005).   
 
Figure A1.5: Schematic of the set up of the Micro CT.  The sample is placed on a rotating 
platform; rotation angles can be set to sample specification.  As the sample rotates an image is 
stored for 3D reconstruction using analysis software. 
 
1.1.4 Compositional characterisation 
Solid matter can be described as: amorphous, where the atoms are arranged in a random way 
similar to the disorder we find in a liquid; glasses are amorphous materials, or crystalline, 
where the atoms are arranged in a regular pattern, and there is as smallest volume element that 
by repetition in three dimensions describes the crystal.   
 
XRD  
X-Ray diffraction is used to identify the chemical composition of a crystalline phase.  When a 
narrow beam of monochromatic X-rays penetrates the face of a crystal, diffraction will occur 
(Figure A.6).  The condition of the diffracted beam is unique for every mineral and given by 
a relationship called the Bragg equation or the Bragg’s law.  Crystalline materials of high 
symmetry tend to give strong patterns with high and narrow peaks, while materials of lower 
crystal symmetry give weaker patterns with wider and lower peaks (Pflugrath 1999).  XRD 
207 
 
was performed on the initial powder components, the cement during hardening and the end 
product.  XRD patterns of the samples were recorded by step scanning using a microprocessor 
controlled diffractometer system (Siemens D500, Siemens AG, Munich, Germany) with a Ni-
filter for the Kα of the Cu. The step scanning was performed with an integration time of 3 sec. 
at intervals of 0.05º (2θ). 
 
Figure A1.6: X-ray diffraction. A beam of monochromatic X-rays penetrates the crystals of 
the sample and diffracts to produce a pattern unique to the crystal phases present. 
 
Rietveld refinement method  
The Rietveld method allows precise quantitative phase analysis of building materials 
(Walentaa & Füllmannb 2004).  A consistent, accurate and very reproducible method to 
quantify the relative phase abundances in cement materials is to use XRD in combination with 
the Rietveld method.  This analysis is a powerful method for the determination of quantitative 
phase amounts in multiple phase mixtures. 
 
The Rietveld method was developed by Hugo M. Rietveld in 1969 (Rietveld 1969) to refine 
neutron diffraction data.  The principal of the method is that the intensities calculated from a 
model of the crystalline structure are fitted to the observed X-ray powder pattern by a least 
squares refinement.  This is done by varying the parameters of the crystal structures and of the 
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peak profiles to minimise the difference between observed and calculated powder patterns 
(Walentaa & Füllmannb 2004).  As the whole powder pattern is taken into consideration 
problems of peak overlap are minimised and accurate quantitative analyses can be obtained.  
To verify the precision and accuracy of the method it is therefore necessary to compare the 
results with alternative analysis methods.  Detailed information of the theory and mathematics 
of the Rietveld method have been translated by many authors (Albinati & Willis 
2004;G.Walentaa & T.Füllmannb 2004;Young et al. 1977). 
 
Fourier Transform Infrared (FTIR)  
FTIR Spectroscopy is an analysis technique that provides information about the chemical 
bonding or molecular structure of materials, whether organic or inorganic.  It is used to 
analyse and identify unknown materials present in a specimen.  The technique works on the 
principle that bonds and groups of bonds vibrate at characteristic frequencies.  A molecule 
that is exposed to infrared rays absorbs infrared energy at frequencies which are 
characteristic to that molecule.  During FTIR analysis, a spot on the specimen is subjected to 
a modulated IR beam.  The specimen's transmittance and reflectance of the infrared rays at 
different frequencies is translated into an IR absorption plot consisting of reverse peaks.  The 
resulting FTIR spectral pattern is then analyzed and matched with known signatures of 
identified materials in the FTIR library.   
 
FTIR is a quick and simple method of initially identifying unknown materials, no sample 
preparation is required and no special conditions are required for the FTIR; no need for a 
vacuum like SEM or EDX.  FTIR analysis can be applied to minute quantities of materials, 
whether solid, liquid, or gaseous. 
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Figure A1.7: A schematic illustration of the FTIR equipment set-up. 
 
1.2 Cement reactant characteristics  
CPC reaction rates must be controlled; the CPC must react slowly enough to provide enough 
time to the surgeon for implantation, and fast enough to prevent delaying the operation 
(Bohner 2007).  There are many factors that control the rate of reaction of a given chemical 
equation.  Here we explore the effects of particle size on and the different methods used to 
determine the particle size of the powdered components and also the morphology of the end 
products. 
 
1.2.1 Particle size 
Particle size analysis and measurement is an important parameter across many industries for 
material analysis and characterization.  The stability, chemical reactivity, opacity, flowability 
and material strength of many materials are affected by the size and characteristics of the 
particles within them.  A number of different methods may be used to determine the particle 
size distribution of a powder; in this work only scanning electron microscopy (SEM) and laser 
diffraction methods were used. 
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Laser diffraction  
In recent years particle sizing using the laser diffraction techniques has become the dominant 
method of choice.  Laser diffraction units do not measure particle size distributions (PSD) but 
carry out light scattering experiments.  The relationship between the light scattered by the 
particles and the final particle size distribution reported depends critically upon assumptions 
made about the optical properties of the material under study.  Main advantages of the LD 
technique for PSD determinations include;
 
short time of analysis (5–10 min per sample), high 
repeatability,
 
and small sample size needed ( 1 g).  The most important advantage is the wide 
range of size
 
fractions into which the entire range of particle sizes can
 
be divided, rather than 
an arbitrary
 
division of the particles among a limited number of size fractions.  This enables a 
more detailed
 
data analysis and a simultaneous use of the same data sets for
 
classification of 
the analyzed samples under different national
 
classification systems (Eshel et al. 2004). 
 
Figure A1.8: Laser diffraction for measurements of particle size distribution. A laser beam 
hits the particle flow and diffracts in angles inversely proportional to the particle sizes. 
 
SEM  
The SEM is an electron microscope that images the sample surface by scanning it with a high-
energy beam of electrons in a raster scan pattern.  The electrons interact with the atoms that 
make up the sample producing signals that contain information about the sample's surface 
topography, composition and other properties such as electrical conductivity. 
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The types of data signals produced by an SEM include; secondary electrons, back-scattered 
electrons (BSE), characteristic X-rays, light, specimen current and transmitted electrons.  
Secondary electron detectors are common in all SEMs, but it is rare that a single machine 
would have detectors for all possible signals.  The signals result from interactions of the 
electron beam with atoms at or near the surface of the sample.  In the most common or 
standard detection mode, secondary electron imaging or SEI, the SEM can produce very high-
resolution images of a sample surface, revealing details about less than 1 to 5 nm in size.  Due 
to the very narrow electron beam, SEM micrographs have a large depth of field yielding a 
characteristic 3D appearance useful for understanding the surface structure of a sample.  The 
electron beam is thermionically emitted from an electron gun fitted with a tungsten filament 
cathode.  Tungsten is normally used in thermionic electron guns because it has the highest 
melting point and lowest vapour pressure of all metals, thereby allowing it to be heated for 
electron emission, and because of its low cost. 
 
Figure A1.9: A schematic diagram of the SEM apparatus in a typical Joel 7000 SEM. 
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Appendix Two  
Components of the monetite cements paste 
Chapter 4 covered the key drawbacks of CPC’s when used as bone replacement cements; one 
of which has been researched was the formulation of an alternative end product that had a 
suitable solubility, without the risk of hydrolysis to HA.  Much research has covered this 
problem of hydrolysis of brushite to form HA.  In chapter 5 we discussed a formulation of 
novel paste cements that set post operatively to form hardened monetite cement.  This is the 
first of its kind at ambient conditions.  Here we discuss the possible use of non-aqueous 
liquids and gelling agents which combine with the powdered components of the cement to 
produce a paste which is stable until it is immersed in an aqueous environment, whereby the 
setting reaction takes place. 
 
2.1 Non-aqueous liquids 
2.1.1 Glycerol 
Glycerol, also well known as glycerin; is a colorless, odorless, hygroscopic, and sweet-tasting 
viscous liquid (McGraw-Hill 2009).  Glycerol is a sugar alcohol and has three hydrophilic 
alcoholic hydroxyl groups (OH
-
) that are responsible for its solubility in water; glycerol forms 
the backbone of triglycerides.  Glycerol is completely soluble in water and alcohol but is only 
slightly soluble in many common solvents, such as ether, ethyl acetate, and dioxane.  Its 
specific gravity is 1.262 at 25 °C (77 °F) referred to water at 25 °C, and its molecular weight 
is 92.09 (Lide 1994).  It has a very low mammalian toxicity; therefore, glycerol has a wide 
range of applications in all industries, including the food and cosmetics industry to paint and 
lubrications.  
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Figure A2.1: Chemical arrangement of Glycerol molecule with a parochial spatial 
arrangement of atoms (McGraw-Hill 2009). 
 
Glycerol is used in nearly every industry.  With dibasic acids which react to make the 
important class of products known as alkyd resins, which are widely used as coating and in 
paints (McGraw-Hill 2009).  It is used in innumerable pharmaceutical and cosmetic 
preparations; it is an ingredient of many tinctures, elixirs, cough medicines, and anaesthetics; 
and it is a basic medium for toothpaste.  In foods, it is an important moistening agent for 
baked goods and is added to candies and icings to prevent crystallization.  It is used as a 
solvent and carrier for extracts and flavouring agents and as a solvent for food colours.  Many 
specialized lubrication problems have been solved by using glycerol.  Many millions of 
pounds are used each year to plasticise various materials (McGraw-Hill 2009). 
 
2.2 Gelling agents 
Gelling agents are materials used to thicken and stabilize liquid solutions.  They dissolve in 
the liquid phase as a colloid mixture that forms an internal structure giving the resulting gel an 
appearance of a solid matter, while being mostly composed of a liquid, in turn thickening the 
solution.  There are various types of materials used as gelling agents.   
 
Polysaccharides are commonly used as polymer scaffolds in tissue engineering.  The 
incorporation of these polymer scaffolds in tissue regeneration has been ongoing since the 
early 1980’s (Yoon & Fisher 2006).  Natural polymers are generally suitable to be used within 
the body as scaffolds and posses the ability to be degraded enzymatically.  There are also 
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many disadvantages of using natural polymers, such as degradation rate and the lack of 
control of this property, the lifespan of the polymer in vivo may pose difficult to determine, 
and also the crucial property in this case, the mechanical strength, which can be reinforced 
using cross-linking. 
 
Table A2.1: Properties of Degradable Natural Homopolymers that have been Utilization in 
the Fabrication of Tissue Engineering Scaffolds (Yoon & Fisher 2006).  
 
 
2.2.1   Alginate 
Alginate is present in the cell walls of brown algae as the calcium, magnesium and sodium 
salts of alginic acid.  The uses of alginates are based on three main properties (Fabia et al. 
2005).  The first is their ability, when dissolved in water, to thicken the resulting solution 
(more technically described as their ability to increase the viscosity of aqueous solutions).  
The second is their ability to form gels; gels form when a calcium salt is added to a solution 
of sodium alginate in water.  The gel forms by chemical reaction, the calcium displaces the 
sodium from the alginate, holds the long alginate molecules together and a gel is the result.  
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No heat is required and the gels do not melt when heated.  This is in contrast to the agar gels 
where the water must be heated to about 80 °C to dissolve the agar and the gel forms when 
cooled below about 40 °C.  The third property of alginates is the ability to form films of 
sodium or calcium alginate and fibres of calcium alginates.   
 
Figure A2.2: Structural illustration for alginates: (A) the monomers in alginate; (B) the 
alginate chain (Sriamornsak & Sungthongjeen 2007). 
 
Alginate is used in the controlled release of medicinal drugs and other chemicals.  In some 
applications, the active ingredient is placed in a calcium alginate bead and slowly released as 
the bead is exposed in the appropriate environment (Chan et al. 2002).  More recently, oral 
controlled-release systems involving alginate microspheres, sometimes coated with chitosan 
to improve the mechanical strength, have been tested as a way of delivering various drugs 
(Pandey & Khuller 2004). 
 
2.2.2 Agarose 
Agarose is a linear polysaccharide extracted from marine red algae, and consists of β-1,3 
linked D-galactose and α-1,4 linked 3,6-anhydro-αL-galactose residues.  Sometimes, traces of 
sulphate groups can be present on the agarose chain, and may modify the gel properties 
(Normand et al. 2000).   
216 
 
 
Figure A2.3: Structure of Agarose (Normand et al. 2000). 
 
Agarose gel has been commonly used for the cell culture of cartilage and soft tissue and also 
been used as phantom material for material property characterization using image techniques 
due to its good elastic property and availability (Chen et al. 2004).  For tissue culture systems, 
agarose hydrogels are widely investigated because they permit growth of cells and tissues in a 
three-dimensional suspension (Yoon & Fisher 2006).  Agarose gels have been found to 
maintain chondrocytes, the predominant cell type in cartilage, in culture for several weeks and 
also, agarose hydrogels embedded with chondrocytes allow the expression of type II collagen 
and proteoglycans and  results show promise for using agarose gels in cartilage repair (Yoon 
& Fisher 2006).  
 
2.2.3 Carrageenan  
Carrageenans are large, highly flexible molecules which curl forming helical structures.  This 
gives them the ability to form a variety of different gels at room temperature.  They are 
widely used in the food and other industries as thickening and stabilizing agents (Mangione et 
al. 2005).  A particular advantage is that they are pseudoplastic, they are thin under shear 
stress and recover their viscosity once the stress is removed (Garcia & Ghaly 1996).  This 
means that they are easy to pump but stiffen again afterwards.  All carrageenans are high 
molecular weight polysaccharides (MacArtain et al. 2003).  There are three main commercial 
classes of carrageenan: 
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 Kappa: strong, rigid gels. Gels with potassium ions, reacts with dairy proteins. 
 Iota: soft gels. Gels with calcium ions.  
 Lambda: Does not gel, used to thicken dairy products.  
 
Figure A2.4: Schematic representation of the iota-carrageenan (top), kappa-carrageenan 
(middle), and lambda-carrageenan (bottom) (Serge et al.2009). 
 
A recent publication (Borthakur et al. 2007) indicates that carrageenan induces inflammation 
in human intestinal epithelial cells.  Consumption of carrageenan may have a role in intestinal 
inflammation and possibly inflammatory bowel disease, mutations of which are associated 
with genetic proclivity to Crohn's Disease. 
 
2.2.4 Chitosan 
Chitosan is a polysaccharide that is not only naturally abundant, but it is also non-toxic and 
biodegradable; as well as being a naturally regenerating resource (e.g., crab and shrimp shells) 
that can be further enhanced by artificial culturing.  Made up of a linear polysaccharide (Yoon 
& Fisher 2006).  
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At the present, chitosan is the world’s second most abundant polymer, following cellulose (Li 
et al. 1992).  One of the most useful properties of chitosan is chelation whereby, chitosan can 
selectively bind desired materials such as cholesterol, fats, metal ions, proteins, and tumor 
cells (Hon & Tang 2000).  Chelation has been applied to areas of food preparation, health 
care, water improvement, and pharmaceutics. 
 
Figure A2.5: A schematic diagram of the chemical structure of Chitosan 
(http://170.107.206.70/drug_info/nmdrugprofiles/nutsupdrugs/chi_0067.shtml). 
 
Chitosan haemostatic products have been shown to reduce blood loss in comparison to gauze 
dressings and increases patient survival (Pusateri et al. 2003).  Chitosan also posses natural 
bactericide properties; a recent study demonstrates the antibacterial activity of chitosan was 
investigated by assessing the mortality rates of Escherichia coli and Staphylococcus aureus 
based on the extent of damaged or missing cell walls (Chung & Chen 2008).   
 
2.2.5 Gellan Gum 
Gellan gum is a water-soluble polysaccharide produced by Sphingomonas elodea, an aerobic 
gram-negative bacterium (Hamcerencu et al. 2008).  The biopolymer gellan is a more recent 
addition to the family of microbial polysaccharides that is gaining much importance due to its 
novel property of forming thermo-reversible gels when heated and cooled (Jansson et al. 
1983).  As a food additive, gellan gum is used as a thickener, emulsifier, and stabilizer. 
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Figure A2.6: A schematic diagram of the chemical structure Gellan gum 
(http://commons.wikimedia.org/wiki/File:Gellan_gum_structure.png). 
 
Gellan gum can be used to produce easy-to-swallow solid dosage forms, such as gels and 
coated tablets, and to modify the rate of release of active ingredients from tablets and 
capsules.  Also, conveniently used for controlled or sustained release of various drugs (Paul et 
al. 1986) and also for microencapsulation preparation. 
 
2.2.6 Hyaluronic acid 
Hyaluronan, also called hyaluronic acid is a polymer of disaccharides ( Yoon & Fisher 2006); 
found distributed throughout connective, epithelial, and neural tissues and forms in the plasma 
membrane instead of the Golgi and can be very large with its molecular weight often reaching 
the millions (Fraser et al. 2003).  One of the chief components of the extracellular matrix, 
hyaluronan contributes significantly to cell proliferation and migration, and may also be 
involved in the progression of some malignant tumours.   
 
Figure A2.7: Hyaluronic Acid; D-glucuronic acid (left) and D-N-acetylglucosamine (right); 
(http://www.corgenixonline.com/ed_programs/Intro_to_HA.pdf). 
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More recently, many research groups have found that hyaluronan's properties for tissue 
engineering and regenerative medicine are significantly improved with cross-linking, 
producing a hydrogel (Shu et al. 2003).   
 
2.2.7 Gelatine  
Gelatine is a non-toxic, biodegradable, non-carcinogenetic, non-immunogenic and 
inexpensive natural polymer, which has been largely investigated for the preparation of nano- 
and micro- particles (Vandelli et al. 2004b).  Gelatin is a protein produced by partial 
hydrolysis of collagen extracted from the bones, connective tissues, organs and some 
intestines of animals such as domesticated cattle, pigs, and horses.   
 
Gelatine is soluble in aqueous solutions, gelling makes it possible for a product with a liquid 
structure to turn into one with a gel structure.  The gel state looks similar to the solid state but 
differs by its instability; the gel is thermo-reversible.  When a gelatin solution is cooled, the 
viscosity increases progressively and passes from a sol to a gel (Yoon & Fisher 2006).  On the 
other hand, if the gel is heated, it dissolves and once again becomes a solution.  Unlike most 
hydrocolloids of polysaccharide origin, gelatin gels independently of pH and without the need 
for other reactive agents.  The sol/gel conversion is reversible and can be repeated, however, a 
succession of heating and cooling processes may cause gelatin to deteriorate to some extent.  
Due to this property, gelatin is often cross-linked to control drug release for the 
pharmaceutical industry and research (Vandelli et al. 2004c). 
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Figure A2.8: Gelatine (http://www.medsafe.govt.nz/Profs/datasheet/p/Prografcapinf.htm) 
 
2.2.8 Hydroxypropyl methylcellulose (HPMC) 
HPMC was petitioned as an ingredient of hard capsules used for encapsulating powdered 
herbs, used as an alternative to gelatine (animal based) capsules (National Organic Standards 
Board Technical Advisory Panel Review 2002).  HPMC has many other uses as an emulsifier, 
thickening agent, stabilizer, gellant, and suspending agent.  HPMC as a gelling agent can be 
mixed with the powder to improve the cohesiveness of the paste.  The ratio of combined 
constituents is broad and the resulting paste can be formulated to control rather precisely the 
physical properties of the paste, including injectability, porosity and hardening time. 
 
Figure A2.9: Structure of HPMC; 
 (http://images.chemnet.com/suppliers/chembase/190059_1.gif). 
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Appendix Three 
Experimental data 
 
Figure A3.1: A calibration curve for Vancomycin Hydrochloride. 
 
 
Figure A3.2: A calibration curve for Gentamicin Sulphate. 
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Abstract. The hydrolysis of brushite in calcium phosphate cements to form hydroxyapatite is 
known to result in the long term stability of the material in the body.  It has previously been 
established that this hydrolysis reaction can be influenced by implant volume, media refreshment 
rate and media composition.  In this study, the effect of macroporosity on the rate of degradation of 
the material is investigated.  Macroporosity was incorporated into the material using calcium 
alginate beads mixed into the cement paste.  The inclusion of the calcium alginate beads did not 
influence the degree of conversion of the material and allowed the incorporation of porosity at up to 
maximum of 57%.  The macroporosity weakened the cement matrix (from 46.5 to 3.2 MPa).  When 
aged the brushite in the macroporous cement dissolved completely from the matrix resulting in a 
weight loss of 60wt% in a period of 28 days.  This suggests that the controlled incorporation of 
calcium alginate beads into brushite cements in vivo can be used to control implant degradation rate. 
Introduction 
Depending on the stoichiometry and pH of the cement slurry, calcium phosphate cements (CPCs) 
can set to form a matrix consisting of hydroxyapatite (Ca10(PO4)6OH2; HA) at a pH value of >4.2 or 
brushite (CaHPO4.2H2O) at a pH value of ≤4.2.  HA cements have typically attracted more research 
as they can set at or close to neutral pH and exhibit a composition similar to that of the mineral 
component of bone.  Researchers have, however, demonstrated that HA cements can remain in vivo 
for a considerable period of time following implantation and therefore pose a risk of catastrophic 
brittle failure [1].  To address this problem some researchers have begun to focus on the production 
and refinement of brushite cements.  Brushite is a sparingly soluble calcium phosphate in 
physiological conditions and therefore can be resorbed both by cell-mediated mechanisms [2] and 
dissolution, meaning that they are potentially fully resorbable in the body [3].  Brushite is, however, 
metastable in physiological conditions and can hydrolyse to form HA which has been shown to 
result in long-term implant stability [4].  Several studies have been published which have 
investigated the factors that influence the hydrolysis of brushite cements both in vitro [5] and in vivo 
[6], including implant volume, liquid refreshment rate and media composition [5].  In this study, the 
influence of implant porosity on the in vitro degradation of brushite cement was investigated.  
Porosity was varied by incorporating calcium alginate beads into the setting cement, which 
subsequently dissolved into the ageing medium, leaving a macroporous structure. Here we report 
the influence of porosity on the mechanical and in vitro degradation properties of a brushite cement 
system. 
Materials and Methods 
Cross-linked alginate beads were prepared by the ‘drop-wise’ addition of 20 mL of sodium alginate 
solution into 100 mL of calcium chloride solution through steel hypodermic needles of internal 
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Abstract. There is a current need for the localized delivery of antibiotics in order to treat implant 
based infections.  In this study, the efficacy of hydroxyapatite (HA) gels, HA cements, and silica 
gels in the delivery of vancomycin have been investigated and compared. Vancomycin release was 
monitored at set time points using a UV/VIS spectrophotometer (288 nm). The activity of the 
vancomycin released from the cements and gels was assessed using an agar diffusion test with 
Staphylococcus aureus. Vancomycin was released rapidly from both HA matrices, and the silica gel 
in the first day of the experiment, but the release rate was slowed considerably after 3 days for the 
HA gels. Following ten days of aging, 70% of the vancomycin remained in the HA gel matrix and 
the quantity released from the gel was shown to retain its effectiveness against Staphylococcus 
aureus.         
Introduction 
Osteomyelitis is a bacterial infection of bone that can cause a loss of blood supply to the infected 
bone and can spread to adjacent tissues.  For traditional treatment of osteomyelitis, surgery may be 
required along with the administration of antibiotics [1].  The delivery of antibiotics to the site of 
infection is useful to allow the prophylactic treatment of osteomyelitis [2]. It offers the delivery of 
effective concentrations of antibiotics to implant areas susceptible to infection.   Currently, the 
localized delivery of antibiotics in the treatment of osteomyelitis is accomplied using 
poly(methylmethacrylate) (PMMA) beads as carriers for antibiotics such as gentamicin sulphate [3] 
or mixing bone cement with antibiotics encapsulated in PMMA [4]. However, because PMMA 
beads are not resorbable [5], they have to be surgically removed after a few months, after which 
they may be replaced either by new beads to prolong the antibiotic therapy or an alternative bone 
graft.  In this study, biodegradable, and nontoxic bioceramics such as, HA gel [6] and HA cement 
[7] have been used for delivery of vancomycin.  The effectiveness of the released vancomycin 
against Staphylococcus aureus was used to evaluate microbiological efficacy.    
Materials and method 
HA cements were formed by mixing equimolar amounts of tetracalcium phosphate (TTCP) and 
dicalcium phosphate anhydrous (DCPA) (Merck, Germany), combined with water at P: L ratio 4 
g/ml.  The liquid component of the cement contained 0.8 mg/mL vancomycin hydrochloride (Sigma 
Chemical Co., Germany). Once hardened, cement cylinders were immersed in 5 mL of distilled 
water at 37 °C.  HA gels were formed as described by Barralet et al. [6]. The resulting suspension 
was filtered using a Büchner funnel to form a filter cake, the cake was combined with 20 mL of 0.8 
mg/ mL vancomycin for 24 h at room temperature following which the suspension was refiltered.  
The filter cake loaded vancomycin was formed into pellets of 3 mm diameter and 10 mm height 
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Abstract 
There is a current need for the localised delivery of antibiotics in order to treat implant based 
bacterial infections.  Existing treatments use non-resorbable materials such as poly (methyl 
methacrylate) (PMMA) beads [1] loaded with antibiotics such as vancomycin hydrochloride 
(VH); unfortunately as they are not resorbable these beads require secondary surgery for 
removal [2].  Calcium phosphate cements (CPCs) have considerable potential for the localised 
delivery of drugs since they can be resorbed to some extent within the body [3], eliminating 
the need for a secondary surgical procedure.  In this study, the efficacy of CPCs in the 
delivery of vancomycin hydrochloride (VH), a drug used in the treatment of osteomyelitis, 
has been investigated.  VH release was monitored at set time points using a UV/VIS 
spectrophotometer (280 nm).  The activity of the VH released from the cements was assessed 
using agar diffusion and broth dilution methods with Staphylococcus aureus. 
 
Introduction 
Osteomyelitis is a bacterial infection of bone that can cause necrosis due to a loss of blood 
supply to the infected tissue.  The organism commonly isolated from all forms of 
osteomyelitis is S. aureus [4]; an anaerobic, gram-positive coccus, which can spread to 
surrounding tissue rapidly.  Traditional treatments for osteomyelitis involve surgery, to 
remove the infected bone and the systemic administration of antibiotics [5], such as VH for a 
prolonged period of time.  Intramuscular or intravenous administration of the antibiotic, 
however, does not allow sufficient concentrations of the drug to the local area as blood 
circulation is limited and often uncertain [6].   Currently, the localized delivery of antibiotics 
in the treatment of osteomyelitis is accomplished using poly(methyl methacrylate) (PMMA) 
beads as carriers for the drugs [1] or mixing CPC with antibiotics encapsulated in PMMA [7].  
PMMA beads are, however, not resorbable [2] and require surgical removal after which they 
may be replaced either by new beads to prolong the antibiotic therapy or an alternative bone 
graft.  In this study, three calcium phosphate based cement formulations [8] have been 
investigated for the delivery of VH.  The effectiveness of the released VH against S. aureus 
was used to evaluate microbiological effectiveness of the released drug.    
DOI: 10.1002/adem.200800179
3D Powder Printing of b-Tricalcium Phosphate Ceramics Using
Different Strategies**
By Elke Vorndran,Michael Klarner,Uwe Klammert, LiamM.Grover, Sarika Patel, Jake E. Barralet
andUweGbureck*
b-Tricalcium phosphate (b-TCP) is an osteoconductive and
resorbable bone substitute material which is either applied as
granules or a sintered monolithic body with defined
shape.[1,2] Fabrication of the latter is done by slip casting,[3]
isostatic pressing [4] and more recently by using rapid proto-
typing (RP) techniques.[5,6] Rapid prototyping is a technology
where a near net shape three dimensional component is creat-
ed by the layer by layer deposition of a material. One of the
major advantages of RP methods, when compared with tradi-
tional ceramic processing methods, is that they allow the
fabrication of patient specific implants from computer tomo-
graphy (CT) data.[6] This is beneficial especially for large-size
or geometrically complex defects since it is possible to pro-
duce implants with a high dimensional accuracy which guar-
antees optimal implant integration into the defect. Various
RP techniques have been described in literature for the fabri-
cation of calcium phosphate bioceramics, these methods can
be divided into either direct or indirect techniques. The latter
typically use wax or polymer structures which are produced
by stereolithography and then infiltrated with a calcium
phosphate slurry. After the slurry has hardened the inverse
wax / polymer pattern is either dissolved at room tempera-
ture[7] or burned out during heat treatment[8,9] to leave the de-
sired pore geometry. Direct RP techniques for bioceramic fab-
rication include selective laser sintering of polymer-modified
ceramic powders,[10] computer aided design (CAD) guided
fused deposition modelling[11] or 3D powder printing.[6] The
latter uses organic or inorganic binders which are sprayed
onto a flat powder bed and locally binds the ceramic particles
due to adhesive forces or a hydraulic cement setting reaction.
Subsequently a thin layer of powder is applied on top and
the process is repeated resulting in a 3D set component. 3D
powder printing is a commercially established process, using
gypsum or starch powders for technical applications;[12,13]
various groups have adapted the technique to other (bio)-
material systems, e.g. polymers like polylactic acid (PLA)
with chloroform[14] or a mixture of ethanol and acetone[15]
were used as binder or calcium phosphate powders, used
pure [16-18] or with polymeric additives,[19,20] combined with
polymeric or acidic binder solutions. Most of these research-
ers dealt with the fabrication of insoluble hydroxyapatite
implants. Inorganic binder solutions were used to allow
hydraulic setting of the powder matrix as it is known from
self setting calcium phosphate cements,[21,22] e.g. phosphoric
acid solution which reacts with tricalcium phosphate powder
to produce a matrix of dicalcium phosphate dihydrate
(CaHPO4·2H2O, DCPD, brushite) or citric acid in conjunction
with tetracalcium phosphate (Ca4(PO4)2O, TTCP) which
forms calcium citrate complexes. Up to now only one manu-
script has been published which describes the fabrication of
porous b-TCP implants using 3D printing.[6] Although the
authors reported the successful production of a clearly de-
fined ceramic structure, an organic binder was used, which
resulted in ceramics that exhibited relatively poor mechanical
properties and were produced with a poor resolution.
The aim of the current work was to avoid these drawbacks
by using an inorganic binder solution. Binding the powder
through a hydraulic hardening process enabled, for the first
time, the fabrication of phase pure b-TCP monoliths of
defined macroporosity at high resolution by a cement setting
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Abstract: A number of calcium phosphate materials have been investigated as drug release
matrices for the prophylactic treatment of implant-related osteomyelitis. However, some
studies have shown the influence of processing on the efficacy of the delivered drug. The
objective of this study was to evaluate the influence of pH during processing on the efficacy of
vancomycin hydrochloride (VH) against Staphylococcus aureus. VH was loaded into a brushite
cement (CaHPO42H2O; pH 2.4); a hydroxyapatite cement (Ca10(PO4)6OH2; pH 9.4); and an
apatite xerogel (pH 7.4). The pH of the material during processing had a significant influence
on the mechanism of release from the cement. VH released from the apatite cement (pH 9.4)
was not released in accordance with the Higuchi model. In addition to affecting release, the
basic pH was shown to diminish the antibacterial potency of the released VH. Despite
exceeding the minimum inhibitory concentration, the eluent from the apatite cement was
ineffective against a culture of S. aureus. The findings of this study reinforce the importance of
evaluating not only the release of the drug from the material matrix but also the antibacterial
potency of the released drug. ' 2009 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater
93B: 51–58, 2010
Keywords: hydroxyapatite; drug delivery; cement; xerogel; brushite; vancomycin
INTRODUCTION
Bone-related infections, such as osteomyelitis, which
causes a loss of blood supply to the infected bone and
spreads to adjacent tissues, are complications associated
with open fractures and the placement of implants. The
treatment of osteomyelitis typically requires the removal of
the injured tissue; however, bacteria are not thoroughly
eradicated by debridement, and therefore, the systemic
administration of an antibiotic may also be required.1 Van-
comycin hydrochloride (VH) is an antibiotic that is speciﬁ-
cally used against Staphylococcus aureus in the treatment
of bone-related infections. However, to achieve the desired
antibacterial effect, it is necessary to supply a relatively
high dose, for example, 500 mg to 5 g,2–4 which can lead
to both nephro- and ototoxicity.5,6 A local drug delivery
system is advantageous because it is thought to decrease
the systemic toxicity and side effects of parenteral antibiot-
ics, and it may also improve efﬁcacy by delivering higher
drug concentrations to the infected bone.7,8
Poly(methyl methacrylate) beads have previously been
used for the local delivery of VH9,10; however, the highly
exothermic setting reaction and nonresorbability of the ma-
terial remain a problem.11 Other resorbable materials have
been evaluated for drug release, including plaster of Paris,
ﬁbrin, and poly(lactic acid).12–14 The successful application
of these materials would negate the need for a second clini-
cal procedure. Calcium phosphate cements (CPCs) have
also been evaluated for localized release of VH.15–19 These
materials are seen as advantageous because they exhibit a
similar composition to the mineral component of bone and
are already used widely for the replacement of hard tis-
sues.20–26 Calcium phosphate-based cements27–30 are partic-
ularly desirable for the localized delivery of molecules
because they are plastic following mixing and can be
applied either as a mouldable paste or through a hypoder-
mic needle.31 Furthermore, they set with little or no exo-
therm and therefore can be used for the encapsulation of
temperature-sensitive therapeutic molecules. As a result,
some studies have reported the delivery of bone morpho-
genic proteins,32 vascular endothelial growth factor,33 and
nanomicelles34 from hardened cement matrices with signiﬁ-
cant success. Furthermore, a number of research groups
have investigated the local delivery of antibacterial drugs
such as VH from CPCs for the prophylactic treatment of
*These authors contribued equally to this work.
Correspondence to: L. M. Grover (e-mail: l.m.grover@bham.ac.uk)
Contract grant sponsors: Advantage West Midlands (AWM) and European
Regional Development Fund (ERDF)
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51
 250 
 
 
Silver doped calcium phosphate cements with antimicrobial activity 
Andrea Ewald
1
, Daniel Hösel
1
, Sarika Patel
2
, Liam M. Grover
2
, Jake E. Barralet
3
, Uwe 
Gbureck
1* 
 
1
Department of Functional Materials in Medicine and Dentistry, University of Würzburg,  
D-97070 Würzburg, Germany  
2
 School of Chemical Engineering, University of Birmingham, Edgbaston, UK, B15 2TT. 
3 
Faculty of Dentistry, McGill University, Montreal, Quebec, Canada 
 
*Corresponding author 
Tel:  + 49 931 201 73550 E-mail: uwe.gbureck@fmz.uni-wuerzburg.de  
 
Abstract 
There is a current need for the localised delivery of antibiotics in order to treat implant based 
bacterial infections.  Existing treatments use non-resorbable materials such as poly (methyl 
methacrylate) (PMMA) beads (Bohner M, Lemaitre J, Van Landuyt P, Zambelli PY, Merkle 
HP, & Gander B 1997) loaded with antibiotics; unfortunately as they are not resorbable these 
beads require secondary surgery for removal (Penner, Masri, & Duncan 1996).  Calcium 
phosphate cements (CPCs) have considerable potential for the localised delivery of drugs 
since they can be resorbed to some extent within the body (Xia, Grover, Huang, 
Adamopoulos, Gbureck, Triffitt, Shelton, & Barralet 2006), eliminating the need for a 
secondary surgical procedure.  Both α- and ß-tricalcium phosphate (α- and ß-TCP) bone 
substitutes are osteoconductive and resorbable bone substitute materials.  Therefore, in this 
study, the efficacy of, both hydroxyapatite (HA) and brushite, in the delivery of Silver ions 
(Ag
+
), has been investigated.  The activity of the Ag
+
 released from the cements was assessed 
against the growth of both Staphylococcus aureus and epidermidis; the brushite cement 
exhibited excellent antibacterial properties and also showed an increase in compressive 
strengths of over 30% with the addition of Ag
+
.  Cellular interactions with the cements doped 
in Ag
+ 
were also investigated and demonstrated toxicity with high concentrations.  In this 
study we have found that with a few changes in Ag
+ 
concentrations we can produce a fully 
resorable, osteoconductive bone replacement material that is combined with an antibacterial 
scaffold with controlled release over a period of time, which will inhibit bacterial infections 
such as osteomyelitis. 
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Abstract 
Calcium phosphate cements (CPC’S) are used in the repair of craniofacial and orthopaedic 
defects.  The majority of CPCs harden to form a matrix formed either of hydroxyapatite (HA; 
Ca10(PO4)6OH2) or brushite (CaHPO4.2H2O), depending upon the stoichiometry and pH value 
of the cement mix (Barralet, Lilley, Grover, Farrar, Ansell, & Gbureck 2004;Charriere, 
Terrazzoni, Pittet, Mordasini, Dutoit, Lemaitre, & Zysset 2001;Grover, Knowles, Fleming, & 
Barralet 2003;Hatim et al. 1998;Johnsson & Nancollas 1992).  While historically the majority 
of research in this area has focussed on the development of HA based cements, much recent 
interest has been dedicated to the development of brushite based cements.  This is because 
brushite is two orders of magnitude more soluble than HA and hence it has been reported to 
be more rapidly replaced by bone in vivo (Grover, Knowles, Fleming, & Barralet 2003).  In 
some conditions, however, brushite hydrolyses to form a poorly crystalline apatite, which 
significantly slows the rate at which the material is replaced by bone.  Recent work has 
shown that the dehydrated form of brushite (monetite – CaHPO4) is considerably more 
resistant to hydrolysis than HA.  To date, however, monetite can only be made through 
thermal dehydration of brushite at temperatures of greater than 100˚C or through the use of 
highly acidic cement mixes that would be inapproriate for use in vivo (Hsu, Chang, & Liu 
1998).  Here, a new cement formulation is reported that can be provided in paste form and 
following exchange of water with the aqueous milieu can set to form a matrix formed 
predominantly of monetite.  The material exhibited a compressive strength of ~8 MPa and 
could be stored in paste form for a period of 90 days at 4˚C.   
 
Keywords: Brushite, Monetite, Cement, Calcium, Phosphate, Alginate, Modification     
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Synthesis and properties of macroporous brushite cements by introducing 
alginate beads 
 
Abstract 
  The objectives of this study were to synthesize the controllable degradation macroporous 
brushite cement by controlling the porosity using different size and amount of calcium 
alginate beads. And also the effect of cement:beads ratio on porosity and mechanical 
properties of macroporous cements were investigated. The in vitro degradation behaviour was 
performed by soaking the samples into the PBS solution for different periods of time. The 
weight of cements with lower porosity (0%) decreased much faster in the first 14 days than 
the last 14 days. The weight of cements with higher porosity (50%) decreased greatly and 
decreased more rapidly towards the end of the experiment. The weight of cements with 
intermediate porosity (30%), decreased constantly during the whole study. Compared with 
using different cross-linked hydrogels, the degradation speed of the cement cross-linked 
CaCl2 was faster than that cross-linked with MgCl2. This suggests that the alginate beads can 
be used to synthesize the macroporous cement and to control the porosity and the degradation 
rate. 
 
Keywords: calcium phosphate cement, brushite, macroporous, degradation, alginate, tissue 
engineering 
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